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Abstract 
Leishmania spp. are protozoan parasites that infect humans and other 
vertebrates to cause a spectrum of disease, ranging from cutaneous ulceration 
to visceral dissemination dependent on the species. Leishmaniasis is prevalent 
across the developing world and is a major global health issue, yet difficulties in 
the efficacy and administration route of current anti-leishmanial treatments 
means the existing drug repertoire is inadequate. To address this, further 
research and development measures are necessary to identify Leishmania 
proteins representing useful targets for drug inhibition. Essential genes encode 
proteins that are necessary for parasite survival and therefore represent suitable 
drug targets, but the study of such genes is limited by the absence of a 
conditional deletion system. A family of proteins which has previously been 
shown to regulate crucial aspects of Leishmania biology are the protein kinases. 
Protein kinases have been validated in mammalian systems as drug targets in 
cancer therapy, therefore they represent a promising avenue for research into 
anti-leishmanial drugs. The cdc-related kinases CRK3 has been studied in 
particular depth in Leishmania, and current reverse genetic techniques have 
implicated expression of CRK3 as essential to promastigote survival. CRK3 
regulates the cell cycle as demonstrated by treatment of cdc2 inhibitors, but a 
lack of a system to regulate expression prevents more specific phenotypic 
dissection of the role of CRK3. In addition the validation of CRK3 as a drug target 
has been limited by an absence of a conditional genetic system to ablate the 
gene in mammalian infective amastigotes.  
To regulate CRK3 expression in a conditional manner to assess its function in the 
cell cycle of promastigotes and validate it as essential for amastigotes, we have 
implemented an inducible gene deletion system based on a dimerised Cre 
recombinase (diCre) for use in L. mexicana. Cre recombinase mediates the 
excision of DNA sequences flanked by 34bp loxP sites (‘floxed’). diCre is encoded 
as two separate subunits each linked to rapamycin binding domains (FRB and 
FKBP12); therefore recombinase activity is induced by rapamycin treatment 
which causes dimerisation of the subunits. Our method involves replacing both 
CRK3 alleles with a ‘floxed’ CRK3 open reading frame and the diCre coding 
sequence through promastigote transfection and homologous recombination. 
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Induction of diCre through rapamycin treatment of promastigotes results in 
highly efficient deletion of CRK3 and a distinct growth arrest phenotype 
corresponding to a block in G2/M. Induced loss of CRK3 can be complemented by 
expression of a CRK3 transgene but not by expression of an inactive site (T178E) 
CRK3 mutant, showing that protein kinase activity is crucial for CRK3 function. 
Significantly, inducible deletion of CRK3 in stationary phase promastigotes 
prevents the establishment of murine infection, thereby demonstrating an 
essential role in the amastigote cell cycle to further validate CRK3 as a drug 
target. 
Promisingly, inducible deletion is functional in lesion-derived amastigotes and 
will enable direct phenotypic assessment following essential gene loss in this life 
cycle stage. To establish a basis for future in vivo application of diCre in 
Leishmania, a murine infection model was developed with which to track 
bioluminescent parasite burden by in vivo imaging and assess innate immune cell 
recruitment to the site of infection by flow cytometry analysis. The combination 
of functional gene regulation in amastigotes and measures of parasite burden 
and immune response will yield a powerful tool for the further study of 
Leishmania genes encoding suitable drug targets.  
The application of the diCre technique to Leishmania would be greatly 
benefitted by targeting genes where there is evidence of a regulatory role of 
orthologous genes in model organisms. The utilisation of genome or protein 
family-wide RNAi screens in Trypanosoma brucei has identified a number of 
protein kinases which regulate the differentiation of the parasite between life 
cycle stages. The repressor of differentiation (RDK1) protein regulates 
bloodstream form to procyclic form differentiation in T. brucei, and the 
identification of a protein in L. mexicana with high sequence identity suggested 
a potentially analogous role in preventing Leishmania from undergoing 
amastigote to promastigote differentiation in vivo. To assess this, a cell line was 
generated deficient in RDK1 but no effect on differentiation was identified, as 
parasites were able to maintain murine infection and differentiate between life 
cycle stages.  
This study represents an important addition to the reverse genetic toolkit to 
study aspects of cell cycle regulation in vitro, and further assess essential genes 
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as drug targets by deletion in amastigotes. The application of the diCre 
conditional deletion method will enhance the discovery and evaluation of 
suitable drug targets in Leishmania by phenotypic analysis.   
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1 GENERAL INTRODUCTION 
1.1 Leishmania sp. 
1.1.1 Disease prevalence 
Leishmania are parasitic protozoa causing a spectrum of disease in 98 countries, 
ranging from localised cutaneous lesions to visceral infections of the liver and 
spleen. Approximately 1.3 million new cases occur each year (Alvar et al. 2012), 
and an estimated 20,000 to 30,000 deaths annually. Leishmaniasis manifests as a 
spectrum of disease which ranges from Old World cutaneous infections in 
endemic areas such as North Africa, the Mediterranean, the Middle East, India 
and Central Asia to deadly visceral infections in East Africa and the Sudan (L. 
donovani) (WHO  Committee 2010). Cutaneous infections can arise from 
anthroponotic transmission mainly in urban areas (L. tropica) resulting in skin 
lesions that usually heal within 6-15 months or zoonotic transmission in more 
rural areas (L. major) which also causes lesions which heal within 2-4 months but 
can persist for up to five years. In New World leishmaniasis, the main incidences 
occur in Central and South America, and mainly manifest as cutaneous lesions (L. 
mexicana, L. braziliensis, L. panamensis, L. guyanensis) or chronic 
mucocutaneous infections where infections spread to mucosal membranes in the 
throat, mouth and nose. Such infections cause severe damage and disfiguration 
to these areas and are caused by species such as L. braziliensis, and L. 
panamensis, whilst visceral leishmaniasis is generally caused by L. infantum, 
also referred to as L. chagasi in South America (Figure 1:1).  
The WHO highlights the fact that the major contributor to the wide-spread 
prevalence and risk of infection with leishmaniasis is poverty (WHO Committee 
2010). Poor socioeconomic conditions makes those at risk more susceptible to 
infection. For example, malnutrition increases the risk of the disease becoming 
visceral, and is compounded by the increased risk of transmission already 
associated with poverty. Environmental factors exacerbate the risk of infection 
by increasing human interactions with the sand fly vectors that are attracted to 
areas of overcrowding which yield a good source of blood-meals. Urbanisation 
exacerbates infection risk by increasing the concentration of hosts and therefore 
disease reservoir, but also through the expansion of cities into previously 
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forested areas where sand fly populations are established. Migration of non-
immune people to endemic areas acts as a reservoir of susceptible hosts for the 
parasite can also lead to an accelerate incidence of infection. Much of the 
industry and therefore available jobs in countries where leishmaniasis is 
prevalent involve agriculture and mining which take place in previously forested 
areas, bringing labourers in contact with sand fly populations and increasing the 
rate of transmission (Ramdas 2012). Compounding this increased transmission 
rate, access to primary health care in such regions may also be difficult.  
To tackle the global health issue associated with leishmaniasis, a number of 
programmes have been established. The London Declaration was drawn up in 
2012 as a collaborative effort between funding bodies such as the Bill and 
Melinda Gates Foundation and pharmaceutical companies such as Novartis to 
tackle the neglected tropical diseases (NTDs). A chief implementation of this 
strategy is the expansion of existing drug access programmes to increase the 
availability of anti-leishmanial treatments, with a further provision of funds to 
advance research and development into new treatments, improved access to 
diagnosis and interventions for visceral leishmaniasis. The aim of the declaration 
is to achieve control of visceral forms of the disease by 2020, and an increased 
availability and reduced cost of anti-leishmanials. The publishing of the third 
progress report of the London Declaration (2015) indicates a reduced rate of 
visceral leishmaniasis between 2011-2013, however the number of drug 
donations to treat the disease are low relative to other NTDs such as lymphatic 
filariasis and onchocerciasis.  
The Drugs for Neglected Disease initiative (DNDi) was established in 2003 as a 
collaborative effort between researchers across the world to expand the current 
repertoire of anti-leishmanial drugs. Development of compounds through 
combination of existing therapies and further assessment of existing lead 
compounds are their short and medium term approaches which have yielded 
success in the field (DNDi, 2015). A long term approach is the focus on the 
development of safe, cheap and efficacious medicines with a simple 
administration route to enhance the cure rate of visceral and cutaneous 
leishmaniasis. The emphasis on improved drug research and development 
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demonstrates that the potential for this field of research is critical for helping 
treat the leishmaniasis.  
1.1.2 Leishmaniasis: recent classification of an ancient disease  
The diseases caused by Leishmania have been documented over the course of 
recorded human history, from descriptions of cutaneous lesions from texts 
owned by the Assyrian King Ashurbanipal dating back as far as 2500BC (Cox 
2002), to the representation of mucocutaneous lesions by intricate, 
anthropomorphic pottery called ‘huacos’ from pre-Hispanic Peru and Bolivia in 
AD200-1000 (Gade 1979). More recently, rounded bodies were observed by light 
microscopy from lesion biopsies and implicated as the causative agents of 
‘tropical ulcers’ by many including Henry Wright in 1903 (Wright 1903), leading 
to the subsequent classification as L. tropica in 1906 (Lainson 2010). However, it 
was the Scottish pathologist and army medical officer William Leishman who 
first classified these parasites as the causative agents of the visceral disease 
‘kala-azar’ after being stationed in colonial India. In 1903, he published an 
account of the discovery of amastigotes in the British Medical Journal by staining 
infected spleen samples with ‘Leishman’s stain’, a methylene blue and eosin 
mixture. The parallel discovery of Leishmania parasites by light microscopy of 
biopsies obtained from patients presenting with visceral disease by Charles 
Donovan in India led to the first species being named Leishmania donovani. The 
identification of a distinct, New World species was conducted by the Brazilian 
clinican Gaspar Vianna, who identified the causative agent of American 
cutaneous Leishmaniasis in 1911, naming it L. braziliensis (Lainson 2010). The 
distinction of this species from L. donovani and L. tropica was an early 
indication of their diversity, and over the course of the 20th century our 
increased understanding of the variety of Leishmania species has been aided by 
advancing genetic techniques to phenotype and categorise the genus (Lye et al. 
2010, Fraga et al. 2013). To date, over 40 species are deemed as Leishmania, 
and all are parasitic in lifestyle. There are two sub genus within Leishmania 
broadly corresponding to Old World, L. (Leishmania) and New World, L. 
(Viannia), however some species such as those in the L. mexicana complex and 
L. chagasi do not fit this generalisation because they can be grouped into the L. 
(Leishmania) sub genus despite presenting as New World infections. 
Interestingly, L. chagasi is not distinct from L. infantum and likely represents 
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the same species but in South America as opposed to the Old World. In terms of 
the human disease which each species cause, these can be broadly categorized 
in terms of four main clinical manifestations; local cutaneous or diffuse 
cutaneous, mucocutaneous, and visceral (Figure 1:1). A further complication with 
categorising the variety of Leishmania species was first documented by Ravel et 
al in 2006, where hybrids between L. major and L. infantum were isolated from 
immunocompromised patients in Portugal. These genetic chimeras are evidence 
that cross-species genetic exchange could be driven by selective pressure, and 
further complicates the classification of Leishmania genus. In addition, such 
selection could drive the generation of drug resistance in the field, and signifies 
the adaptability of Leishmania sp.  
 
 
Figure 1:1- A phylogenetic representation of the key human infective Leishmania species, 
their clinical forms and geographical distributions. LCL, localised cutaneous leishmaniasis; 
DCL, diffuse cutaneous leishmaniasis; MCL, mucocutaneous leishmaniasis; VL, visceral 
leishmaniasis. Adapted from Fraga et al. (2013). 
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1.1.3 Available treatments for leishmaniasis 
Unlike the accelerated rate of species discovery, methods for treatment and 
prevention of leishmaniasis have remained comparatively stagnant over the 
course of the 20th century. There are no prophylactic drugs, nor vaccines 
available to confer resistance to infection. This is mainly due to the complexity 
of the immune response to leishmania infection, with research into this area 
uncovering ever expanding complexities into the host-parasite interactions which 
mediate immunity and drive infection (Kaye & Scott 2011). The practice of 
deliberate infection with leishmania (termed ‘leishmaniasation’) at an obscured 
location on the body such as the buttocks has been a method to prevent 
subsequent infection and establishment of lesions on a more visible site such as 
the face. Although highly undesirable, the concomitant immunity conferred by 
leishmanisation highlights the potential of vaccine strategies, with the use of 
attenuated parasites a possible route for canine vaccination if not possible for 
humans. Instead, recombinant protein formulations yielding some success and 
the application of DNA vaccination (Dunning 2009) may yield useful preparations 
for the induction of an appropriate anti-leishmanial response. The development 
of such vaccines is comprehensively reviewed by (Kumar & Engwerda 2014). 
In contrast to an available vaccine, there is a repertoire of drugs with which to 
treat leishmaniasis (Table 1-1). The first use of urea stibamine by Sir Upendranath 
Brahmachari over 100 years ago marks the start of drug strategies against 
leishmaniasis. The use of this pentavalent antimonial was instrumental in saving 
the lives of millions of people infected with visceral leishmaniasis during the 
1922 epidemic in India. In such a severe circumstance the efficacy of the drug 
was preferable to the morbidity caused by such a widespread epidemic, however 
the toxic side effects of the drug rendered it a dangerous treatment for routine 
use. The compound was engineered into a less toxic form during the Second 
World War, and established as the gold standard for anti-leishmanial treatment 
for over 60 subsequent years. Pentavalent antimonials are still available today as 
Pentosam® in the UK, Glucantime® in France and a more affordable sodium 
stibogluconate (SSG) formulation (Croft & Olliaro 2011). Treatment with these 
compounds remains far from ideal due to their cardiotoxicity, relative expense 
and the necessity to be administered by a healthcare professional by 
intramuscular or intravenous injection over the course of four weeks. In 
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addition, significant levels of antimony resistance have been reported in 
epidemic areas of India from as early as 1970, with a more recent case study 
from the Northern state of Bihar showed that treatment of visceral patients with 
antimony resulted in a high failure rate of 65% (Sundar et al. 2000). This 
compares with a failure rate of 14% when treating patients from the Uttar 
Pradesh region, an area also epidemic for visceral leishmaniasis shows an 
inherent resistance to the drug in Bihar. Since this study, resistance has become 
more widespread and more than 60% of visceral leishmaniasis patients do not 
respond to front-line treatment (Bhandari et al. 2012). The molecular 
mechanisms of resistance in L. donovani is now a significant field of study.  
A key aim of the 2007 WHO report on the control of the leishmaniasis is the 
development of new medicines for orally and topically administered treatments 
which rely on a shorter administration cycle (WHO 2007). Promisingly, a number 
of initiatives now have established programmes to accelerate research and 
development into novel cures for leishmaniasis, such as the Drugs for Neglected 
Disease initiative (DNDi) who have separate strategies for the treatment of CL 
and VL. In addition, ongoing funding from the Gates Foundation and increased 
collaborative efforts with industry to facilitate anti-leishmanial compound 
screens are accelerating the process of drug discovery. A number of alternative 
anti-leishmanial compounds have been identified over the past two decades, 
such as Amphotericin B, Miltefosine, Paromomycin and Pentamidine (Table 1-1).  
Amphotericin B was originally developed as an antifungal agent, but treatment 
of Leishmania results in the formation of complexes with sterols, leading to the 
permeabilisation of the Leishmania cell membrane by pore formation and a 
resulting lethal cell lysis (Saha et al. 1986). Amphotericin B is an effective anti-
leishmanial agent and utilised for the treatment of all manifestations of the 
disease; however side effects of treatment do occur. To address this, a less toxic 
but equally efficacious formulation was developed to treat fungal infection of 
immuno-compromised patients by the incorporation of amphotericin B into 
liposomes. The reduced toxicity was associated with the preferential binding to 
high density lipoproteins (Wasan et al. 1994). This lipid preparation termed 
AmBisome is a potent anti-leishmanial, but despite efforts from the WHO to 
negotiate a reduced price of $18/50mg vial, the total cost of treatment remains 
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unaffordable for many. Recent efforts aim to make AmBiosome more affordable 
to enable widespread distribution, and in 2011 the WHO secured a partnership 
deal with the suppliers Gilead to donate 445,000 vials over five years (2015).  
Miltefosine is an incredibly useful compound in regards to efficacy and oral route 
of administration (Croft & Olliaro 2011). This route is particularly important for 
the distribution of anti-leishmanial compounds to areas where primary 
healthcare is not accessible, therefore intravenous and intramuscular injections 
cannot be conducted appropriately. The successful treatment of VL with this 
compound makes it a powerful addition to the current drug repertoire, 
particularly in overcoming antimonial resistance; yet there can be variation in 
regards to the efficacy of this compound resulting from the 28 day course of oral 
administration, opening up the possibility of improper or irregular dosing by the 
patient (Croft & Olliaro 2011). The use of paromomycin has been instrumental in 
tackling the drug resistance observed in VL infections in India by its high efficacy 
of 94% in phase III clinical trials (Sundar et al. 2007). By intramuscular injection 
of this aminoglycoside the use of paromomycin is an alternative treatment to 
antimonials and the course of treatment is inexpensive at 15$ for a 15 day 
course. Antoher alternative to antimonial treatment is pentamadine isethionate, 
however a case study in Suriname demonstrates that the high cost of $90 for 3 
rounds of injections either intralesional or into the buttocks is unaffordable to 
most (Ramdas 2012). In addition, the administration of pentamidine is viewed as 
exceptionally painful, and is partially responsible for a cultural move against 
seeking treatment for New World CL, with those infected utilising harsh, 
alternative ‘treatments’ such as battery acid and pesticide to treat their lesions. 
Topical paromomycin for CL has been developed which would be viewed as less 
painful, but are not available in this region. Compounding this socio-
psychological aspect, those studied were at high risk of infection by working in 
densely forested areas as labourers due to constant interaction with infected 
sand fly, and who are poorly paid so are unable to afford treatment.  
To address the issues with efficacy and resistance to individual drugs, DNDi have 
prioritised the implementation of combination therapies (2015). The utilisation 
of SSG and paromomycin combination treatment has been in effect since 2010 to 
enhance cure rates and prevent visceral leishmaniasis resistance in East Africa, 
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whilst pilot trials to test combination therapies utilising AmBisome, Miltefosine 
and Paromomocyin have yielded >97.5% cure rates and are extremely important 
to address antimony resistance in India. Despite the efficacy of these therapies, 
existing issues with cost and administration remain. In a bid to make more 
effective therapy for cutaneous leishmaniasis, DNDi aim to combine 
chemotherapy with immune-moduation. By this method, the majority of 
parasites will be eliminated by drug treatment whilst persistent or subsequent 
infection resistance will be driven by vaccine or adjuvant treatment to enhance 
the immune response against the parasites. Modulators currently utilised in 
cancer treatment may have efficacy in this strategy. The range of treatments 
available against the various forms of leishmaniasis have variable efficacy and 
problems, however the recent increase in research and funding efforts aim to 
accelerate the development of better treatments and address such issues.  
Drug Property and administration route Disease treatment 
Pentavalent antimonials; 
(Pentostam, Glucantime, 
WHO approved SSG) 
Organo-metal complexes; intravenous 
and intramuscular 
VL and CL 
Amphoterecin B 
(Fungizone) 
Polyene antibiotic; intravenous VL, CL and MCL 
Liposomal amphotericin B 
(AmBisome) 
Unilamellar liposome; intravenous VL, CL, MCL and PKDL 
Miltefosine (Impavido) Hexadecylphosphocholine; oral CL (variable) and VL 
Paromomycin Aminoglycoside, intramuscular (VL) or 
topical (CL) 
VL and CL 
Pentamidine Diamidine, intramuscular CL 
Table 1-1- The available drug repertoire for treatment of leishamaniasis. Current treatments 
available for visceral (VL), cutaneous (CL), mucocutaneous (MCL) and post-kalazar dermal (PKDL) 
leishmaniasis. Adapted from (Croft & Olliaro 2011). 
1.1.4 Life cycle in the vector 
The nature of Leishmania transmission was unknown until the Edouard and 
Etienne Sergent published experimental proof of the transmission of Leishmania 
to humans by sandflies of the genus Phlebotomus in 1921, with direct 
demonstration of such transmission in 1941 (Cox 2002). This genus is responsible 
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for the spread of Old World leishmaniasis, and in 1922 the vector spreading the 
New World disease was identified as the Lutzomyia genus. Leishmania have a 
complex, dimorphic life-cycle in order to transmit from mammalian host to 
sandfly vector. Transmission from one mammalian host to another is facilitated 
by the uptake of intracellular amastigotes during a blood meal. Upon release 
into the ambient temperature of the sand fly gut these amastigotes undergo 
differentiation to replicative, extracellular procyclic promastigotes. By 
examination of L. braziliensis and L. mexicana infections of sand fly, the original 
classification of Leishmania into two distinct subgenus of L. (Viannia) and L. 
(Leishmania) was defined by the differential adherence of promastigotes to 
structures within the gut (Lainson et al. 1977). In the context of discussing 
promastigote differentiation within sand fly in this introduction, most references 
will concern the latter subgenus to which L. mexicana belongs, and which has 
been studied more in depth. Differences in establishment of infection in sand fly 
by different Leishmania species is permissive only when the two organisms 
reside in the same geographical location, with such specificity resulting from the 
expression of lipophosphoglycan (LPG) (Kamhawi et al. 2004). LPG is necessary 
to prevent removal of the parasites by fluid flow over the gut, and interestingly, 
this epithelial anchoring by attachment of LPG to Phlebotomus PpGalect, an 
abundant galectin expressed in abundance on the surface of the midgut. 
Galectin expression is a key mediator of the species-specificity of sand fly 
infection by Leishmania. Environment factors such as temperature also influence 
the establishment of sand fly infection, as seen by the difference in optimal 
growth temperatures between even closely related species both of which infect 
the same L. longipalpis vector (Hlavacova et al. 2013).  
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Figure 1:2- The Leishmania life cycle within the sand fly vector. Leishmania undergo multiple 
differentiation steps from amastigotes ingested in blood meal to the hindgut (HG). Differentiation to 
a. replicative, procyclic forms occurs in the anterior midgut (AMG), to b. non-dividing nectomonads 
which migrate upwards towards the thoracic mid gut (TMG). Differentiation to replicative c. 
leptomonads in the TMG is followed by differentiation to infectious, non-dividing d. metacyclics and 
also to haptomonads which attach to the cardiac or stromodeal valve (CV/SV). Heavy infection 
results in the accumulation of promastigote salivary gel (PSG) in the TMG and some metacyclic 
promastigotes may infiltrate the foregut (FG). Scale bar: 1mm, adapted from Rogers (2012). 
This vector stage of the life cycle represents a huge challenge to the parasites as 
they must also resist proteolytic attack by digestive enzymes in the gut which 
are secreted by epithelial cells following the extraction of a blood meal and 
uptake of intracellular amastigotes into a peritrophic matrix (PM) in the 
posterior midgut. In this context, the expression of LPG on the promastigote cell 
surface and the release and accumulation on the surface of a secreted 
proteophosphoglycan (PPG) are implicated in the evasion of proteolytic lysis 
(Secundino et al. 2010). The expression of such factors facilitates the 
establishment of infection and the differentiation to a number of distinct, 
intermediate forms occurs as the parasites migrate up towards the mouthparts in 
order to establish transmissible levels of infectious metacyclics to facilitate re-
infection (Figure 1:2). Differentiation to replicative procyclic promastigotes 
occurs after 24-48 hours post blood meal to establish colonisation of the 
posterior midgut, with the differentiation to longer, non-dividing nectomonads 
which then escape from the PM and migrate to the anterior midgut 48-72 hours 
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post blood meal feeding. Subsequent differentiation to replicative leptomonads 
which establish colonisation of the thoracic midgut occurs after 4-7 days, at 
which time the differentiation of two distinct stages play a role in subsequent 
infection; the first is the differentiation to haptomonads, a static stage which 
adheres to the lining of the stomodeal valve and to neighbouring parasites, 
thereby blocking the opening of the valve (Kamhawi 2006). The second is the 
differentiation of infectious, metacyclic promastigote.  
The study of this pathologically significant cell type has been amenable for 
around forty years through axenic in vitro culture (Berens et al. 1976). A model 
for differentiation in the sand fly uses cultures seeded with promastigotes at a 
low cell density, which multiply as procyclic promastigotes until they undergo 
growth arrest and differentiation to the virulent, stationary metacyclic stage 
begins. A seminal study by Da Silva & Sacks (1987) demonstrated the infectivity 
of metacyclic forms compared with procyclic promastigotes, whereby infection 
of BALB/c mice with in vitro replicative, or Leishmania purified from the midgut 
of recently infected Lutzomyia anthophora sand fly was not established. In 
contrast, infection with promastigotes derived from stationary cultures or from 
the midguts of L. anthophora infected for twice the time as previously was 
robust. These findings were in agreement with others, and now metacyclic forms 
are routinely purified from stationary phase culture. This pre-adaptation of the 
metacyclic form for infectivity in the mammalian host is a crucial stage in the 
life cycle, and the differentiation from procyclic to metacyclic promastigotes is 
termed metacyclogenesis. The production of a promastigote salivary gel (PSG), a 
proteophosphoglycan gel secreted by the leptomonad promastigotes in thoracic 
mid-gut is implicated in the establishment of a dense, protective niche within 
the sand fly thoracic midgut. The production of PSG thereby enables the 
enrichment of metacyclic cells and subsequent infectivity (Rogers 2012). In 
addition, the differentiation of ‘pear shaped’ haptomonad parasites and their 
adherence to the stromodeal valve by way of a hemidesmosome (Walters et al. 
1989) establishes a ‘plug’, thereby acting in conjunction with PSG to enrich the 
thoracic midgut with metacyclics and prevent their clearance by the sand fly. 
Haptomonad attachment can result in cellular damage to the valve, forming 
openings which facilitate the entry of metacyclics into the foregut and proboscis 
(Kamhawi 2006). Finally, the PSG obstruction results in more frequent feeding as 
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the sand fly is unable to procure an adequate blood meal (Stierhof et al. 1999), 
potentially enhancing the transmission into mammalian hosts.  
1.1.5 Development in the mammalian host 
The establishment of infection by the inoculation of around 600 metacyclic 
promastigotes into the host by sand fly inoculation (Kimblin et al. 2008). Once in 
the skin, these parasites are internalised by innate, skin derived phagocytes such 
as dendritic cells (DC) and macrophages. For metacyclic forms, establishing 
intracellular infection and avoiding phagocyte mediated killing is facilitated by 
the expression of the metalloprotease gp63 and lipophosphoglycan (LPG) on the 
surface of metacyclic promastigotes. LPG is expressed in abundance on the 
surface of procyclic promastigotes to facilitate binding to the sand fly midgut, 
but is elongated in metacyclic promastigotes by the addition of phosphorylated 
disaccharide repeat units (Sacks et al. 1995). LPG elongation functions in the 
establishment of infection by two mechanisms; binding to the mid gut epithelial 
cells no longer occurs, allowing transmission of free, infectious metacyclic 
promastigotes during bloodmeal feeding. In addition, elongated LPG results in a 
thickened glycocalyx to prevent complement mediated lysis. The establishment 
of intracellular infection is facilitated by the release of additional components 
derived from the sand fly vector into the infection site. These include the PSG, 
which is regurgitated at the bite site, leading to the active recruitment of 
macrophage and the synthesis of compounds essential for intracellular growth 
(Rogers et al. 2009). The role of sand fly saliva in enhancing virulence is 
reviewed by Gomes & Oliveira (2012), with vasodilation and anti-inflammatory 
properties of salivary peptides such as maxadilan contributing to the 
establishment of disease. In contrast, pre-exposure to sand fly saliva derived 
protein has been cited as a potential mediator for induction of host immunity to 
L. chagasi, whereby immunisation of dogs with recombinant salivary gland 
proteins induced a Th1 response, leading to enhanced lymphocyte mediated 
parasite killing (Collin et al. 2009). Once intracellular infection is established, 
the differentiation to immotile amastigotes occurs inside the acidic 
phagolysosomal compartment, with decreased pH and increased temperature 
the external cues for this event (Alexander et al. 1999). Replication of this cell 
cycle stage and lack of an appropriate host immune response results in the 
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manifestation of lesions or dissemination to visceral organs, and the 
maintenance of infection.  
1.2 An understanding of the immune response to 
Leishmania infection; implications on therapeutic 
design 
The survival of Leishmania as an intracellular pathogen is dependent on its 
ability to modulate and disrupt an appropriate host immune response. The 
immense complexity of the host-parasite interactions taking place during 
infection have become explained in more detail by the use of murine models of 
infection, with ever increasingly sophisticated methods to image, manipulate 
and analyse the resulting immune response (Peters 2008; Ng et al. 2008; Hurrell 
et al. 2015a). Such studies have been amenable by the genetic manipulation of 
Leishmania to generate transgenic reporter lines, whilst virulence factor 
deficient mutants enable the dissection of how the parasites directly modulate 
the immune response (Beattie et al. 2008). All these efforts are conducted to 
identify the crucial factors in mediating immunity to Leishmania infection. As 
the immune response is so closely linked to disease outcome, the development 
of appropriate chemotherapy to treat leishmaniasis necessitates an evaluation of 
the influence on the immune response.  
1.2.1 Murine models for studying cutaneous leishmaniasis in vivo 
1.2.1.1 Establishing the Th1/Th2 paradigm 
Animal models of human leishmaniasis have been utilised since the infection of 
L. infantum in dogs in 1909 by Nicolle and Comte, with subsequent use of 
hamster, mouse, Guinea-pig and even monkey models throughout the 20th 
century (Bryceson et al. 1970). Such studies showed the necessity of lymphocyte 
transformation and the release of lymphokine factors in the resolution of 
Leishmania infection. It was not until 1987 that Locksley et al.  showed that 
resistance was correlated to the expansion of phenotypically distinct CD4+ T 
cells. This conclusion was drawn from a series of experiments using murine 
models of L. major infection, and today the majority of studies at present utilise 
experimental mouse models. The use of murine models of L. major infection has 
facilitated in depth analysis of the T helper (Th) cell paradigm, revealing that 
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infection resolution is dependent on the activation and differentiation of CD4+ T 
cells to inflammatory, Th1 producers of interleukin-12 (IL-12) and interferon-
gamma (IFN-γ) to drive cell-mediated killing of intracellular amastigotes by iNOS 
production (Constantinescu et al. 1998). In this Th1 context, comparisons 
between protective immune responses in C57BL/6 or C3H mice, and susceptible, 
chronically infected BALB/c infected mice have enabled dissection of the 
importance of particular cellular subsets in mediating an appropriate immune 
response. The susceptibility or resistance to infection in these models is related 
to their cytokine profiles; resistant C57BL/6 and C3H mice express cytokines 
such as IL-2, IL-12 and IFN-Y which drive a cell mediated immune response and 
are implicated in disease resolution (Heinzel et al. 1991). The timings of such 
expression can have an impact on disease resolution, as IL-12 production appears 
crucial only during the early development of a Th1 response whereas IFN-Y is 
necessary for parasite clearance throughout (Constantinescu et al. 1998). In 
contrast, BALB/c mice produce a Th2 response upon infection with expression of 
IL-4, IL-5 and IL-10 (Heinzel et al. 1991). C57BL/6 mice can become 
immunocomprimised by physiological manipulation as exemplified by C57BL/6 
mice deficient in skin draining lymph nodes being unable to develop a Th1 
response to L. major infection (Ehrchen et al. 2008). Further use of mice 
deficient in inflammatory cytokines has established their importance for disease 
resolution (Belkaid et al. 2000),. By direct comparisons in these animal models, 
the development of immunity to Leishmania reveals important stages in an 
adaptive response.  
1.2.1.2 Advanced in vivo imaging techniques 
Murine models are desirable for the study of host-parasite interactions in vivo as 
the complexity of the host parasite interface is difficult to reproduce using 
reductionist in vitro methods (Filipe-Santos et al. 2009). Sophisticated methods 
to track fluorescent immune cell migration by intravital multi-photon laser 
scanning microscopy (MPLSM) imaging at both the ear and draining lymph node 
(Gibson et al. 2012), or the use of transgenic, photo-switchable ‘Kaede’ mice 
(Tomura et al. 2008) enable the dissection of the immune response in a 
relevant, in vivo context. MPLSM has enabled the study of interactions of 
Leishmania with cells such as neutrophils or dermal dendritic cells which 
represent intracellular niches for the establishment of infection (Ng et al. 2008; 
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Peters & Sacks 2009; Hurrell et al. 2015a). The resolution of Leishmania 
infection is understood in the context of cytokine expression as a result of T cell 
differentiation; yet the induction of this response is ill-defined in regards to 
immune cell motility, clustering behaviour and the formation of immunological 
synapse between T cells and DC. Evidence for impaired immunity resulting from 
reduced DC-T cell interactions and co-stimulation has been presented during 
malaria infection of mice (Millington et al. 2007), with the application to 
Leishmania having important implications for the future.  
Such analyses are dependent on murine models, yet there exist important 
differences between humans and mice such as T helper cell differentiation, 
cytokine types and their receptors (Mestas & Hughes 2004) which must be 
considered when translating the results obtained by murine infection into useful 
data for human disease resolution. Despite this, mouse models for Leishmania 
infections are an important tool for studying both the immune response in ever 
increasing detail. The application of in vivo models are indispensable for the 
testing of effective therapeutics for translation into the treatment of human 
leishmaniasis. A limitation of in vivo approaches has always been the use of live 
animals as test subjects, however the adoption of new methods to facilitate 
more efficacious, longitudinal study is easing this burden. In this regard, the 
generation of bioluminescent reporter lines represents a sophisticated method to 
measure the outcome of treatment whilst reducing the number of necessary test 
subjects (Millington et al. 2010), thereby facilitating the study of host-parasite 
interactions.  
1.2.2 The immune response to Leishmania infection 
The use of murine infection models has advanced the study of Leishmania 
infection from the simple Th1/Th2 paradigm, to identifying how distinct cell 
subsets contribute to the resolution or susceptibility to infection site. The major 
immune cell subsets and immune mediators which have been studied in the 
context of Leishmania infection are summarised below.  
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1.2.2.1 The complement system 
Immediately following inoculation into the mammalian host, extracellular 
metacyclic promastigotes must evade complement mediated lysis. Opsonins are 
soluble peptides which bind to microorganisms and represent the main arm of 
the complement system. The opsonin C3 which is cleaved to C3b and mediates 
phagocytosis by binding to the cell surface of extracellular microorganisms, 
which are subsequently recognised by the complement receptors, such as CR1 
and CR3 present on the surface of phagocytes (Da Silva et al. 1989). Leishmania 
metacyclic promastigotes are bound by C3b, but the expression of gp63 on their 
surface catalyses the cleavage of C3b to inactive C3b (iC3b) (Figure 1:3); iC3b is 
still recognised by CR1 to induce phagocytosis results in an impaired cytotoxic 
activity (Brittingham et al. 1995). In addition, the LPG coat expressed on the 
surface of metacyclic promastiogtes is elongated by the addition of 
phosphorylated disaccharide repeat units (Sacks et al. 1995), acting as a barrier 
to prevent the insertion of a C3b attack complex. LPG has been identified as a 
virulence factor by generation of LPG null mutants though gene replacement 
(Späth et al. 2003) and by protein destabilisation (Madeira da Silva et al. 2009). 
Expression of LPG is necessary to prevent complement mediated lysis by a C5b-
C9 membrane attack complex (MAC) which forms pores in the microbial cell 
surface. By expression of these virulence factors, Leishmania mediate entry into 
phagocytes without eliciting an appropriate response.  
1.2.2.2 Skin resident cells; keratinocytes and dermal dendritic cells 
The interaction between Leishmania parasites and host immune cells occurs 
immediately upon taking a blood meal as the proboscis of the sand fly damages 
the tissue surrounding the site of injection causing an inflammatory response 
(Peters et al, 2008). As the metacyclic promastigotes are regurgitated into the 
host they move through the skin and primarily encounter a variety of resident 
immune cells such as dermal macrophages and non-immune epithelial 
keratinocytes. Experimentation with cutaneous L. major infections of 
experimental mice by Ehrchen et al. (2010) revealed that keratinocytes in 
particular may be particularly important at releasing immunomodulatory 
cytokines such as IL-4 and IL-6 early in infection (Figure 1:3). This initial release 
was shown to be crucial at driving the direction of T helper cell differentiation 
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to a Type 1 response which has long been shown to help confer resistance to 
Leishmania infection (Locksley et al. 1987).  
At this early stage of infection, dermal dendritic cells (DDC) also play an 
important defensive role by actively capturing Leishmania cells. This was only 
discovered by the use of in vivo 2-photon imaging of such cells by Ng et al. 
(2008), who observed in real-time that DDC act as gatekeepers, patrolling the 
dermal interstitial space until encountering L. major at which point they become 
sessile, conventionally DC shaped and actively capture and internalise the 
parasites with elongated pseudopodia. 
1.2.2.3 The interaction of Leishmania and neutrophils 
Neutrophils are the most rapid responders to the tissue damage caused by 
feeding, with substantial accumulation occurring a few hours following 
inoculation (Peters et al. 2008). Neutrophils circulate in the blood vasculature 
and extravasate in response to skin inflammation through dermal vessels. 
Extravasation is driven by the release of chemokine (C-X-C motif) ligands 1 and 2 
(CXCL1, CXCL2) by macrophages (Racoosin & Beverley 1997), and interleukin 4 
and 6 release by keratinocytes (Ehrchen et al. 2010), in addition to parasite 
factors. Neutrophils play a key role in the killing of microorganisms by 
phagocytosis and subsequent lysis by the production of radical oxygen species, 
such as inducible nitric oxide synthase (iNOS) and the release of cytotoxic, 
antimicrobial granules (Faurschou & Borregaard 2003). However, Leishmania 
evade such intracellular lysis, remaining viable for extended periods within 
neutrophils in vivo (Laufs et al. 2002). As neutrophils compose the majority 
population of responding cells at the infection site (Peters et al. 2008), these 
represent an abundant intracellular initial niche for metacyclic parasites. 
Leishmania are primed to mediate an immunologically ‘silent’ entry into 
neutrophil before a blood meal is taken through the build up of apoptic 
promastigotes in the sand fly vector. When immune cells such as neutrophils 
encounter apoptic markers on the promastigotes cell surfaces, they release anti-
inflammatory cytokine TGF-β as apoptotic cells pose no infection risk. The result 
of this is that the infective, live parasites are shielded from an inflammatory 
response by oxidative burst and degranulation (Ritter et al. 2009). The presence 
of PSG is important at this stage by enhancing neutrophil recruitment to the bite 
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site, thereby allowing parasite uptake. Infected neutrophils undergo delayed 
apoptosis, resulting in their uptake along with intracellular parasites by 
macrophage and dendritic cells in the absence of an inflammatory response (van 
Zandbergen et al. 2004). To further avoid cell death once inside the neutrophils, 
L. major prevent the fusion of lysosomal vesicles with the parasitophorous 
vacuole (Mollinedo et al. 2010). Neutrophil mediated L. donovani lysis is shown 
to be avoided by the lipophosphoglycan (LPG) which massively inhibits the fusion 
of lysosomal vesicles to parasitophorous vacuoles containing Wt parasites 
compared to mutants with reduced levels of LPG forming enzymes (Gueirard et 
al. 2008). It is important to note that the role of LPG in neutrophils differ 
between species of Leishmania (Beattie et al. 2008). Leishmania parasites 
appear to manipulate neutrophil uptake by macrophage as an immunologically 
silent route of entry, using neutrophils as ‘Trojan Horses’.  
 
Figure 1:3- The early immune response to Leishmania infection. Tissue damage caused by 
inoculation through the epidermis and dermis causes the release of IL-4 and IL-6 from 
keratinocytes to drive the extravasation of neutrophil from the circulating blood to the infection site. 
These are the first host cells for Leishmania metacyclic promastigotes, which avoid complement 
mediated lysis by the C5b-C9 attack complex through LPG expression or C3b complement binding 
through cleavage of C3b to inactive C3b by gp63. The promastigote secretory gel (PSG) induces 
increased recruitment of macrophage to the bite site, which subsequently take up apoptopic 
neutrophil containing viable Leishmania (‘Trojan Horse’) or by uptake of live promastigotes 
alongside neutrophil particulate (‘Trojan Rabbit’).  
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To establish the dynamics of neutrophil recruitment and parasite entry into 
these cells, the infection site was imaged in vivo using 2-photon intravital 
microscopy (Peters et al. 2008). Following ear infection with transgenic RFP 
reporter L. major, extracellular promastigotes were immotile in the dermis, 
resulting in sequestration by increasing numbers of neutrophils. Despite the 
presence of viable, intracellular Leishmania, neutrophils became less motile and 
underwent apoptosis, with some parasites escaping the neutrophils before 
complete apoptosis had occurred (Peters et al. 2008). Such a situation has been 
hypothesised by Ritter et al. (2009) as a potential ‘Trojan rabbit’ route of entry, 
whereby macrophage engulf apoptic neutrophils and free promastigotes at the 
same time (Figure 1:3). By imaging the process in vivo, (Peters et al. 2008) 
confirmed active entry of L. major into neutrophils in real time, the subsequent 
reduction of infected neutrophils and importantly an increase in the number of 
infected macrophages over time. By this method they established this entry 
mechanism manipulation of the host immune cells as a ‘Trojan’ route of 
infection. They also demonstrated that reduction in the number of viable 
parasites and therefore virulence could be achieved by inhibiting neutrophils 
binding via antibodies, further demonstrating the key role of neutrophils in 
initiating Leishmania infection. A more recent study by Hurrell et al. (2015) 
provides further evidence of the inhibitory role neutrophils play in the resolution 
of Leishmania infections. L. mexicana infections of Genista mice deficient in 
mature neutrophils resolve lesions by 8 weeks by the induction of an 
inflammatory, Th1 response. By 2-photon imaging, an increased recruitment of 
DC to the infection site in neutrophil depleted mice was observed, resulting in 
the subsequent recruitment of monocytes and monocyte-derived DC to the 
infection site, and migration to the draining lymph node. This comprehensive 
study provides compelling evidence for neutrophils as mediating an 
inappropriate immune response, and serves as an example of how by viewing 
interactions in vivo, in vitro studies can be confirmed, new dynamics discovered 
and the groundwork required for development of therapeutics can be laid.  
Neutrophils have recently been demonstrated as eliciting a more complex 
method of targeting invading Leishmania compared with phagocytosis. 
Inflammatory neutrophils recruited to the site of infection release DNA, elastase 
and histone to produce extracellular ‘traps’ (NETs) to ensnare and kill 
  35 
 
amastigotes. DNAse treatment of NETs formed in response to L. amazonensis 
infection causes increased pathogenicity, suggestive of an inhibitory role of 
these structures (Guimarães-Costa et al. 2009). NETs are also formed in response 
to L. mexicana infection, but in contrast the parasites are able to survive NET 
mediated killing both in vivo and in vitro (Hurrell et al. 2015a). The absence of 
L. mexicana to NET-mediated killing is suggestive of a differential mechanism of 
immune-evasion, and the role of virulence factors such as inhibitors of serine 
peptidases (ISP) in conferring resistance is an important area of research 
(Eschenlauer et al. 2009), particularly because ISP1 has been shown to inhibit 
neutrophil elastase, a chief component of NETs (Morrison et al. 2012).    
1.2.2.4 Leishmania interactions with macrophage 
Macrophages play a crucial role in the completion of the Leishmania life cycle as 
they are the predominant intracellular niche for long term parasite growth (Kaye 
& Scott 2011). Recruitment of monocyte derived macrophage (mo-MΦ) is driven 
by the expression of CCL3 and CCL4 by infiltrating neutrophils, with Leishmania 
infection resulting in substantial levels of MΦ recruitment (van Zandbergen et al. 
2004). Entry of MΦ by promastigotes via the ‘Trojan Horse’, ‘Trojan Rabbit’ or 
by direct uptake results in the formation of a parasitophorous vacuole (PV) 
(Figure 1:3). This is formed by the fusion of a phagosome with endosomes and 
lysosomes containing antimicrobial hydrolases. In addition the PV is acidic, yet 
intracellular Leishmania survive in this environment by inhibiting the production 
of reactive oxygen species and impairing the development of oxidative enzymes 
(Moradin & Descoteaux 2012). Upon macrophage uptake, many species of 
Leishmania have evolved the means to manipulate macrophage cytokine 
signalling. Cleavage of the NF-кB subunit p65RelA, a potent transcriptional 
activator to p35RelA by gp63 alters macrophage transcriptional regulation, 
resulting in altered cytokine expression (Gregory et al. 2008). L. mexicana 
parasites have also been shown to use cysteine peptidase B (CPB) to inhibit the 
release of IL-12 by modulating Nf-кB signalling, thereby preventing a T helper 
type 1 response (Cameron et al. 2004). Interestingly, the recruitment of 
macrophages can also be enhanced at the bite site via PSG, and the responding 
macrophages are enhanced in their production of polyamines which are essential 
to intracellular parasitic growth (Rogers et al. 2009). Once differentiated to 
amastigotes, subsequent internalisation by macrophage is driven by the binding 
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of IgG opsonisation of L. mexicana and subsequent uptake by macrophage via the 
invariant Fcγ receptors. Uptake of parasites by this process results in the release 
of IL-10 and IL-12. Infection of mice lacking antibody production results in 
reduced lesion development, indicating the necessity of antibody to exacerbate 
disease (Kima et al. 2000). By such immune modulation, the parasites establish 
an amenable intracellular niche. 
1.2.2.5 Dendritic cells are important mediators of Leishmania resistance 
The impact of dendritic cell signalling and antigen presentation is being studied 
in increasing depth. DCs are ‘professional’ antigen presenting cells (APC) which 
drive T cell priming and development of an appropriate adaptive immune 
response at the draining lymph node, as evidenced by the depletion of DCs 
during immunisation abrogates subsequent LN hypertrophy (Webster et al. 2006). 
By driving an adaptive immune response by this mechanism, DCs have a crucial 
role as mediators between the innate and adaptive arms of the immune 
response, and as a consequence are implicated as important intermediaries of 
immunity to Leishmania infection. Key to this is the importance of an 
appropriate Th1 mediated response originating from the draining lymph node. 
This is evidenced by the work of Ehrchen et al. (2008), where the absence of 
cutaneous lymph nodes draining the site of L. major infection prevented the 
development of an appropriate Th1 response in the resistant C57BL/6 infection 
model. Therefore clearance of Leishmania at the infection site is dependent on 
the migration of DC to the draining LN (Figure 1:4a).  
DC migration from the skin is driven by the increased expression of the 
chemokine receptor 7 (CCR7) on the cell surface, as demonstrated by loss of 
lymph node migration in CCR7 null mice (Tal et al. 2011). Once DCs are 
activated, the increased expression of CCR7 on their cell surface enables binding 
of chemokine ligand 21 (CCL21) at localised regions on lymphatic vessels. DCs 
rapidly enter lymphatic vessels by passing through endothelial flap valves 
located on the basement membrane and into the lumen (Pflicke & Sixt 2009), 
where they subsequently migrate to the draining lymph node through the 
lymphatics. DCs induce lymph node expansion by initiating vascular growth to 
increase the influx of circulating cells (Webster et al. 2006), whilst also 
presenting parasite antigen to in fluxing naïve CD4+ T cells to induce an 
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appropriate T cell response. In L. major infection of resistant C57BL/6 mice, the 
CCR7 dependent migration of DCs to the dLN is regulated by the expression of 
toll-like receptor 9 (TLR9) on the cell surface of non-infected, ‘bystander’ DC 
(Carvalho et al. 2012). It is not known how these uninfected cells detect the 
presence of parasites to up regulate TLR9, but loss of TLR9 expression on these 
DCs prevents subsequent upregulation of CCR7, thereby inhibiting migration to 
the dLN and resulting in non-resolving L. major infection.  
The role of infiltrating, monocyte-derived dendritic cells (mo-DC) in mediating 
resistance to Leishmania infection is an expanding area of research (Ribeiro-
Gomes et al. 2012; Petritus et al. 2012; Hurrell et al. 2015a). Blood circulating 
monocytes are formed in the bone marrow and are recruited to sites of 
inflammation in particular foci such as infected skin, or expanded lymphoid 
organs. During L. major skin infections of C57BL/6 mice, infiltrating monocytes 
undergo de novo differentiation to mo-DC in both the dermis and dLN (León et 
al. 2007) (Figure 1:4a). In resolving C57BL/6 infections with L. major, mo-DC 
differentiation occurs at the same rate as in susceptible L. mexicana infections, 
but the overall increased recruitment of monocytes to L. major infections results 
in a significant population of these cells at the infection site early in infection 
(Petritus et al. 2012). The increased uptake of L. major into mo-DC results in 
enhanced cellular migration to the dLN resulting in LN hypertrophy. A 
significantly lower production of iNOS is indicative of an impaired inflammatory 
response; recruitment of monocytes and iNOS production can be significantly 
increased by ablating the anti-inflammatory cytokine IL-10 from L. mexicana 
infected ears (Petritus et al. 2012). The impaired recruitment of monocytes may 
result from an early impaired neutrophil response. In the resistant C57BL/6 
model, neutrophils express high levels of CCL3 24 hours after infection to recruit 
mo-DC to the infection site (Charmoy et al. 2010). Reduced mo-DC recruitment 
is induced by the blocking of CCL3 with Evasin-1 or using CCL3 deficient mice, 
resulting in a delayed onset of an appropriate Th1 response. The significant 
reduction of recruited DCs is indicative of the role neutrophils play in mediating 
a response, but also implicate mo-DC as important cells for driving the resolution 
of Leishmania infection.  
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1.2.2.6 CD4+ T Cells: Drivers of inflammation 
CD4+ T Cells play a crucial role in the ultimate clearing of Leishmania infections, 
in particular type 1 T helper cells (Th1) which release cytokines that cause a cell 
mediated immune response to activate phagocytosis by macrophage and clear 
invading microorganisms. In contrast, Th2 cells enable the intracellular 
pathogens to establish a chronic infection (Filipe-Santos et al, 2009). T cell 
differentiation is affected by many of the early immune interactions detailed 
above, therefore it is important to understand the effect of the early response 
as it dictates the resulting infection dynamics in terms of memory and effector 
functions (Garside and Brewer, 2010). An appropriate inflammatory response is 
the accepted prerequisite for clearance of Leishmania, with the hypertrophy of 
the draining lymph node (dLN) facilitating antigen presentation and the 
maturation of effector T cells (Carvalho et al. 2012). This process is driven by 
dendritic cells (DC), which stimulate the differentiation of CD4+ T helper 1 (Th1) 
cells by antigen presentation and release of IL-12 (Schwarz et al. 2013), which in 
turn induces expression IFN-γ by these effector T cells to mediate disease 
resolution and drive phagocyte-mediated killing of intracellular amastigotes (Hsu 
& Scott 2007). L. mexicana directly inhibits dLN hypertrophy and differentiation 
of such cells by immune mediation, as exemplified by mutants deficient in the 
multi-copy, cysteine protease B (CPB) genes unable to establish long term 
infection due to the development of a Th1 response in susceptible C3H mice 
(Buxbaum et al. 2003a). Inhibition of an appropriate inflammatory response to L. 
mexicana infection in another susceptible strain, the C57BL/6 mouse appears 
directly influenced by the production of IL-10, with its absence resulting in 
disease resolution by gene deletion (Buxbaum & Scott 2005), or by blocking with 
an αIL-10 antibody (Petritus et al. 2012). Interestingly, a recent study dissects 
this phenomenon further, showing that loss of Il-10 expression from CD4+ and 
CD8+ T cells results in an appropriate immune response, whereas loss of 
expression from macrophage and granulocytes has no effect (Buxbaum 2015).  In 
agreement with this, adoptive transfer of naïve CD3+ T cells into IL-10 deficient 
mice and subsequent L. mexicana infection did not result in increased CD4/8 T 
cell differentiation, IFN- γ production or LN expansion by 4 weeks post infection 
(Figure 1:4b), demonstrating that loss of IL-10 early in infection is not sufficient 
to induce a Th1 response (Hsu & Scott 2007). LN hypertrophy and an appropriate 
Th1 response can be initiated by inoculation of L. mexicana in combination with 
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the immuno-adjuvant CpG, a ligand for toll-like receptors 9 (TLR9) expressed on 
dendritic cells (DC) (Hsu & Scott 2007), which is necessary for the early 
resistance to L. major in C57BL/6 mice (Carvalho et al. 2012). These data 
implicate the activation and migration of professional antigen presenting cells 
such as DC in priming a CD4+ Th1 response to Leishmania infection. By 
comparing resolving L. major infections with chronic L. mexicana infections of 
C57BL/6 mice, the influence of these cells has been studied further. 
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Figure 1:4- The resolution of Leishmania infection by an inflammatory immune response. a. 
Between 24 to 48 hours post infection the infiltration of monocytes in response to CCL3 released 
by neutrophils results in the de novo differentiation of monocyte-derived dendritic cells (mo-DC). 
Phagocytosed amastigotes are killed by the release of iNOS and the mo-DC migrates to the 
draining lymph node (LN) via the lymphatic vessel to present antigen to naïve T cells. b. Following 
LN hypertrophy around 1 week post infection, antigen specific Th1 CD4+ T cells differentiate and 
migrate to the infection site where they release inflammatory cytokines such as IFN-Y. This 
adaptive immune response results in a subsequent accumulation of leukocytes such as neutrophil 
and monocytes which differentiate to mo-DC and monocyte derived macrophage (mo-MΦ). By Th1 
cell mediation, these activated phagocytes are able to induce sufficient levels of iNOS to kill the 
resident amastigotes.  
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1.3 Genetic manipulation of Leishmania 
1.3.1 Leishmania: cultured parasites 
Leishmania have many established models to study their biology and the disease 
they cause. The axenic propagation of the sand fly infective promastigotes has 
been amenable in cell culture medium for 40 years (Berens et al. 1976), whilst 
the ability to infect murine and hamster models have facilitated the studies of in 
vivo disease maintenance. Such methods have allowed the exploration of a 
variety of biological aspects of Leishmania as they move through their complex 
life cycle, such as the regulation of gene and protein expression, altered 
metabolism between host and vector and the differentiation to multiple life-
cycle stages. Given the debilitating spectrum of disease caused by these 
parasites, the founding of such robust culture methods and subsequent disease 
models paved the way for studying the basic principles of disease establishment 
with the aim of identifying novel methods to confer resistance to infection or 
appropriate disease resolution by appropriate therapeutic treatment.  
1.3.2 Homologous recombination and drug resistance selection 
Despite the established culture and disease models, the manipulation of 
Leishmania to study aspects of disease maintenance was limited. It was not until 
1990 that a method for genetically engineering Leishmania was established (Cruz 
& Beverley 1990) by exploiting the inherent propensity of Leishmania to undergo 
homologous recombination. This method relies on the cloning of gene 
replacement vectors containing a gene encoding a protein which confers 
resistance to an antibiotic, flanked by homologous regions for a target gene 
amplified from genomic DNA by PCR. Following restriction digestion and 
purification from the plasmid backbone, transfection of replicative 
promastigotes with an individual drug resistance marker allows replacement of 
the target gene (Figure 1:5a). The polycistronic expression of RNA precursors in 
Leishmania negates the need for inclusion of a promoter, and instead the 
expression of the encoded drug resistance protein by a trans-splicing reaction 
requires transgenic flanks containing a splice acceptor site (SAS) and a poly-
adenylation site (PAS) (Cruz & Beverley 1990). Such regulatory sequences are 
commonly derived from flanks amplified from the sequences surrounding the 
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tubulin, actin or dhfr genes. RNA polymerase II mediates the transcription of 
long, pre-mRNAs which become individually capped at the 5’ mini-exon ‘splice 
leader’ sequence derived from the SAS, and then poly-adenylated at the 3’ PAS 
to generate transcribed, messenger RNA (Parsons et al. 1986). Selection of drug 
resistant clones which constitutively express the resistance marker are checked 
for integration, and subsequently transfected to replace the second endogenous 
gene copy to generate null mutants for phenotypic analysis. By in vitro drug 
selection, gene replacement by integration of drug selectable markers into the 
genome results in their vertical transfer over subsequent generations. There 
exists a relatively large repertoire of drug resistance genes for application to 
clonal selection of Leishmania (Table 1-2). 
 
Encoded selectable marker  Antibiotic Reference 
 
Hygromycin phosphotransferase 
 
HYG Hygromycin B Cruz et al. 1991 
 
Neomycin phosphotransferase 
 
NEO G418 Cruz et al. 1991 
 
N-acetylglucosamine-1- 
phosphate transferase 
NAGT Tunicamycin Liu & Chang 1992 
 
Puromycin acetyltransferase 
 
PAC Puromycin 
Freedman & Beverley 
1993 
Dihhydrofolate reductase- 
thymidylate synthase 
 
DHFR-TS 
 
 
Methotrexate 
 
 
Arrebola et al. 1994 
 
 
Phleomycin resistance 
 
PHLEO 
Phleomycin/ 
Bleomycin 
Freedman & Beverley 
1993 
 
Streptothricin acetyltransferase 
 
SAT Nourseothricin Joshi et al. 1995 
 
Blasticidin deaminase 
 
BLA Blasticidin 
Goyard & Beverley 
2000 
Table 1-2- Available drug selectable markers for Leishmania genetic manipulation. 
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Leishmania have been shown to undergo intra and inter-specific genetic 
exchange in extracellular promastigotes by the crossing of heterologous drug 
resistant lines to form double drug resistant progeny in sandfly (Inbar et al. 
2013; Romano et al. 2014). In addition, the isolation of L. major and L. infantum 
hybrids provides further evidence for the propensity of Leishmania to undergo 
sexual recombination (Ravel et al. 2006). Despite this, recombination during in 
vitro culturing is infrequent and clones can be maintained by drug selective 
pressure. By this method, a vast array of genes have been investigated by null 
mutant generation to investigate a multiplicity of aspects of Leishmania biology, 
with an expanded repertoire of drug resistance markers facilitating multiple 
rounds of transfection (Table 1-2). A powerful outcome of this technique is the 
inoculation of viable, null mutant metacyclic promastigotes into murine hosts to 
establish the outcome of gene deletion in the context of virulence of the 
amastigote form. By this method, a number of encoded proteins have been 
identified as essential to survival in vivo, or which directly alter the immune 
response to Leishmania infection (Buxbaum et al. 2003a; Wang et al. 2005; 
Eschenlauer et al. 2009; Faria et al. 2011). An original proposal of this method 
was the generation of such cells whereby gene deletion of virulence factors 
(CPB) or essential components of metabolism rendered the parasites avirulent, 
thereby validating their use as prophylactics to confer resistance to subsequent 
infection; however despite their possible efficacy the safety implications of such 
a ‘live’ vaccine negate their use in humans (Beattie et al. 2008).  
Despite the efficacy of this method, the approach is limited to a ‘proof of 
principle’ approach when applied to ablate the expression genes encoding 
proteins which are essential to the viability of promastigotes. For such genes, 
replacement and selection of double drug resistant clones results in the 
generation of cells with dramatic changes in their genome structure, resulting in 
aneuploidy or tetraploidy (Cruz et al. 1993). Such genotypic plasticity in 
Leishmania has been described in ever increasing detail, with strong selection on 
the retention of the gene indicative of its essentiality. To expand this genetic 
proof further, endogenous gene replacement in the absence of altered ploidy is 
amenable by expression of an ectopic target transgene as an episome or from an 
exogenous gene locus (Figure 1:5b). This method has been applied to study a 
range of genes encoding proteins with crucial regulatory aspects of cell cycle 
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control, life cycle differentiation and organelle segregation (Wiese 1998; Paul 
Hassan et al. 2001; Wang et al. 2005; Ambit et al. 2008). This method can be 
applied further by murine infection, whereby the purification of parasites 
retaining the gene as an episome in the absence of drug selective pressure 
establishes essentiality for amastigote viability in vivo, and where conversely 
episome loss is indicative of a non-essential gene (Wang et al. 2005). The 
limitations of essential gene targeting are discussed further in section 4.1. 
 
Figure 1:5-Gene replacement by homologous recombination of drug resistance markers. a. 
Replacement of both gene loci by genes encoding drug resistance proteins (drugR) with 
appropriate 5’ splice (SAS) and 3’ polyadenylation sites (PAS); in this case conferred from the dhfr 
locus. FR are flanking regions homologous to the target gene locus. b. Replacement of essential 
genes necessitates the expression of an episomal copy on a plasmid before endogenous gene 
replacement.   
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being addressed; for example the generation of clones expressing high levels of 
fluorescent protein enables multi-photon laser scanning microscopy (MPLSM) of 
infection sites allows detection of the invasion of particular subsets of host 
immune cells by metacyclic promastigotes (Peters et al. 2008; Ng et al. 2008), 
by fluorescence detection of intracellular amastigotes, an appropriate 
fluorochrome-conjugated antibody panel permits phenotyping of infected 
immune cells by flow cytometry (Ribeiro-Gomes et al. 2012; Hurrell et al. 
2015a). Such studies implicate particular cell subsets in mediating the immune 
response to Leishmania infection, whereas the generation of parasites 
expressing bioluminescent protein enables the tracking of infection in the 
context of parasite burden and dissemination within the whole host (Michel et 
al. 2011). Assessing parasite burden by detection of the light signal emitting 
from the infected mouse is a powerful approach for testing of novel chemical 
entities for anti-parasitic activity in vivo. This method circumvents the need to 
assess parasite burden by the lengthy, labour intensive approach of limiting 
dilution until a ‘hit’ has first being validated by loss of emitted light. These 
distinct approaches have their own limitations in regards to the limitations of in 
vivo signal detection, therefore the generation of reporter lines has a range of 
advantageous applications in the assessment of leishmaniasis, as reviewed by 
Millington et al. (2010). 
1.3.4 Exploiting homologous recombination for manipulating 
Leishmania; advanced molecular tools 
The process of transgene transfection and selection of drug resistant parasites 
has been greatly enhanced by an expanded repertoire of drug resistance markers 
and increasingly efficient transfection techniques. In parallel, methods to 
manipulate the expression of Leishmania genes to probe their function have also 
advanced from the original gene replacement strategy (Cruz & Beverley 1990). 
The main limitation of this approach is the inability to regulate gene expression 
in a conditional manner, with a general aim of more recently developed 
molecular approaches to regulate the expression of the target gene, transcript 
or protein. Conditional regulation of the molecular target is a desirable tool to 
probe the function of said target by its inducible loss or gain of expression, 
permitting analysis of the resulting phenotype by appropriate assays. The 
implications of such a tool and the development of a method to conditionally 
  46 
 
delete essential genes in Leishmania is discussed in more depth in chapters 4 
and 5. This introduction will focus on discussing the existing molecular toolkit 
for regulating gene and protein expression in Leishmania.  
 
 
Figure 1:6- The current molecular toolkit for regulation of Leishmania gene, transcript and 
protein expression. a. Destabilisation domain enables expression of a dd-conjugated protein 
expressed by 1. open reading frame (ORF) transgene integration and replacement at the 
endogenous locus or 2. episomal expression and subsequent endogenous gene deletion. The 
translated protein is regulated by the stabilising ligand Shield-1 (Shld-1). b. Functional RNAi 
pathway in L. (Viannia) enables targeting of mRNA by integration of an RNAi targeting sequence 
(TS) into a ribosomal small subunit (SSU) integrative construct. Transfection of the stem-loop 
construct generates dsRNA by transcription from the ribosomal RNA (rRNA) promotor. Dicer-like 
(DCL) enzymes process the TS dsRNA into siRNA duplexes that are processed into single 
stranded siRNA by Argonaute (AGO1) and loaded to form the RNA-induced silencing complex 
(RISC). c. Plasmid shuffle utilises episomal expression of a target gene in array with the negative 
selectable thymidine kinase (TK) and positive markers for green fluorescent protein (GFP) and 
drug resistance (drugR). Transgene complementation (i) enables deletion of endogenous gene 
copies and ganciclovir (GCV) treatment induces selection for plasmid retention and the expression 
of GFP if essential or loss of expression if non-essential. A fourth round of complementation with a 
mutated version of the target gene ORF (MUT) (ii) enables the identification of active residues 
within the encoded protein. By GCV negative selection, retention of the ORF and GFP expression 
is indicative of a deleterious mutation which prevents active protein expression. In contrast, loss of 
the non-mutated ORF by inducible complementation the MUT gene identifies a functional mutated 
protein.  
The development of molecular tools in Leishmania as alternatives to gene 
replacement have had variable success. Some of the main approaches which 
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have contributed to the expanding toolkit will be discussed below, summarised 
in Table 1 and depicted in Figure 1:6. 
1.3.4.1 Destabilisation domain 
An approach to regulate protein expression by conferring inducible stability 
involves the linkage of a target protein to a regulatory, destabilisation domain 
(DD) derived and modified from an FKBP domain (Banaszynski et al. 2006). 
Protein stability and therefore activity is conferred by Shld-1 addition. This 
approach was utilized effectively in L. braziliensis promastigotes by Madeira da 
Silva et al. (2009) to stabilise a variety of target proteins such as yellow 
fluorescent protein (YFP), luciferase (LUC) and components of the C1 carbon 
metabolism pathway formate tetrahyrofolate ligase (FTL) and  5,10-
methenyltetrahydrofolate cyclohydrolase/5,10-methylene tetrahydrofolate 
dehydrogenase (DHCH). These manipulations were as proof of principle to 
establish the efficacy of ligand mediated protein stabilisation, with expansion of 
the technique facilitating the regulation of the key surface glycoprotein LPG to 
be regulated. By integration of a ddGLF construct into a homozygous, glf- null 
mutant L. major line, stability of a dd conjugated UDP-galactopyranose mutase 
(ddUGM) was conferrable by Shld-1 treatment, with removal of Shld-1 rapidly 
resulting in the inducible susceptibility to complement mediated lysis by 
expression of LPG truncated in the glycan region. Attempts to complement 
Leishmania with dd-conjugated proteins and generate essential gene null 
mutants has proven difficult. Personal communication suggests that the use of 
this technique can result in regulation of the stability of essential genes such as 
FTL and DHCH, yet a copy of the endogenous gene remains by selective pressure 
to retain expression of the endogenous protein lacking a dd domain. Such issues 
may arise by the relatively large size of the dd fusion tag, as protein tagging 
with even small epitopes such as 6xHis can result in altered biochemical 
properties (Wu & Filutowicz 1999), thereby repressing enzymatic activity at key 
residues at either protein terminus.  
In addition, one could speculate that the process of 20S proteosomal degradation 
or endoplasmic reticule dependent turnover in Leishmania necessitates the 
target protein being trafficked to the cytoplasm (Robertson 1999), however if a 
protein functions as part of a complex inside a distinct cellular compartment, 
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such as the nuclear membrane, then the degradative process following 
destabilisation would be delayed. An absence of published studies where the dd 
is utilised to functionally assess even non-essential factors is a likely outcome of 
the inherent difficulties in manipulating Leishmania, particularly when 
regulating the expression of proteins which are essential to their survival. 
Table 1-3- Development and application of the expanding Leishmania molecular toolkit. Bold 
font represents the key target(s) being manipulated, transgenic reporter for proof of principle 
analysis are underlined and normal font represents targets which were not fully assessed or were 
inefficiently knocked down. 
Molecular 
method 
Molecular 
target(s) 
Application Reference 
Protein 
destabilization 
domain (dd) 
 
UGM, YFP, 
LUC, FTL,  
DHCH1 
 
Conditional stabilisation of the precursor 
required for biosynthesis of the virulence 
factor LPG in L. major 
 
 
(Madeira da Silva et 
al. 2009) 
 
 
Small inhibitory 
RNA interference 
(RNAi) 
 
 
PFR1, PFR2, 
AGO1, GFP, 
LPG1, LPG2, 
LPG3, HGPRT, 
LUC 
 
 
Efficient knockdown of paraflagellar rod 
proteins and an essential component of the 
RNA pathway in L. braziliensis 
 
(Lye et al. 2010) 
 
 
 
 
 
 
 
Plasmid  
Shuffle 
 
DHCH1 
 
STI1 
 
 
 
MPK4 
 
 
 
 
CYP51 
 
 
 
 
NMT 
 
Confirming essentiality in L. major 
 
Confirming essentiality in L. donovani, 
application to generate partial null mutants 
to probe essential phosphorylation sites  
 
Confirming essentiality in L. major; 
application to generate partial null mutants 
with altered differentiation phenotypes and 
impaired infectivity 
 
Confirming essentiality in L. donovani; 
application to generate enhance sensitivity 
to inhibitors of the sterol biosynthesis 
pathway by CYP51 deficiency 
 
Establishment of essentiality by murine 
infection of L. donovani 
 
(Murta et al. 2009) 
 
(M. a. Morales et al. 
2010) 
 
 
(Dacher et al. 2014) 
 
 
 
 
(McCall et al. 2015) 
 
 
 
 
(Paape, unpublished 
data) 
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1.3.4.2 RNA interference 
RNA interference (RNAi) is an established and useful tool for regulating the 
expression of protein at the transcript level which was rapidly utilized in the 
kinetoplastid T. brucei following its discovery over 17 years ago (Ngô et al. 
1998). The RNAi pathway functions by the expression of Dicer-like enzymes DCL1 
and 2 which process long dsRNA into small, double stranded duplexes. dsRNA is 
‘sliced’ into single stranded siRNA and loaded as a guide sequence by Argonaute 
enzyme mediated processing, forming the RNA-inducing silencing complex (RISC) 
to degrade full length transcript (Kolev et al. 2011). Exploitation of this inherent 
biological pathway has enabled conditional transcript knockdown by inducible 
stem loop formation, resulting in its application to powerful, high-throughput 
studies of gene function in a variety of T. brucei screens (discussed further in 
chapters 3 and 5). However, knockdown by a non-inducible RNAi strategy in both 
L. major and L. donovani has no effect (Robinson & Beverley 2003) due to the 
absence of the RNAi pathway in the parasites of the Leishmania sub genus by the 
evolutionary loss of Dicer-like and Argonaute proteins (Lye et al. 2010). In 
contrast, the retention of such cellular machinery in the L. (Viannia) subgenus 
holds promise for the utilization of RNAi as a method for functional analysis of 
genes in parasite species such as L. braziliensis. RNAi was functionally assessed 
in this species by Lye et al. (2010) by electroporation of promastigotes in the 
presence of dsRNA, yielding variability in the efficacy of this method by low 
levels of knockdown against mediators of LPG expression (LPG1, LPG2, LPG3) but 
efficient reduction of the paraflagellar rod proteins (PFR1 and PFR2). An elegant 
assay was utilized to demonstrate the efficacy of RNAi; a LUC reporter line 
containing a stem loop construct to degrade LUC transcript was transfected with 
a second stem loop construct targeting Argonaute, the protein mediating the 
‘slicing’ of dsRNA to siRNA (Figure 2ii), thereby recovering the bioluminescent 
signal due to loss of Argonaute mediated RISC formation. Despite this assay, the 
highly variable levels of RNAi knockdown elicited for non-essential transcript is 
challenging, whilst the absence of an inducible method for dsRNA generation 
limits the approach to non-essential targets. In addition, data presented at the 
recent Kinetoplastid Molecular Cell Biology meeting (Lye et al, unpublished data) 
show that efficient RNAi relies on large (>250nt) stem loop constructs that are 
necessary for efficient knockdown, with such large fragments generated 
increasing the potential for ‘off target’ effects, whilst the observed 
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accumulation of extremely high levels of target siRNA may also contribute to 
such off-target effects. Yet there holds some promise for this tool, as the author 
also presents the reduced activity of quinonoid-dihydropteridine reductase 
(QDPR) by transfection with a targeting stem loop construct, a previously 
challenging factor to genetically regulate due to its genomic location between 
two encoded genes in a multiple, tandem array (Lye et al. 2002). The limited 
application of RNAi to the L. (Viannia) subgenus, in addition to its variability in 
knockdown and poor utilization since 2009 necessitates its optimization, and 
additional approaches for regulation of endogenous Leishmania factors are 
necessary.  
1.3.4.3 Plasmid shuffle 
Complementation of an essential gene with a transgene is necessary to replace 
the endogenous gene copies without altering ploidy, thereby implicating the 
encoded product as essential. This criteria was deemed suitable for assessing a 
gene as essential, however a more stringent approach to test this has been 
adapted from fission yeast (Kiely et al. 2000) for use in Leishmania. This 
‘plasmid shuffle’ methodology expands on episomal complementation to confer 
negative selection against expression of the transgene; expression in array with 
a thymidine kinase (TK) ‘suicide’ cassette confers sensitivity to ganclicovir (GCV) 
(Murta et al. 2009). Active TK synthesises GCV into the toxic metabolite GCV 
triphosphate which inhibits DNA synthesis (Barese et al. 2012) leading to the 
Leishmania cellular stress (LeBowitz et al. 1992), thereby exerting strong 
selective pressure on the loss of the plasmid. The inclusion of positive marker 
cassettes for drug resistance and green fluorescent protein (GFP) facilitate 
clonal selection and downstream gene expression analysis (Figure 1:6). By this 
method, a negative selection line can be generated by episomal 
complementation and subsequent endogenous gene replacement. Murta et al. 
(2009) validated the essentiality of the DHCH gene encoding a dual-function 
protein involved in 10-Formyl-THF metabolism which was previously targeted by 
dd-tagging (Madeira da Silva et al. 2009) and implicated as necessary for 
survival. Negative selection was induced by 24 hour GCV treatment, followed by 
clonal selection in 96 well plates and subsequent FACs analysis, leading to a 
substantial proportion of resulting populations (478 GFP+ out of 672 measured) 
retaining high levels of GFP expression, and therefore expression of the DHCH 
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protein. A benefit of this strategy was the high number of individual populations 
analysed in this manner, thereby providing a robust measure of DHCH retention.  
Further application of the plasmid shuffle technique enabled the L. donovoni 
CYP51 to be identified as essential to promastigote survival by retention of the 
gene on a TK expression plasmid in the presence of GCV treatment (McCall et al. 
2015). In addition, the generation of a cell line absent in endogenous CYP51 
copies enabled the treatment of these deficient lines with an inhibitor 
developed against the T. cruzi CYP51 homologue. The increased sensitivity to 
treatment with this compound by deficient promastigotes implicates CYP51 and 
its activity in the regulation of sterol biosynthesis, thereby identifying this 
pathway as a potential mechanism by which parasite growth may be chemically 
attenuated.    
Despite the use of negative selection to confirm essentiality, this application is 
limited in respect to exploring gene function. A further development of this 
technique enables the generation of ‘partial’ essential gene null mutants for 
functional analysis of protein domains by inducible complementation (Figure 1:6 
c. ii) by loss of the TK plasmid and subsequent retention of a second plasmid 
encoding the gene yet lacking the suicide cassette (Morales et al. 2010; Dacher 
et al. 2014). The identification of active site residues encoded within Leishmania 
essential gene sequences was previously limited to yeast complementation and 
recombinant protein functional assays, therefore the application of plasmid 
shuffle for the identification of key residues within viable Leishmania represents 
an important advancement. In the first of these studies conducted by  Morales et 
al. (2010), phosphoproteomic analysis identified a complex implicated in the 
regulation of the heat-shock response elicited when promastigotes are 
inoculated into their warm-blooded mammalian host. An amastigote specific 
chaperone complex containing STI1/HOP was identified and subsequently 
manipulated by endogenous STI1 deletion in the presence of an episomal copy in 
array with the TK and GFP cassettes. By negative selection with GCV, the 
plasmid was retained and the encoded protein established as essential, however 
the authors expanded on this method to identify phosphorylation sites essential 
to the activity of STI1. This elegant approach involved the further 
complementation of the plasmid shuffle line with a second episome containing 
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an STI1 open reading frame which had undergone mutagenesis at potential 
active sites. Negative selection following complementation with five such 
mutated sequences enabled the identification of two phosphoserine residues 
essential for the function of the encoded chaperone.   
Plasmid shuffle was also applied to identify the essentiality of the gene encoding 
L. major map kinase 4 (MPK4), a protein kinase which is implicated in mediating 
differentiation through the life cycle (discussed further in chapter 6). By further 
complementation of this line with MPK4 ATP binding site mutants, partial null 
mutants were generated by GCV treatment to establish clones which replicate in 
the presence of negative selection, but have altered protein kinase activity in 
subsequent differentiation assays. Inducible complementation allowed the 
identification of K59 residue MPK4 expressing mutants which undergo increased 
metacyclic differentiation in vitro but have reduce intracellular macrophage 
survival. The development of a potentially more robust approach for such 
inducible complementation by diCre mediated inducible complementation will 
also facilitate such in situ study is discussed in Chapter 5, however Dacher et al. 
(2014) here demonstrate the further potential of plasmid shuffle.  
A final application of the plasmid shuffle approach is the in vivo confirmation of 
the essentiality of N-Myristoyltransferase (NMT) for the maintenance of murine 
infection by L. donovani (Paape, manuscript in production). This currently 
unpublished study utilises plasmid shuffle to establish the essentiality in 
amastigotes during murine infection by applying GCV treatment to L. donovani 
expressing the NMT transgene in array with TK to confer selective pressure 
during infection. NMT was previously established as essential to L. major 
promastigotes by the inability to replace all endogenous gene copies (Price et al. 
2003), therefore this important work establishes that the NMT gene is retained 
in the presence of negative selection in vivo, establishing an essential role for 
active NMT in the survival of amastigotes. This work further implicates NMT as a 
suitable drug target against the replicative amastigote stage.  
The rapid adoption of plasmid shuffle is testament to the powerful biological 
insights that can be uncovered for a target gene (Table 1-3). Its application to a 
variety of genes in different contexts represents the flexibility of plasmid shuffle 
to probe gene function. 
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1.3.5 The future of genome engineering: CRISPR/Cas9 
The CRISPR/Cas9 DNA editing methodology has been rapidly adopted by the 
scientific community since its demonstration in early 2013, with the 
comprehensive review by Sternberg & Doudna (2015) identifying 1000 
publications since that time. This huge number of studies performed in a diverse 
array of organisms opens up the potential for CRISPR/Cas9 mediated editing of 
the Leishmania genome, and the recent online publication of its application to 
the paraflagellar rod 2 (PFR2) locus to replace both loci by one round of 
transfection (Sollelis et al. 2015). The efficacy of CRISPR/Cas9 mediated 
integration was variable, however clones were obtained which were absent in 
PFR2 expression by limited dilution. The potential to ablate both copies of a 
gene in one round of selection has important implications on the study of 
Leishmania, particularly as many potentially important genes are encoded on 
supernumerary chromosomes (Rogers et al. 2011) rendering their regulation 
difficult by current methods. The study of gene dosage, a phenomenon in which 
Leishmania alter gene expression by copy number variation is implicated in drug 
resistance (Leprohon et al. 2015), virulence (Dickens, personal communication) 
and the rapid adaptation of promastigotes and amastigotes to survival in culture 
media or in vivo (Spaeth, unpublished data). The investigation of this 
phenomenon would be greatly enhanced by the potential for CRISPR/Cas9 
mediated manipulation to reduce overrepresented genes to investigate dosage 
on such significant aspects of infection.   
1.4 Protein kinases as drug targets in Leishmania 
1.4.1 Protein kinases: validated drug targets 
Protein kinases in eukaroytes (ePKs) belong to an extensive superfamily of 
homologous proteins which modulate a target substrate by the phosphorylation 
of key residues. This process of phosphorylation elicits a functional change in the 
target protein, leading to altered activity, localisation or interactions with other 
proteins. All ePKs mediate this process and share a conserved catalytic core 
involved in ATP binding and phosphoryl transfer. This ATP binding site is located 
between the N- and C-terminal domains in a deep cleft. It is composed of a 
hinge region which connects the two domains, a large, hydrophobic ‘gatekeeper’ 
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residue which controls the size of a hydrophobic, purine binding cavity. There is 
an additional activation loop or T-loop which activates protein kinase function 
following phosphorylation and translocation (Jänne et al. 2009). Activity of the 
PK is also dependent on the orientation and binding to the target substrate, as 
mediated by the recognition of a specific distal docking motif (Cheng et al. 
2011). The γ-phosphate is derived from a nuclear triphosphate, most commonly 
ATP which is covalently linked to an amino acid residue on the target protein. 
The specificity of the phosphorylated substrate is based on the protein kinase 
catalytic domain, and is a useful criteria for the categorisation of protein 
kinases; they are classified as either dual specificity serine/threonine kinases or 
protein tyrosine kinases (Hanks & Hunter 1995). The protein kinases are further 
classified into various sub-groups and families based on their catalytic domain 
sequence similarity, with the main groups being composed of AGC, CAMK, TK, 
TKL, GMGC, STE and others (Hanks & Hunter 1995). 
The human genome contains 518 predicted typical eukaryotic protein kinases 
(ePKs), composing around 2% of protein encoding genes in humans and around 2-
2.5% in yeast (Hanks 2003). Other protein kinases include the diverse, atypical 
protein kinases, which have no structural similarity to ePKs, and the lipid and 
sugar kinases that phosphorylate small molecules. ePKs mediate many aspects of 
cellular function such as proliferation and survival by phosphorylation of other 
proteins, therefore deregulation of substrate phosphorylation can impair a wide 
variety of biological functions (Cicenas & Valius 2011). Cancer therapy by protein 
kinase inhibition was therefore a desirable outcome, and competitive binding of 
small molecules to the ATP binding pocket was deemed a potential mechanism 
for ablating kinase function. However, such inhibition was deemed impossible 
due to the conservation of this active site on all protein kinases as an inhibitor of 
one ePK would lead to inhibition that of all other ePKs. In 1996, Buchdunger et 
al. challenged this dogma by the dual inhibition of an BCR-ABL protein-tyrosine 
kinase complex and the platelet-derived growth factor (PDGF) receptor tyrosine 
kinase by small molecule inhibition. Previous studies had established the 
formation of a brc-abl oncogene by chromosomal translocation, resulting in the 
expression of a constitutively active ABL tyrosine-kinase. Substrate 
phosphorylation by this PK induces the onset of chronic myelogenous leukemia 
(CML) unless activity is inhibited by treatment with the compound CGP 57148. 
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This crucial work established the basis for the first clinical trials of the kinase 
inhibitor (later termed Imatinib) in 1998 (reviewed by Druker 2004). To date, the 
use of high-throughput screening of potential kinase inhibitors, protein kinase 
crystallography and nuclear magnetic resonance (NMR) spectroscopy have 
enabled the design of specific kinase inhibitors which sit within the ATP binding 
pocket of the target PK or at allosteric sites (Jänne et al. 2009).  
This structural based approach to the design of inhibitors represents a rational 
method to specifically inhibit target PKs. To date, there are 28 inhibitors against 
single or multiple PKs which have been approved for clinical use as cancer 
therapies, with the application of targeted PK inhibitors yielding a better 
success rate than conventional chemotherapeutics (Knapp & Sundström 2014). In 
addition, the development of kinase inhibition has important implications on the 
treatment of auto-inflammatory disorders such as rheumatoid arthritis, psoriasis, 
inflammatory bowel syndrome and Crohn’s disease (Patterson et al. 2014). 
Structural studies have enabled the classification of inhibitors based on their 
binding to different regions of the ePK; type I are ATP competitive and bind the 
region occupied by the adenine ring of ATP, whilst forming hydrogen bonds with 
the hinge region. In addition, some inhibitors can occupy one of two distinct 
hydrophobic regions, the ribose region or the phosphate binding region to fix ePK 
in its active confirmation (Figure 1:7). Despite always occupying the adenine ring, 
the various regions which type I inhibitors also occupy forms the basis for 
increased selectivity over other ePKs (Liu & Gray 2006). Type II inhibitors (such 
as Imatinib) bind adjacent to the active site when the PK is inactive, thereby 
preventing subsequent conformational changes to the active form (Liu & Gray 
2006). Type III and IV inhibitors bind away from the active site to cause 
allosteric changes to the protein that directly inactivates the protein or prevents 
it from becoming activated. Such ‘target based’ drug development has yielded 
potent inhibitors and a wealth of information on the specific binding moieties of 
inhibitors, however a possible criticism of the use of such screens is focussed on 
biochemical selectivity assays as opposed to cellular assays. Inhibition of a 
recombinant or purified protein complex may identify the compound as a potent 
inhibitor, however this negates crucial biological aspects of drug inhibition such 
as cell membrane permeability and the abundance of ATP within the cell. A dual 
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approach is therefore desirable to ascertain both selectivity of an inhibitor, in 
addition to its efficacy in vivo. 
 
Figure 1:7-The mechanism of Type I ePK inhibition. The protein kinase is fixed in an active 
confirmation by Type I inhibition. Adapted from (Liu & Gray 2006). 
1.4.2 The Leishmania kinome 
The use of PK inhibitors against mammalian kinases establishes the application 
of therapeutic kinase inhibitors in other organisms. The ability to inhibit a 
specific ePK in humans opens up the possibility for the development of protein 
kinase inhibitors against parasite PKs. This represents an important area of 
research to identify lead compounds with anti-leishmanial properties by 
Leishmania specific protein kinase inhibition, thereby expanding the poor drug 
repertoire against leishmaniasis. A number of important protein kinases encoded 
by Leishmania were identified by polymerase chain reagent (PCR) amplification 
and subsequently identified as essential for parasite survival. These include 
members of the CMGC group; mitogen activated protein kinases (MAPK) and 
cyclin-dependent protein kinases (CDK). The former are implicated in the 
transduction of cellular signals to react to environmental cues such as 
temperature and pH changes (Wiese 2007; Morales et al. 2010; Cayla et al. 
N-terminal domain
C-terminal domain
Active confirmation
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2014), whereas the latter are homologues of the mammalian cdc2 kinase and are 
essential for mediating the transition through the G1 and G2/M cell cycle stages 
in procyclic promastigotes (Mottram et al. 1996; Paul Hassan et al. 2001). In 
particular, the CDK related (CRK) 3 protein has been studied extensively in terms 
of function and small molecule inhibition by recombinant protein activity 
investigation and inhibitor screens (as discussed in depth in chapter 5) (Grant et 
al. 2004; Cleghorn et al. 2011; Walker et al. 2011). Despite being a chemically 
and validated drug target in procyclic promastigotes, genetic validation has only 
been indirect by the inability to remove all copies of the gene in promastigotes, 
whilst such testing has not been applied to probe the function of this protein 
kinase during the amastigote stage of L. mexicana.  
The identification of a few PKs and much of the functional assessment was 
conducted prior to the publication of the genome for L. major in 2005 (Ivens et 
al.). This work enabled the identification of 179 ePKs and 16 atypical PKs (aPKs) 
composing the Leishmania kinome based on bioinformatic analysis and 
comparisons between the L. major, T. brucei and T. cruzi genomes (Parsons et 
al. 2005). The kinome comprises 2% of the genome as in humans, however there 
are fewer PKs encoded in the Leishmania genome and many of the human ePK 
groups are completely unrepresented in L. major (Figure 1:8), particularly the 
tyrosine kinase (TK) and tyrosine kinase-like (TKL) groups. Interestingly, the 
most abundant ePK group is the GMGC, which comprises those Leishmania PKs 
classified as CDKs and MAPKs which were studied prior to the genome 
publication alongside the glycogen synthase kinases (GSK) and CDK-like kinases 
(CLKs).  
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Figure 1:8- Comparison of L. major and human ePK classification. Adapted from (Parsons et 
al. 2005).  
Further research into the function of the protein kinome will enable the 
identification of potentially powerful regulators of the cell cycle and 
differentiation of Leishmania. Our knowledge that protein kinases are 
‘druggable‘ targets further establishes the promise of these proteins in therapy, 
whilst the expansion of unique Leishmania protein kinases holds promise for 
specific inhibition in the absence of human kinase inhibition. Advances in 
regulation of gene expression and testing of compound screens against these 
targets will potentiate the discovery of antiparasitic agents. 
1.4.3 Mining the kinome: RNAi kinome screens in T. brucei as a 
reference point for Leishmania drug target validation 
The published Leishmania kinome enables the functional analysis of other ePKs 
by the available genetic methods to establish whether the deletion of the 
encoded gene confers a suitably pronounced effect on survival to be a target for 
drug inhibition. Current methods do not exist to conduct genetic analysis in a 
high-throughput manner for Leishmania (as discussed in section 1.3), however 
the utilisation of a kinome-wide RNAi screen of 190 protein kinases in T. brucei 
has enabled the identification of protein kinases which are essential for 
proliferation of the mammalian infective bloodstream form (Jones et al. 2014). 
In addition, two protein kinases termed repressor of differentiation (RDK) 1 and 
2 were identified which regulate the differentiation of bloodstream to procyclic 
  59 
 
forms. The regulation of differentiation is a key step in maintenance of the 
parasite’s life cycle, therefore these kinases represent very interesting targets 
for inhibition to induce inappropriate cellular differentiation during infection. 
 Due to the highly conserved kinases between the kinetoplastids (Parsons et al. 
2005), the transfer of information from such a comprehensive screen to form 
rational hypotheses for functional analysis of Leishmania kinases in a more 
targeted manner is feasible. Chapter 6 of this thesis utilises this strategy to 
study a potential repressor of differentiation (RDK1) identified by kinome-wide 
screening of T. brucei for application to the L. mexicana homologue, with the 
application of this method to the other protein kinases having important 
implications in identifying proteins with a key role in regulating many aspects of 
the Leishmania life cycle.  
1.5 Project aims 
Leishmaniasis remains a considerable public health issue with the development 
of drug discovery programmes an important step in identifying novel anti-
leishmanial targets. Leishmania protein kinases are important regulators of cell 
signalling pathways. The cdc2-related protein kinase, CRK3 represents a partially 
validated drug target due to its essential function in regulating the cell cycle. 
The efficacy of protein kinase inhibition by small molecules is further evidence 
of the potential for small molecule inhibition of CRK3 as a route of therapy, yet 
our understanding of how this protein functions in the mammalian infective 
amastigote is currently limited by an absence of an existing method for inducible 
gene deletion. This prevents the regulation of gene expression during in vitro or 
in vivo infection, and is a severe limitation in assessing the protein as useful 
drug target. 
In addition, functional assessment of T. brucei kinases by RNAi has identified a 
repressor of differentiation kinase (RDK1) with a homologue of unknown function 
in L. mexicana. If implicated in regulating differentiation in the amastigote 
stage, no method exists with which to regulate gene expression during this life 
cycle stage. To further study proteins implicated as important regulators of 
amastigotes, an in vivo model to assess the onset of a productive immune 
response to L. mexicana infection would enable the study of host-parasite 
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interactions. By conditional deletion of a target gene, the result on the 
mammalian immune response to infection could be assessed.  
This projects aims to: 
1. Develop a method for conditional deletion of essential L. mexicana genes 
using the diCre system. 
2. Apply the system to conditionally delete the essential protein kinase gene 
CRK3 in vitro to assess the function of CRK3 in procyclic promastigotes 
and essentiality for in vivo infection of Balb/c mice.  
3. Generate a model for the study of immune cell recruitment to infection 
with bioluminescent L. mexicana for application in conjunction with 
inducible gene deletion. 
4. Generate a repressor of differentiation (RDK1) deficient L. mexicana cell 
line to assess a hypothetical function in regulating differentiation. 
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2 MATERIALS AND METHODS 
2.1 Bioinformatics 
2.1.1 Genome sequence retrieval 
DNA and amino acid sequences for genes of interest were retrieved from 
TriTrypDB in FASTA format (http://tritrypdb.org/tritrypdb/). TriTrypDB was also 
used to identify syntenic genes between Leishmania mexicana and Trypanosoma 
brucei and to identify the splice and poly-adenylation site locations for each 
gene of interest.  
2.1.2 Sequence manipulation and vector design 
In silico manipulation of DNA and amino acid sequences was conducted using CLC 
Genomics Workbench (CLC Bio). Features of this software allowed the design of 
oligonucleotide primers, sequence alignment, in silico cloning, restriction digest 
mapping and reverse translation of proteins. In addition, the Gateway cloning 
process was conducted in silico to design primers conferring the desired att sites 
for recombination. This software allows PFAM searches to identify protein 
domains to be carried out within it (http://pfam.sanger.ac.uk/). Sequences 
were analysed using the full PFAM library downloaded as an add-on from CLC 
Genomics plugins (http://www.clcbio.com/products/clc-genomics-workbench/). 
A number of vector fragements were designed using the CLC software and 
subsequently synthesised by Dundee Cell Products Ltd (James Lindsay Place, 
Dundee Technopole, Dundee, DD1 5JJ) or GenScript USA Inc. (860 Centennial 
Ave, Piscataway, NJ 08854, USA). 
2.2 Bacterial strains and culture 
2.2.1 E. coli strains used 
For routine transformations of ligation reactions, DH5α competent cells 
(Invitrogen) were used. This strain contains the genetic markers recA1, to 
improve insert stability and prevent unwanted recombination, and endA1, to 
improve yield and quality of plasmid DNA from minipreps. It also contains 
lacZΔM15 for blue/white colour screening of colonies. MAX efficiency DH5α 
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competent cells (Invitrogen), a strain with improved transformation efficiency, 
or OneShot® TOP10 chemically competent E. coli contining hsdR for efficient 
transformation of unmethylated DNA from PCR amplifications were used for 
transformation of Multisite Gateway reactions. For transformation of difficult 
ligation reactions, XL10-Gold Ultracompetent cells (Stratagene) were used. In 
addition to endA, recA and lacZΔM15, these bacteria exhibit the Hte phenotype, 
which increases the transformation efficiency of ligated or large supercoiled 
DNA. 
2.2.2 Transformations 
Aliquots of 50 µl competent cells were thawed on ice before adding 1 – 5 µl (1 - 
10 ng) DNA and incubating on ice for 30 min. Cells were subjected to heat shock 
for 45 sec in a 42oC water bath then incubated on ice for 2 min. 950 µl of pre-
warmed medium were added to each tube, which were then incubated for 1 
hour at 37oC with shaking at 225 rpm. ≤200 µl each transformation were plated 
out onto selective LB agar plates and incubated overnight at 37oC. For 
blue/white colour screening of ligation reaction transformations, cells were 
plated out on selective LB agar plates containing IPTG/X-Gal before overnight 
incubation at 37oC. 
2.2.3 Bacterial culture and storage 
Individual colonies of transformed bacteria were inoculated into LB broth with 
suitable antibiotic (Ampicillin 100 µg/ml; Kanamycin 50 µg/ml (Sigma)) and 
cultured overnight, to select for bacteria expressing plasmid DNA of interest, at 
37oC with shaking at 225 rpm. For long term storage of bacteria, 0.5 ml of 
culture was mixed with an equal volume of 2 % (w/v) peptone and 40 % (v/v) 
glycerol and stored at -80oC. 
2.2.4 Preparation of plasmid DNA from E. coli 
Plasmid DNA from E. coli was purified from a cell pellet harvested from 5 ml of 
LB culture using the QIAprep Spin Miniprep kit (Qiagen), following the 
manufacturer’s protocol for “QIAprep Spin Miniprep Kit Using a Microcentrifuge”. 
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2.3 Molecular Biology 
2.3.1 DNA Sequencing 
DNA sequencing was primarily performed by DNA Sequencing & Services 
(MRCPPU, College of Life Sciences, University of Dundee, Scotland, 
www.dnaseq.co.uk) using Applied Biosystems Big-Dye Ver 3.1 chemistry on an 
Applied Biosystems model 3730 automated capillary DNA sequencer. After two 
years the sequencing provider was changed to Eurofins MWG Operon (i54 
Business Park, Valiant Way, Wolverhampton, WV9 5GB) SmartSeq kit sequencing 
by cycle sequencing technology on Applied Biosystems model 3730XL DNA 
sequencer.  
2.3.2 Polymerase Chain Reaction 
Oligonucleotide primers were designed using CLC Genomics Workbench and 
synthesised by Eurofins MWG Operon (Ebersber, Germany). 
Standard PCRs such as colony PCR and PCR amplification of genomic DNA to 
identify inducible loss of a floxed gene: template DNA (100 ng genomic DNA, 
100pg plasmid DNA or bacterial inoculation), 2.5 µl of 10 x PCR mix (1.13 mg ml-1 
BSA, 450 mM Tris pH 8.8, 110 mM ammonium sulphate, 45 mM MgCl2, 68.3 mM β-
mercaptoethanol, 44 µM EDTA pH 8.0, 10 mM dCTP, 10 mM dATP, 10 mM dGTP, 
10 mM dTTP), 5 pmol of each primer, 1 unit of Taq polymerase and sterile 
distilled deionised water to a final volume of 25 µl.  Thermocycling was 
programmed for an initial denaturation step of 96°C for 5 minutes, followed by 
30 cycles of: denaturation 96°C for 30 seconds; annealing at [prmer specific Tm]  
for 30 seconds; extension at 72°C for Taq polymerase, 30 seconds per 0.5 kb of 
sequence. PCR conditions were subject to optimisation for specific primer 
pairs/templates and primer annealing temperature and elongation time were 
adjusted as required.  
For generating PCR products for Gateway cloning or molecular cloning a 
proofreading enzyme was used, in this study Phusion (New England Biolabs) was 
used exclusively due to its robustness and reliability. Phusion reactions were set 
up as follows; Phusion HF buffer at 1x (stock at 5x), each dNTP at 200 M, 
64 
 
primers at 0.5 M each, template DNA and Phusion polymerase at 0.02 U/l. 
Reactions were usually set up to 50 l. 
2.3.3 Quantification of DNA concentration and purity 
DNA concentration, given in ng ml-1, and purity were quantified on a NanoDrop 
1000 Spectrophotometer (NanoDrop), through absorption at 260 nm (A260), and 
the ratio of A260 to A280 (nucleic acids to proteins) respectively. 
2.3.4 Restriction Enzyme Digests 
All restriction endonucleases used in this study were sourced from New England 
Biolabs (NEB) and used according to the manufacturers instructions and buffers. 
For double digests, the optimum reaction buffer was checked using the Double 
Digest Finder tool (https://www.neb.com/tools-and-resources/interactive-
tools/double-digest-finder#.T0ODjfVLeU4). For restriction mapping of plasmids 
or generating fragments/backbones for cloning reactions were allowed to 
proceed for at least 20 minutes if using a time-saver enzyme prior to band 
resolution by agarose gel electrophoresis. Plasmids that were being linearized in 
10 g amounts in preparation for transfection were generally digested overnight 
in 100ul volumes to ensure complete digestion. 
2.3.5 Agarose Gel Electrophoresis 
DNA sequences in this study were analysed by agarose gel electrophoresis which 
also serves as a method for purifying DNA fragments by size. UltraPure agarose 
(Invitrogen) was dissolved in 0.5 x TBE buffer (20mM Tris, 20 mM boric acid, 
0.5mM EDTA, pH 7.2) at 1% w/v. For resolving larger fragments this was reduced 
to 0.8% w/v. After allowing the gel to cool SYBR-safe DNA stain (Invitrogen) was 
added to allow the visualization of DNA. Gels were then cast in the required size 
of gel support. DNA was prepared by addition of 6x Loading Buffer (0.25 % (w/v) 
bromophenol blue, 0.25 % (w/v) xylene cyanol FF, 30 % (v/v) glycerol, in H2O) 
and loaded into wells. Gels were run at between 80-120 V for 60 min depending 
on expected fragment sizes. For Southern blotting, 0.8% w/v gels were run at 
50V for over 5 hours to resolve the bands. Gels were imaged using a GelDoc 
(BioRad) and the associated Quantity One Software (BioRad). 
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In order to purify DNA fragments from agarose gels the DNA was visualised using 
a DarkReader blue light transilluminator, the band excised using a sterile scalpel 
blade and extracted from the agarose gel with a Gel Extraction kit (Qiagen) for 
general purposes, or a MinElute Kit (Qiagen) for more sensitive applications such 
as Gateway cloning. This was performed on a Qiacube (Qiagen) according to the 
manufacturer’s instructions. 
2.3.6 Ligations 
When molecular cloning constructs by the cohesive end technique compatible 
DNA fragments were ligated together using T4 DNA ligase (NEB) and the 10x 
Ligase Buffer supplied with it. Insert and plasmid backbone DNA fragments were 
mixed in equimolar amounts, 1:3 or 1:5 backbone:insert ratios in a 10 µl volume 
of 1xLigase buffer plus T4 DNA Ligase. These were incubated overnight at 16°C 
or room temperature for 1 hour. Some inserts were first subcloned into P-GEMT 
Easy (Promega) or PCR-Script (Stratagene) depending on the size of the insert. 
PCR-Script was typically used for inserts over 2 Kb due to its greater efficiency 
for larger inserts. 
2.3.7 Site Directed Mutagenesis 
Mutations of single bases and deletions of multiple bases were conducted using 
the Q5 Site-Directed Mutagenesis kit (NEB) according to manufacturers 
instructions. Mutagenesis primers were designed using the NEBaseChanger 
software (http://nebasechanger.neb.com). Mutations were carried out to 
remove and insert restricition sites into existing vectors such as the loxP 
pDONR221 vector. In addition, mutagenesis of the T-loop residue in CRK3 was 
conducted by this method. All mutations were checked by subsequent DNA 
sequencing (MWG Operon). 
2.3.8 MultiSite Gateway® 3-fragment vector construction 
Gene replacement vectors were generated using the Multisite Gateway three 
fragment vector construction kit (Invitrogen), following the manufacturer’s 
guidelines. The aim was to create diCre and loxP expression plasmids for specific 
integration at a target gene locus by the addition of 500bp of 5’ and 3’ gene 
flanking regions. These knockout constructs could then be transfected into 
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Leishmania to replace the target gene by homologous recombination. A detailed 
diagram of this approach is represented in section 3. The diCre and loxP vectors 
were synthesised by GenScript and subcloned into pDONR 221 vectors. attB 
primers were designed to amplify 5’ and 3’ flanking regions from L. mexicana 
genomic DNA using the primers annotated below. These amplicons were resolved 
by gel electrophoresis, and purified by Gel extraction (Qiagen). 50fmoles of each 
amplicon was used in a BP recombination reaction with 150ng of pDONR P4-P1r 
or P2R-P3, 2ul of BP clonase II enzyme mix to a final volume of 10ul with 1xTE 
buffer (10mM Tris-HCl, 1mM EDTA, pH8.0). The reaction was performed at 25°C 
for 1 hour and stopped by the addition of 2ug Proteinase K (2ug/ul in 10mM Tris-
HCl pH7.5, 20mM CaCl2, 50% glycerol) and incubation at 37°C for 10 minutes. 2µl 
of each reaction was used to transform either max-efficiency DH5a or OneShot 
TOP10 E. coli which were spread onto Kanamycin infused plates. Colony PCR was 
used to check insertion of the amplicon into the vector and integrated plasmids 
picked for mini-preparations of entry clones (Qiagen). 
The final vector was generated by combining the entry clones with either the 
diCre, loxP or drug resistance cassette pDONR221 vectors (pGL2206, 2207, 2208 
and 2209) into a final pDEST expression clone in an LR clonase mediated 
reaction. 10fmoles of each entry clone and 20fmoles of the pDEST R4-R3 vector 
II were combined in a 10µl reaction with TE buffer and 2µl of LR Clonase II Plus 
enzyme mix. The reaction was performed at 25°C overnight and stopped by the 
addition of 2ug Proteinase K and incubation at 37C for 10 minutes. 2µl of each 
reaction was used to transform either max-efficiency DH5α or OneShot TOP10 E. 
coli which were spread onto Ampicillin infused plates. Colonies were picked and 
plasmid prepared by mini-preparation (Qiagen). Restriction enzyme digest and 
sequencing was utilised to identify appropriate recombination and generation of 
gene replacement vectors.  
2.3.9 Ethanol precipitation  
To purify and concentrate DNA for transfection into Leishmania spp., a 10% 
volume of 3 M sodium acetate pH 5.2 and one volume of 100% isopropanol were 
added to the sample. The sample was centrifuged at 13 000 x g for 30 min at 4 
°C. The DNA pellet was washed in 700 µl 70% ethanol and centrifuged at 13 000 x 
g for 30 min at 4 °C. The supernatant was removed and the DNA pellet was air-
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dried in a fume hood. The DNA pellet was resuspended in 30 µl molecular grade 
water for Leishmania transfection.  
2.3.10 Southern blotting 
For analysis of L. mexicana ΔRDK1 mutants, 5 µg DNA from resistant clones were 
digested with SacI and resolved overnight on a 0.7 % agarose gel in TBE buffer at 
30 volts. The DNA in the gel was depurinated by soaking for 10 min in 0.25 M 
HCl, denatured for 15 – 30 min in denaturation solution (1.5 M NaCl, 0.5 M 
NaOH), then neutralised by soaking for 15 – 30 min in neutralisation solution (3 M 
NaCl, 0.5 M Tris-HCl, pH 7), washing between these steps with distilled water. 
The DNA was transferred onto a Hybond-N+ nylon membrane (Amersham, GE 
Heatlhcare) in 20 x SSC (3 M NaCl, 0.3 M sodium citrate, pH 7). The membrane 
was layered on top of the gel, with two sheets of blotting paper and excess 
weighted paper towels added to draw the 20 X SCC buffer up the wick by 
capillary transfer overnight. Transferred DNA fragments were covalently cross-
linked to the membrane by UV cross-linking in a UV Stratalinker 2400 
(Stratagene) at 1200 mJoules. The probe (5’ UTR sequence of L. mexicana RDK1) 
was prepared at 10 ng/µl, labelled with an AlkPhos Direct labelling kit 
(Amersham, GE Healthcare) following manufacturer’s instructions, and 
incubated with the membrane overnight at 60oC in hybridisation buffer (GE 
Healthcare). After washing, signal was detected using CDP-Star detection 
reagent (Amersham, GE Healthcare) and exposed using Kodak photographic film. 
For detection of floxed GFP loss, the process was repeated but with the 
following amendments; 2.7µg of genomic DNA was digested per sample with SacI 
and SpeI double digests and the probe was prepared from a GFP CDS amplicon. 
For detection of floxed CRK3 loss; the NruI restriction enzyme was used to digest 
3ug of genomic DNA per sample and the probe was prepared from a CRK3 CDS 
amplicon. 
2.3.11 RNA extraction  
For each sample, RNA was isolated from 1 x 107 promastigotes using the RNAeasy 
kit (Qiagen) processed in the automated QIAcube (Qiagen) according to 
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manufacturer’s instructions. An additional DNAse step was included once 
purified RNA was derived. cDNA was produced from 1 μg of isolated RNA using 
random hexamer primers (Invitrogen) and SuperScript Reverse Transcriptase III 
(Invitrogen) according to manufacturer’s instructions.  To monitor genomic DNA 
contamination the procedure was performed without reverse transcriptase (-RT).    
Table 2-1- List of primers used for real-time PCR in this study  
 
Oligo No. Gene ID Gene Sequence 
OL4593 LmxM.36.0550 LmxCRK3 GATCGCACTGAGGAGGGTAT 
OL4594 GTGGTCGAACTCTTGCAGAA 
OL4595 LmxM.18.0360 LmxGPI8 GGCTGTCATTGTCTCCTCCT 
OL4596 GTACATGGTAAGCGCATTGG 
OL4691 N/A Cre59 GGCTCCACCTCTGATGAAGT                 
OL4692 CAGGTGTGTTCAGAGAAGGC                
OL4693 N/A Cre60 ACCTGAGGATGTGAGGGACT                
OL4694 AGGTGCTGTTGGATGGTCTT                 
 
2.3.12 Quantitative real time PCR   
qPCR reactions were set up using Applied Biosystems SYBR Green PCR master 
mix, each reaction was performed in triplicate and contained 12.5 l Mastermix, 
2.5 l of each primer (3 M), 5.5 l H20 and 2 l of the template cDNA. 
Reactions were set up in MicroAmp® Optical 96-Well Reaction Plate (Applied 
Biosystems) and sealed with MicroAmp® Optical Adhesive Film (Applied 
Biosystems). Samples were analysed in an Applied Biosystems Prism 7500 using 
the default thermocycling settings with the reaction volume set to 25 l. A 
denaturation step was added to check that only a single product was being 
formed by each primer pair. 
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Oligo No.  Flank Description Gene ID Sequence Annotations 
OL3966  F 5’ Amplification of RDK1 
flanking regions for 
Gateway entry clone 
generation  
LmxM.31.
0810 
GGGGACAACTTTGTATAGAAAAGTTGAAGCTTGCACAGCAATGTTTAAGGGC attB4, HindIII 
OL3967  R GGGGACTGCTTTTTTGTACAAACTTGGGTCGAGGCCGTGCCAGCCGTT attB1r 
OL3968  F 3’ GGGGACAGCTTTCTTGTACAAAGTGGGAACCCTGCGTCCCCGTACC attB2r 
OL3969 R GGGGACAACTTTGTATAATAAAGTTGGAGCTCAAGACAACGTCGCTCCATGAC attB3, SacI 
OL4249 F 5’ Amplification of CRK3 
flanking regions for 
Gateway entry clone 
generation 
LmxM.36.
0550 
GGGGACAACTTTGTATAGAAAAGTTGCCCTTAATTAAAAAGGTAGAGGATGCCGTTTT attB4, PacI 
OL4250 R GGGGACTGCTTTTTTGTACAAACTTGCTTGAAATGTTGCAGGGAGAAA attB1r 
OL4251 F 3’ GGGGACAGCTTTCTTGTACAAAGTGGGGAGTGGAAAAGGCATGACTGAA attB2r 
OL4252 R GGGGACAACTTTGTATAATAAAGTTGCGGTTTAAACTTTCCTCCCCAGCACGCACAC attB3, PmeI 
OL4397 F 5’ Amplification of ribosomal 
18S flanking regions from 
pGL631 for Gateway entry 
clone generation 
LmxM.27.
rRNA 
GGGGACAACTTTGTATAGAAAAGTTGCCTTAATTAATGACGAACAACTG attB4, PacI 
OL4398 R GGGGACTGCTTTTTTGTACAAACTTGCGTTACTCGATATTGGATGGGT attB1r 
OL4399 F 3’ GGGGACAGCTTTCTTGTACAAAGTGGGGCGACTAGACCGTAACGCCTTT attB2r 
OL4400 R GGGGACAACTTTGTATAATAAAGTTGGGTTTAAACATGAGCTGCGCCT attB3, PmeI 
OL4512 F 5’ Amplification of NMT 
flanking regions for 
Gateway entry clone 
generation 
LmxM.31.
0080 
GGGGACAACTTTGTATAGAAAAGTTGTTAATTAAGTGGAAGGGAGAGCCTTGCTG attB4, PacI 
OL4513 R GGGGACTGCTTTTTTGTACAAACTTGTCGTGTGCGTGTGCGTACAGC attB1r 
OL4405 F 3’ GGGGACAGCTTTCTTGTACAAAGTGGTCTACGCACTGCCCCACC attB2r 
OL4406 R GGGGACAACTTTGTATAATAAAGTTGGTTTAAACGGGAACAAGGCGACAAAC attB3, PmeI 
OL4415 F 5’ Amplification of MIF 1 and 
2 flanking regions for 
Gateway entry clone 
generation  
LmxM.32.
1740 
LmxM.32.
1750 
GGGGACAACTTTGTATAGAAAAGTTGCCTTAATTAAGTGGAGCTATGTAGGCTGATT attB4, PacI 
OL4416 R GGGGACTGCTTTTTTGTACAAACTTGCTTTCGCTAAGGGGGAGGGGGG attB1r 
OL4417 F 3’ GGGGACAGCTTTCTTGTACAAAGTGGCTAGCGCCGCGGCCATCACGAAGGA attB2r, STOP 
OL4418 R GGGGACAACTTTGTATAATAAAGTTGCGTTTAAACCCTTCGTTTTGGCGCCTCGGA attB3, PmeI 
OL4705 F 5’ Amplification of β-Tubulin 
flanking regions and the 
CRK3 CDS with G418r 
cassette from pGL2374 for 
pDONR221 insertion and 
Gateway entry clone 
generation 
LmxM.32.
0792 
pGL2374 
GGGGACAACTTTGTATAGAAAAGTTGTTAATTAAAGAAACACAAACATTTTCGCA attB4, PacI 
OL4706 R GGGGACTGCTTTTTTGTACAAACTTGGATGGCAGAGTGGCGAAAGGC attB1r 
OL4715 F CDS GGGGACAAGTTTGTACAAAAAAGCAGGCTCTCGAGATGTCTTCGTTTGGC attB1 
OL4708 R GGGGACCACTTTGTACAAGAAAGCTGGGTCGGACGCGGGCAGCGAGGGGA attB2 
OL4709 F 3’ GGGGACAGCTTTCTTGTACAAAGTGGACGGTGTGTGGGTGAGGTGCG attB2r 
OL4710 R GGGGACAACTTTGTATAATAAAGTTGGTTTAAACCTGGTCCGTCGTGCAGAGACA attB3, PmeI 
       
 
Table 2-2-List of primers used for generation of Gateway entry clones in this study  
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Oligo No.  Description Sequence Annotations 
OL4065 F Amplification of puromycin resistance cassette from 
pGL631 
GATCCTGCAGCGCGTGGATGTCGCGCAG PstI 
OL4066 R GATCGCTAGCCTAGGCACCGGGCTTGCG NheI 
OL4293 F Amplification of SAS-HASPB-mCherry from pGL1893 to 
integrate at reporter site 
GATCCTCGAGAATTGCCCGCTTTCCAT XhoI 
OL4294 R GATCGCGGCCGCGGGATCCTCAATGATGA NotI 
OL4316 F Amplification of GFP from pGL1773 for integration as N-
terminal tag 
GATCCATATGATGGTGAGCAAGGGCGAG  NdeI 
OL4317 R GATCGGTACCCTTGTACAGCTCGTCCAT KpnI 
OL4318 F Amplification of 6xHA integration as N-terminal tag GATCCATATGTACCCTTACGATGTGCCT NdeI 
OL4319 R GATCGGTACCTGCGTAATCGGGCACATC  KpnI 
OL4320 F Amplification of GFP from pGL1773 for integration as C-
terminal tag 
GATCACTAGTATGGTGAGCAAGGGCGAG SpeI 
OL4321 R GATCTCTAGATCACTTGTACAGCTCGTCCAT XbaI, STOP 
OL4541 F Amplification of SAS-HASPB-mCherry for insertion via 
HindIII: enables the replacement of HASPB-mCherry by 
XhoI and NotI  
GATCAAGCTTAATTGCCCGCTTTCCATTTCG HindIII 
OL4542 R GATCGCGGCCGCGGGATCCTCAATGATGATGAT NotI 
OL4067 F Amplification of the CRK3 CDS for insertion into the 
loxP MCS: no Stop codon amplified due to C-terminal 
GFP fusion 
GATCCATATGTCTTCGTTTGGCCGTGTG NdeI 
OL4103 R GATCATCGATCCAACGAAGGTCGCTGAA ClaI 
OL4335 F Amplification of the RDK1 CDS for insertion into the 
loxP MCS: no Stop codon amplified due to C-terminal 
GFP fusion 
GACCCATATGATCCGGAACGCCACGATC NdeI 
OL4336 R GCGCACTAGTAATCAGGAAGGCGAAGGA SpeI 
OL4380 F Amplification of the RDK1 CDS for insertion into the 
loxP MCS: Stop codon amplified due to N-terminal GFP 
fusion 
GATCACTAGTATCCGGAACGCCACGATCCCG SpeI 
OL4381 R GATCTCTAGACTAAATCAGGAAGGCGAAGGAAAG XbaI, STOP 
OL4388 F Amplification of the CRK3 CDS for insertion into the 
loxP MCS: Stop codon amplified due to N-terminal GFP 
fusion 
GATCACTAGTTCTTCGTTTGGCCGTGTGACC SpeI 
OL4389 R GATCTCTAGACTACCAACGAAGGTCGCTGAA XbaI, STOP 
OL4407 F Amplification of the NMT CDS for insertion into the loxP 
MCS: Stop codon amplified due to N-terminal GFP 
fusion 
GATCACTAGTTCTCGCAATTCATCGAACTCT SpeI 
OL4408 R GATCTCTAGACTACAGCATCACCAAGGCAAC XbaI, STOP 
OL4419 F Amplification of the MIF 1/2 CDS for insertion into the 
loxP MCS: Stop codon amplified due to N-terminal GFP 
GATCGAATTCATGCCGGTCATTCAAACGTTT EcoRI 
OL4420 R GATCTCTAGACTAAAAGTTAGTGCCGTTCCA XbaI, STOP 
Table 2-3- Primers used for cloning of a loxP vector for insertion of a target gene flanked by loxP sites  
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fusion 
OL4591 F Amplification of CRK3-his for insertion into pGL2277: 
generate an 18S RNA integration vector for 
complementation of the floxed CRK3 inducible deletion 
line 
CTCGAGATGTCTTCGTTTGGCCGT XhoI 
OL4592 R GCGGCCGCCTAATGATGATGATGATGATGCCAAC
GAAGGTCGCTGAA 
NotI, STOP, 
6xhis 
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Oligo No.  Binding Region Description Sequence 
OL4097 F Upstream Detection of RDK1 loss by amplification of a 5’ 
fragment  
TTGCGAAGCATCTCCAGC 
OL4098 R RDk1 CGAGTGACAGCAAAAGGC 
OL4099 F RDK1 Detection of RDK1 loss by amplification of a 3’ 
fragment  
ATTGCTGTCGACATTCCC 
OL4100 R Downstream GTAGTCCTCATCATCAGC 
OL4101 F BLAr Internal forward and reverse primers to detect 
diCre integration into the genome 
CTGGTTATGTGTGGGAGG 
OL4102 R FKBP12 GATGGTTTCCACCTGCAC 
OL4287 F Upstream Amplification of floxed a GFP fragment to 
detect gene loss by diCre induction 
GCTCGCGTGTGTTGAGCC 
OL4288 R Downstream CATTCGTGGGCTCCAGCT                    
OL4296 F Upstream Primers binding out-with the CRK3 integration 
site 
GATCGTGGGAAGGGGAAG 
OL4297 R Downstream GGAAGTCCAAGTAGCGCG 
OL4298 R CRK3 Primers binding the CRK3 gene   GGTCACACGGCCAAACGA 
OL4299 F CRK3 GCCAAGGAGGCCCTACAG 
OL4300 R loxP vector SAS Primers binding the loxP vector at the 5’ splice 
acceptor site (SAS) and 3’ poly-adenylation site 
(PAS) 
GGTGGACGGCTCAACACA 
OL4301 F loxP vector PAS GTGTGCTGTGCGTTCAGC 
OL4571 F Upstream MIF integration primers which bind upstream or 
downstream of the integration site 
CATGGCAGTGCTCTTCAG 
OL4572 R Downstream CAATACGCGGTGAGCTAC 
OL4573 F Upstream NMT integration primers which bind upstream 
or downstream of the integration site 
GAGTGGGCGCATTGCTGC 
OL4574 R Downstream CTGCCCCATCAATGACAG 
OL4781 F Upstream Amplification of a floxed CRK3-GFP fragment to 
detect gene loss by diCre induction  
AACTGGCAGCAGCGATTTGGCAGGGG 
OL4782 R PACr GCACCGTGGGCTTGTACTCGGTCATG 
OL4748 F Upstream Primers to check for integration of RE9H 
construct (pGL2398) into the ribosomal locus; 
primers 4749 and 4750 can be used to  check 
for episomal retention 
TCGTGAGACGCCCAGCGAATG            
OL4749 F RE9H (middle) GAAGGCGATGGTGCCTGGCAC           
OL4750 R RE9H (middle) ACCGACGCCCACATCGAGGTG            
OL4751 R RE9H (3’ end) GCCACGTAGTCCACGATCTCC             
 
  
Table 2-4- Primers used for analysis of inducible floxed gene loss and for integration confirmation   
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Table 2-5- Sequencing primers used in this study 
Oligo No.  Binding Region Description Sequence 
OL4349 F Backbone Sequencing primers to check for 
loss of NdeI codon from mutated 
pGL631 
GCGCGTTTCGGTGATGACGG 
OL4350 R 5’SSU flank TTGTTACTCGATATTGGATG 
OL4351 F Backbone Sequencing primers for final loxP 
vector (pGL2314): these primers 
give full coverage of the plasmid 
ATAATGCCAACTTTGTACAAA 
OL4352 R 6xHA TACCCTTACGATGTGCCTGA 
OL4353 F 6xHA GGCACGTCGTATGGGTACGC 
OL4354 R PACr GCGGGGTAGTCGGCGAACGC 
OL4355 F PACr CCCCGGGCCGTACGCACCCT 
OL4356 R PAS TCGCGGGGCACCACGACTTG 
OL4357 F PAS GAGCAGGCGCGCTGTGAATC 
OL4358 F 5’ CRK3 Primers to sequence the whole 
CRK3 gene 
ATGTCTTCGTTTGGCCGTGT 
OL4359 R 3’ CRK3 CTACCAACGAAGGTCGCTGA 
OL4360 R RDK1 Primers to sequence the whole 
RDK1  gene (4.095 Kbp) 
TGCGGGTCTGATTCGCATCG 
OL4361 R GCATCTCTCGCAAACTCCGC 
OL4362 F TTCGCGGCATTCACGAGGCC 
OL4363 F GTGCTGCGATGTACGACTGC 
OL4364 F CATGCCAGGGGGCTCGCTGC 
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Oligo No.  Gene/Mutation Description Sequence Annotations 
OL4253 F diCre/ Deletion Deletion of extra ATG start codon from 5’ 
actin region within diCre expression 
construct 
CTTGCCTTTCAGTGCGGG     - 
OL4254 R GGTATTCGACCTACACCG    - 
OL4265 F diCre/ Insertion Insertion of an XhoI NotI site to enable 
integration of an extended 3’ actin  flank 
into diCre vector 
ATCGTTTTGGCGGCCGCTTTCTTCCATCTGCACTCG NotI 
OL4266 R GATTGAAAGTAGGATCCGAGCAACGCACACTCTAAC XhoI 
OL4267 F Actin Amplification of a 655bp 3’ acting flank 
containing a poly adenylation site for 
diCre vector insertion 
GATCGGATCCCTGCCTGGTTCTCGTGCTTA XhoI 
OL4268 R GATCGCGGCCGCGCGTGCACTTGATGCCAAAT NotI 
OL4289 F Deletion Removal of E1α antigen tag from pGL1893 
for mCherry amplification (with OL4293/4) 
AGGATCCAATGGTTAGTAAAG   - 
OL4290 R CCATAGATCCATCCGCAC              - 
OL4291 F Deletion Removal of XhoI site from pGL1893  to 
ready vector for mCherry amplification 
(with OL4293/4) 
TGATCCTATCTATCTCCCCCG    - 
OL4292 R GCTACGGTGGACGGCTCA       - 
OL4339 F Deletion Removal of extra NdeI restriction site 
upstream of 5’SSU flank in pGL631 vector 
CGGTGTGAAATACCGCAC - 
OL4340 R  TATGGTGCACTCTCAGTAC - 
OL4553 F loxP vector/ 
Substitution 
Replacement of XhoI restriction site in 
loxP vector with HindIII to insert to enable 
replacement of reporter cassette by XhoI 
and NotI digest 
GGCTAGCGCTAAGCTTATGGTGAGCAAGGGCGAGGAG 
 
HindIII 
OL4544 R TAGGCACCGGGCTTGCGG - 
OL4601 F CRK3 
mutagenesis 
Mutation of T178 residue to glutamic acid 
to create CRK3T178E 
GCACACCTACgaGCACGAGGTGG mutated site 
OL4602 R ATGGGCACTTGAAACGCAC - 
OL4689 F Mutation of ATP binding pocket at 33-34 
from  TY to AF to create CRK3AF 
GGGAGAGGGAgcgttCGGCGTTGTG mutated site 
OL4690 R  AAAACATCCAAGCGATTGTACCGG - 
 
 
 
 
 
 
Table 2-6-Mutagenesis primers used in this study 
75 
 
pGL No. Gene ID Gene Name Backbone Description 
Drug 
Resistance 
Reporter Plasmids 
2217 N/A LUC pGL631 Luciferase bioluminescent protein in pRib construct AMPr/ PACr 
2233 N/A tdTomato pGL631 tdTomato red-fluorescent protein in pRib construct AMPr/ PACr 
2234 N/A RE9H pGL631 Red-shifted luciferase bioluminescent protein in pRib AMPr/ PACr 
2275 N/A CFP pGL631 Cerulean blue-fluorescent protein in pRib construct AMPr/ PACr 
      
2398 N/A RE9H pGL631 Red-shifted luciferase bioluminescent protein in pRib AMPr/ G418r 
2461 N/A GFP flox pGL631 Floxed GFP in pRib: for functional analysis of diCre AMPr/PACr 
Gateway entry plasmids 
2313 N/A diCre pDONR221 DiCre expression cassette entry vector KANr 
2314 N/A loxP- C-6xHA pDONR221 LoxP (empty) expression cassette: c-terminal 6xHA tag KANr 
2315 N/A loxP-C-GFP pDONR221 LoxP (empty) expression cassette: c-terminal GFP tag KANr 
2316 N/A loxP-N-GFP pDONR221 LoxP (empty) expression cassette: n-terminal GFP tag KANr 
2445 LmxM.36.0550 
5’ CRK3 
flank 
pDONR P41-Pr 5’ Flank (500bp) ready for Gateway recombination KANr 
2446 LmxM.36.0550 
3’ CRK3 
flank 
PDONR P2r-P3 3’ Flank (500bp) ready for Gateway recombination KANr 
2447 LmxM.31.0810 
5’ RDK1 
flank 
pDONR P41-Pr 5’ Flank (500bp) ready for Gateway recombination KANr 
2448 LmxM.31.0810 
5’ RDK1 
flank 
PDONR P2r-P3 3’ Flank (500bp) ready for Gateway recombination KANr 
2449 LmxM.31.0080 5’ NMT flank pDONR P41-Pr 5’ Flank (500bp) ready for Gateway recombination KANr 
2450 LmxM.31.0080 3’ NMT flank PDONR P2r-P3 3’ Flank (500bp) ready for Gateway recombination KANr 
2451 LmxM.32.1740/ 
LmxM.32.1750 
5’ MIF flank pDONR P41-Pr 5’ Flank (600bp) ready for Gateway recombination KANr 
2452 3’ MIF flank PDONR P2r-P3 3’ Flank (300bp) ready for Gateway recombination KANr 
2453 LmxM.27.rRNA 5’ 18S SSU pDONR P41-Pr 5’ Flank (254bp) ready for Gateway recombination KANr 
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2454 LmxM.27.rRNA 3’ 18S SSU PDONR P2r-P3 3’ Flank (960bp) ready for Gateway recombination KANr 
Gateway expression plasmids 
2399 LmxM.27.rRNA 18S pDEST R4-R3 DiCre cassette flanked with 18S SSU homologous arms AMPr/ BLAr 
2455 LmxM.36.0550 CRK3 pDEST R4-R3 DiCre cassette flanked with CRK3 homologous arms AMPr/ BLAr 
2456 LmxM.36.0550 CRK3 pDEST R4-R3 CRK3-GFP
 flox cassette flanked with CRK3 homology AMPr/ PACr 
2457 LmxM.31.0080 RDK1 pDEST R4-R3 DiCre cassette flanked with RDK1 homologous arms AMPr/ BLAr 
2458 LmxM.32.1740/50 MIF1/2 pDEST R4-R3 DiCre cassette flanked with MIF locus homologous arms AMPr/ BLAr 
2459 
LmxM.31.0810 RDK1 
pDEST R4-R3 Blasticidin resistance cassette with 500bp RDK1 flanks AMPr/ BLAr 
2460 pDEST R4-R3 Puromcyin resistance cassette with 500bp RDK1 flanks AMPr/ PACr 
2235 pDEST R4-R3 Streptothrcin resistance cassette with 500bp RDK1 flanks AMPr/ SATr 
2236 pDEST R4-R3 Hygromycin resistance cassette with 500bp RDK1 flanks AMPr/ HYGr 
Table 2-7- List of plasmids (pGLs) generated in this study by restriction enzyme and Gateway mediated cloning 
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2.4 Leishmania culture methods 
2.4.1 Culture of Leishmania promastigotes 
Leishmania mexicana (MNYC/BZ/62/M379) were grown in modified Eagle’s 
medium (designated HOMEM) supplemented with 10 % (v/v) heat-inactivated 
foetal calf serum (HIFCS) and 1 % (v/v) penicillin streptomycin solution (Sigma) 
at 25oC. When referring to the stage of growth of cultures, mid-log phase 
corresponds to ~5 x 106 parasites/ml and stationary phase to ~2 x 107 
parasites/ml. Transgenic parasites were maintained in appropriate antibiotics: 
G418 (Neomycin) at 50 µg/ml; Hygromycin at 50 µg/ml; Blasticidin S at 10 
µg/ml; Puromycin at 10 µg/ml (InvivoGen). 
2.4.2 Determination of cell density 
Culture flasks were homogenised by gentle swirling and pipetting. 50 µl parasites 
were mixed with 50 µl 2 % formaldehyde and mixed by pipetting. 10 µl fixed 
cells were placed in a Neubauer haemocytometer (Weber Scientific) and cells 
counted under a light microscope. To set up a growth curve, a culture was 
started bewteen 1 x 105 to 1x106 cells/ml and cells counted every day for up to 7 
days.  
2.4.3 Creating Leishmania stabilates 
For long term storage of Leishmania cell lines, stabilates were prepared by 
mixing 500 µl cells with 500 µl HOMEM + 20 % HIFCS + 10 % DMSO in a 1.5 ml 
cryotube. These were stored overnight at -80oC before transferring to liquid 
nitrogen.  
2.4.4 Transfection and selection of clones 
Transfections of Leishmania were performed using an Amaxa human T cell 
nucleofector kit (Lonza) following the manufacturer’s instructions. For each 
transfection, 5 x 107 cells in mid-log phase of growth were harvested by 
centrifugation at 1000 g for 10 min at 4oC, and then resuspended in 100 µl T cell 
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nucleofector solution and transferred to a cuvette. Approximately 10 µg DNA in 
30 µl sterile dH2O were added to the cells and tapped gently to mix. Cells were 
electroporated using the U-033 program before being transferred to 10 ml fresh 
HOMEM + 20 % HIFCS. The culture was split between two flasks to select for 
independent transfection events and incubated overnight at 25oC to allow 
recovery. For each transfection a negative control was performed where 30 µl 
dH20 was added instead of DNA. The following day appropriate antibiotics were 
added to select for transfectants. Cells transfected with integrative DNA were 
prepared in serial dilutions of 1 in 5, 1 in 50 and 1 in 500 in HOMEM + 20 % HIFCS 
+ antibiotics and plated out onto 96 well microplates. Plates and flasks were 
maintained at 25oC for 3-5 weeks until transfectants appeared.  
2.4.5 Induction of diCre mediated gene deletion 
Inducible gene deletion in cell lines containing both diCre and loxP flanked genes 
of interest was induced by addition of between 1nM-1µM rapamycin (Abcam) 
from a 100µM stock solution to the culture medium. Promastigotes were induced 
at day 0 when preparing growth curves or for 24 hours for stationary phase 
deletion induction.  
2.4.6 Preparation of protein extracts 
A 10 ml culture of L. mexicana in the desired life cycle stage was pelleted by 
centrifugation at 1,200 g for 10 min, washed in PBS and then lysed by 
resuspending in 1 x SDS-PAGE loading buffer to a cell density of 1 x 107 
parasites/10 µl. Samples were then boiled for 10 min at 100oC on a heat block 
before loading directly into SDS-PAGE gels or storing at -20oC.  
2.4.7 Purification of Leishmania major metacyclic promastigotes 
Metacyclic promastigotes were isolated from late stationary phase cultures using 
peanut lectin agglutination (Sacks et al., 1985). Parasites were centrifuged at 
1000 g for 10 min, washed and resuspended in PBS to a density of 1 x 108/ml. 
Peanut lectin (Sigma) was added to a final concentration of 50 µg/ml and 
incubated for 10 min at room temperature. Metacyclic promastigotes were 
recovered from the supernatant after separation of agglutinated procyclic 
promastigotes by centrifugation at 100 g for 5 min.  
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2.4.8 Extraction of murine bone-marrow for bone marrow 
macrophage differentiation 
Non-differentiated monocytes were extracted from the femurs and tibia of 
BALB/c mice by dissection to remove the bones. RPMI 1640 medium was used to 
was the bone marrow out of the intact bones by syringing with a 25G needle. 
Extracted cells were quantified by dilution in Trypan blue (1:1) and counting 
with a haemocytometer. Monocytes were seeded at 5x105 cells/ml in MΦ Medium  
(DMEM + L-Glut + 20%FCS + 1% P/S + 30% L-Cell M) in 8ml volumes in Petri dishes 
and incubated at 37C with 5% CO2 for 3 days to induce differentiation to 
monocyte-derived macrophage. After this period the medium was replaced and 
by day 5 the cells were removed from the dishes using a cell scraper with ice-
cold RPMI 1640. Purified macrophage were then counted once more and used for 
subsequent assays.  
2.4.9 Macrophage infection 
Bone marrow derived macrophage were adhered overnight in DMEM medium 
(PAA) with 10 % HIFCS onto 8-chamber tissue culture slides (LAB-TEK) at 37oC in 
5 % CO2. Macrophages were then infected with lesion derived L. mexicana 
amastigotes at a ratio of between 2-5 parasites per macrophage and imaged 
between 24 and 120 hours after infection in the DeltaVision Core environmental 
chamber at 37oC and 5 % CO2, after DAPI staining. 
2.4.10 DNA content analysis 
To determine DNA content of cells by flow cytometry cells were fixed in 70% 
methanol 30% PBS overnight at 4oC. Cells were washed in PBS then resuspended 
in PBS + 10 g/ml propidium iodide, 10 g/ml RNase A at 37oC for 45 min. Cell 
fluorescence was measured on a MACSQuant Analyzer (Miltenyi Biotec) using the 
B3 channel (655-750nm) for PI detection. Data analysis was performed using 
FlowJo software (Tree Star Inc.). 
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2.5 Fluorescent microscopy 
2.5.1 DeltaVision systems 
Fluorescent microscopy was performed on an Applied Precision DeltaVision Core 
deconvolution microscope equipped with a Photometrics CoolSNAP HQ2 camera 
and DAPI (381 - 399 nm), CFP (426 - 450 nm), GFP (461 – 489 nm), FITC (461 – 
489 nm), YFP (505 – 515 nm), mCherry (563 – 588 nm), and Alexa594 (621 – 643 
nm) filters. Earlier imaging experiments were carried out using an Applied 
Precision DeltaVision RT deconvolution microscope with a Photometrics 
CoolSNAP HQ camera and DAPI (381 - 399 nm), FITC (461 - 489 nm) and mCherry 
(529 - 556 nm) filters. Both microscopes are fitted with environmental chambers 
with temperature and CO2 concentration regulated by a Weather Station 
temperature controller (PrecisionControl). DIC images were obtained under 
polarised light. Imaging of parasites was performed at 100 x magnification, and 
infected macrophages at 60 x, using immersion oil with the appropriate 
refractive index: live parasites in PBS, 1.516; fixed parasites in DAPI 
Fluoromount-G® (SouthernBiotech), 1.520; infected macrophages at 37oC, 
1.518. 
2.5.2 Live cell imaging 
~1x106 cells were used for microscopic analysis. Promastigotes or amastigotes 
were centrifuged at 1,200g or 2,000g respectively for 10 minutes and the cell 
pellet washed once in 1xPBS by repeat centrifugation. Parasites were then 
resuspended in PBS to the appropriate cell density and a small volume was 
spread thinly on a slide, i.e. 10 µl cells under a 22 x 40 mm coverslip, sealing the 
coverslip with nail varnish. Mounted parasites were observed on the microscope 
immediately, and imaged for up to 1 hour to reduce cellular damage occurring 
due to prolonged exposure to UV light.  
2.5.3 DAPI staining 
DAPI (4’, 6-diamidino-2-phenylindole) was used to stain the DNA of parasites and 
host macrophages. DAPI was prepared as a stock solution of 10 mg/ml in sterile 
water and added to cells at a final concentration of 1 µg/ml, incubated at room 
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temperature for 5 – 10 min then washed in PBS and cells prepared for 
microscopy as above. 
2.6 Biochemical methods 
2.6.1 SDS-PAGE 
Protein extracts from Leishmania were loaded into sodium dodecyl sulphate 
polyacrylamide gels for separation and visualisation of proteins. 12 % (w/v) 
polyacrylamide gels were cast in plastic casting cassettes (Invitrogen), and then 
a 5 % stacking gel was cast over this to allow focussing of the proteins before 
their separation on the 12 % resolving gel. In some cases acrylamide gels 
containing 6 M urea were prepared, by dissolving urea in the tris and acrylamide 
with gentle heating before addition of the other ingredients. Electrophoresis was 
performed in an XCell SureLock Mini Cell chamber (Invitrogen) with 1 x SDS-PAGE 
running buffer (10 x running buffer: 25 mM Tris, 192 mM glycine and 0.1 % (w/v) 
SDS) at 180 volts. A broad range protein marker (New England Biolabs) was 
loaded alongside protein samples at a concentration of 1 – 2 µg per lane to 
determine sizes of protein bands on the gel. 
2.6.2 Western blotting 
For Western blotting, proteins were transferred from a polyacrylamide gel, 
following electrophoresis, to a Hybond-C nitrocellulose membrane (Amersham, 
GE Healthcare). Transfer was carried out by semi-dry blotting using a BioRad 
Trans-Blot SD Semi-Dry Transfer Cell at 20 volts for 30 min, with the membrane 
and filter paper soaked in transfer buffer (20 mM Tris-HCl, 15 mM glycine, 20 % 
(v/v) methanol, in distilled water). The membrane was subsequently incubated 
in a blocking solution of 5 % (w/v) milk powder in TBST buffer (25 mM Tris-HCl 
pH 8, 125 mM NaCl, and 0.1 % Tween) for 1 hour at room temperature or 
overnight at 4oC, with agitation. This blocking step prevents non-specific binding 
of antibodies to the membrane. After blocking, the membrane was incubated 
with primary antibody diluted to an appropriate concentration in fresh TBST 
with 5 % milk for 1 hour at room temperature. Relevant concentrations of 
antibody are described in figure legends. The membrane was washed three times 
in TBST, incubating for 10 min each time, before incubation with horse radish 
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peroxidase (HRP)-conjugated secondary antibodies at 1 in 5000 dilution for 1 
hour at room temperature. After washing three times in TBST, the membrane 
was treated with an ECL (enhanced chemiluminescence) kit (SuperSignal West 
Pico Chemoluminescent Substrate, Pierce) according to manufacturer’s 
instructions and then exposed on Kodak photographic film. 
2.7 Immune cell flow cytometry 
2.7.1 Extraction of immune cells from ear tissue and lymph nodes  
Ears were deposited in PBS and cut repeatedly with surgical scissors, 4 mg ml-1 
collagenase D (Roche) and 100 U ml-1 DNase I were added, then the tissue was 
incubated in a Thermomixer Comfort Eppendorf shaking incubator (Eppendorf) at 
37 °C shaking at 1000 rpm for 45 min. Digested tissue was transferred to a 
gentleMACS C tube (Miltenyi Biotec) containing RPMI 1640 and processed in the 
gentleMACS dissociator (Miltenyi Biotec). Tissue homogenates were filtered 
through a 40 μm cell strainer (BD Biosciences). 
Draining retromaxillary lymph nodes were collected and mechanically 
dissociated by tearing apart with 26G needles in RPMI 1640. Cells were then 
passed through a 40μm cell strainer (BD Biosciences). 
Homogenised tissue samples were centrifuged at 380 x g for 10 min at 4 °C, 
washed in PBS, and resuspended in 1 ml PBS. Cell number was then determined 
by taking 10 µl of cells with a 1:1 ratio of cells to trypan blue (Sigma), and 
counting on a Neubauer chamber. 
2.7.2 Staining cell surface antigens 
All steps were performed at 4 °C and all centrifugation steps were performed at 
380 x g for 5 min. Single-cell suspensions from mouse ear or lymph nodes were 
incubated with an anti-Fc-γ III/II (CD16/32) receptor antibody (2.4G2, BD 
Biosciences) for 30 min, washed twice with PBS, then stained in the dark with 
the fluorochrome-conjugated antibodies for 30 min. The appropriate rat IgG2a, 
rat IgG2b, rat IgG2c, or Armenian hamster IgG isotype controls were used. After 
staining of surface markers, the cells were washed twice with PBS, and stained 
with Fixable Viability Dye eFluor 506 or eFluor 660 (eBioscience) for 30 min, 
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following the manufacturer’s protocol. The cells were washed twice in FACS 
buffer (1% dialysed FCS, 0.05% sodium azide, 2 mM EDTA, in PBS) then fixed with 
methanol-free formaldehyde (Thermo Scientific) for 5 min. Cells were washed 
twice in FACS buffer, then resuspended in FACS buffer and passed through a 
Nitex mesh with a pore size of 50 µm (Cadisch).         
2.7.3 Data acquisition and analysis 
The data were collected using either a MACSQuant Analyzer (Miltenyi Biotec), 
and analysed using FlowJo. Compensation settings were optimised using lymph 
node cells single-stained with anti-mouse CD4 antibodies conjugated to the 
corresponding fluorophores used in Table 2-5, (RM4-5, eBioscience and GK1.5, 
BD Biosciences). Live (based on Fixable Viability Dye staining) innate immune 
cells from the ear and draining lymph node were identified based on size 
(forward scatter) and granularity (side scatter), as well as by surface phenotype 
as indicated in the text and figure legends.  
2.8 Bioluminescence imaging (BLI)  
2.8.1 Preparation of luciferin  
A stock solution of D-luciferin potassium salt (Promega) was prepared at 15 
mg/ml in PBS. The solution was filtered through a 0.2 μm syringe filter. Luciferin 
was administered at 150 mg per kg body weight, 10 μl per g body weight, 
intraperitoneally.  
2.8.2 Preparation of luminol sodium salt  
A stock solution of luminol sodium salt (Sigma) was prepared at 50 mg/ml in PBS. 
The solution was filtered through a 0.2 μm syringe filter. Luminol was 
administered at 200 mg per kg body weight, 4 μl per g body weight, 
intraperitoneally or by cutaneous injection in the scruff.  
2.8.3 BLI image analysis  
Mice were anaesthetised at 4% isoflurane/1.5 L O2 per min
 
then bioluminescent 
light emission was imaged at 10 to 15 min after luciferin or luminol injection, 
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using the IVIS Spectrum bioluminescence imaging system (Caliper Life Sciences). 
Mice were maintained under anaesthesia at 1.5% isoflurane/1.5 L O2 per min
 
whilst in the IVIS. Imaging was performed with an open emission filter, for 1 min 
exposures, large binning, and 1 f/stop, and captured with a charge-coupled 
device (CCD) camera. Analysis was performed using Living Image software 
(Caliper Life Sciences). The absolute unit of photon emission was given as 
radiance (photons/second/cm2/steradian). Regions of interest (ROIs) were 
manually selected over the entire ear to quantify the amount of photon emission 
as total photon flux in photons per second (photons/sec).  
2.8.4 Statistical analysis  
Statistical analysis was performed using GraphPad Prism 5. The analysis of 
significance of the data was performed by an unpaired t-test and 2-way ANOVA 
when comparing data from induced (+Rap) and uninduced (-Rap) 
Δcrk3::DICRE/Δcrk3::CRK3FLOX [SSU RE9H] infections.  
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3 Developing Inducible Gene Deletion in 
Leishmania mexicana 
3.1 Introduction 
3.1.1 The importance of conditional deletion in Leishmania 
Functional genomics of kinetoplastids are limited by the available techniques to 
manipulate target genes, test their function and thereby identify appropriate 
therapeutic targets. A number of genes encoding proteins essential for 
Leishmania survival have been discovered which represent potential targets for 
drug inhibition (M P Barrett et al. 1999), however the chief obstacle preventing 
further functional analysis of such genes is an absence of an effective 
conditional gene deletion system in Leishmania. There are a number of useful 
methodologies for functional analysis of Leishmania genes and proteins, such as 
destabilising domain tagging of protein (Madeira da Silva et al. 2009), the 
potential for small RNA inhibition of target gene transcript (Lye et al. 2010) and 
transposition systems (Damasceno et al. 2010), however no analysis of essential 
targets by these methods have been published to date. Homologous 
recombination of drug selectable markers is a long established methodology to 
replace endogenous Leishmania genes for phenotypic analysis of null mutants 
(Cruz et al. 1991). By this method, null mutant promastigotes can been 
generated to identify the function of the encoded protein as a virulence factor 
(Morrison et al. 2012) for example. However, this method cannot be used to 
generate null mutant lines deficient in an essential gene as a result of the 
intrinsic cytoxicity following gene removal (Ilgoutz et al. 1999; Hassan et al. 
2001; Ambit et al. 2008). The strong selective pressure for retention of an 
essential gene results in the generation of drug resistant lines retaining an extra 
copy of the gene through altered ploidy, and necessitates the complementation 
of an exogenous gene copy for removal of the endogenous gene and an absence 
of altered ploidy. ‘Plasmid shuffle’ develops this further to more definitively 
demonstrate essentiality through retention of the ectopic gene copy following 
negative selection by ganciclovir treatment (Murta et al. 2009), and recent 
studies have further utilised the technique to generate partial essential gene 
null mutants for functional analysis of protein domains (M. a Morales et al. 2010; 
Dacher et al. 2014) and for in vivo confirmation of essentiality (Paape, 
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manuscript in production). Finally, overexpression of a gene can also be used as 
a tool for functional analysis, particularly when the encoded protein is essential 
for survival by mediating drug resistance (Drummelsmith et al. 2004).  
Despite this range of methods for manipulation of gene and protein expression, 
an absence of a strategy to conditionally regulate essential gene expression and 
carry out direct phenotypic analysis remains a barrier to researching crucial 
aspects of Leishmania biology. The ability to modulate expression of proteins, 
such as by inducible RNAi in T. brucei has allowed many key enzymes involved in 
an array of parasitic processes such as immune evasion, DNA repair, 
differentiation and mechanisms of drug resistance to be identified by phenotypic 
analysis of ‘knock-down’ cells. When the targeted protein is essential for such 
biological functions, such studies would have been unfeasible in the absence of a 
conditionally regulatable system. As cited above, the current molecular 
techniques available for studying such a diversity of biologically essential 
cellular and pathological processes in Leishmania hinders our current 
understanding of the parasite, therefore the application of such a tool would 
facilitate a greater understanding of these processes and aid studies into novel 
drug targets.  
3.1.2 Cre recombinase  
The system of Cre-lox recombination was first identified from the linear genome 
of the Escherichia coli bacteriophage P1 by Sternberg and Hamilton (1981). This 
seminal work demonstrated that two elements are essential for the 
recombination of this product; a cre sequence encoding an enzyme necessary to 
catalyse recombination and the presence of two ‘locus of crossover of P1’ (loxP) 
sites where recombination occurs. Also established was the necessity of Cre-lox 
for integration of the linear bacteriophage genetic sequence into the genome of 
its E. coli host via Cre mediated loxP:loxB recombination (Sternberg et al. 1981). 
Further investigation revealed that these loxP sites were smaller than 60bp 
(Abremski et al. 1983) and electron microscopy of liner DNA containing two loxP 
sites in the presence of Cre allowed the formation of a Cre-lox synapse, 
recombination and subsequent circularisation of the DNA fragment to be imaged 
(Hamilton & Abremski 1984). Further dissection of the loxP site revealed a 34bp 
region containing two homologous, 13bp inverted repeats flanking an 8bp spacer 
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where cleavage and recombination occurs (Hoess et al. 1986), and mutagenesis 
of the cre coding sequence identified regions crucial to its function as a 
recombinase (Wierzbicki et al. 1987). Such fundamental analysis of the 
mechanisms of Cre-lox recombination formed the basis for the development of 
the recombinase system as a transgenic tool for genome engineering. Cre-lox 
recombination has been used as a method to conduct genome engineering for 
thirty years. Indeed, a PubMed search for ‘cre loxP’ resulting in over three 
thousand hits is indicative of the wealth of knowledge derived from the use of 
this technique. Following its discovery, the system was rapidly adapted for use 
in a variety of eukaryotic organisms such as yeast (Sauer 1987), mammalian cells 
(Sauer & Henderson 1988) and plants (Russell et al. 1992) to generate knock-out 
of reporter transgenes flanked by loxP sites (‘floxed’ genes). Since its 
implementation (Orban et al. 1992, Lakso et al. 1992), the use of Cre-lox in the 
generation of mouse deletion models by crossing mice expressing Cre controlled 
by a specific promoter and with a partner containing a floxed gene has become 
an established and significant method for generating mice deficient in a number 
of proteins regulating immunological, cancer or other disease pathways, 
reviewed by Nagy (2000).  
3.1.3 Inducible Cre recombinase 
A major benefit of Cre-mediated recombination is the very efficient levels of 
recombination and therefore gene loss, but constant expression of the enzyme 
means a lack of temporal control over knock-out and can result in toxic side-
effects. To address this lack of conditional regulation, a number of systems for 
conditional regulation of Cre expression have been developed. 
 Fusion of Cre to the ligand-binding domain (LBD) of the human estrogen 
receptor (ER) allows induction of CreER activity by administration of the prodrug 
tamoxifen, metabolism to 4-hydroxytamoxifen (OHT) and subsequent binding to 
the CreER complex to stabilise the complex and induce activity (Metzger et al. 
1995). An optimised CreERT2 version of this has been generated through triple 
mutagenesis of the LBD and is currently the recommended tool for inducible 
mouse genome engineering (Parkitna et al. 2009), however such a system would 
not function  in Leishmania due to necessary metabolism of tamoxifen to OHT 
and the toxicity of tamoxifen to Leishmania (Miguel et al. 2008). A more 
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recently developed methodology involving destabilisation domain tagged Cre 
(DD-Cre) represents an alternative to the CreER methodology, as inducible 
stabilisation of the protein by trimethroprim (TMP) treatment results in 
recombinase activity in the brain of DD-Cre transgenic mice (Sando et al. 2013). 
Such a method may represent a useful mechanism to regulate Cre activity in 
Leishmania, however the authors observe some background recombination in the 
absence of TMP, whilst TMP itself is an inhibitor of the essential fusion protein 
dihydrogofolate reductase-thymidilate synthase (DHFR-TS) activity in L. 
braziliensis (Osorio et al. 2013). As such, an alternative strategy for conditional 
regulation of Cre in Leishmania is required.  
The integration of cre downstream of a tetracycline inducible promoter 
represents a potential method for inducible control of Cre expression. By 
conjugating an E. coli tetracycline repressor (TetR) with the activation domain 
VP16 from Herpes Simplex Virus, Bujard and Gossen (1992) were able to 
engineer the tetracycline transactivator protein (tTA) in HeLa cells. Expression 
of a luciferase gene downstream of a promoter region containing tet operator 
(tetO) sequences was ablated by tetracycline treatment, as tetracycline binding 
to the tTA complex prevents tetO binding and gene expression. The adaptation 
of this system in Trypanosoma brucei represents an important progression in 
kinetoplastid manipulation (Wirtz & Clayton 1995). Integration of the tetR 
sequence into the tubulin locus conferred expression of the repressor machinery, 
coupled with the insertion of tetO sequences into the characterised procyclic 
acidic repetitive protein (PARP) promoter region (later renamed GPEET/PAG3) 
with a downstream luc cassette generated clones whereby PolI mediated 
luciferase expression could be induced upon tetracycline treatment. When 
applied to regulating the expression of cre however, there was ‘leaky’ 
expression of the protein in the absence of tetracycline despite the presence of 
two upstream tetO elements (Barrett et al. 2004). In conjunction, induction of 
high-level Cre expression through tetracycline treatment induced death in the 
cells, and the authors speculate that this could be a result of recombination of 
cryptic lox sites in the genome.  Despite the cytoxicity, the rates of cre-loxP 
recombination were highly efficient and could still be utilised with the 
appropriate modifications such as more stringent control of Cre expression. More 
recent work has attempted to address these issues by modifying the splice-
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acceptor site and incorporating a temperature sensitive motif in the 
3’untranslated region (UTR), with both steps reducing expression to significantly 
lower levels (Scahill et al. 2008). In conjunction, their use of bloodstream form 
Trypanosoma brucei results in overall reduced expression due to the GPEET 
promoter being required for procyclin expression during the procyclic life cycle 
stage. The authors also applied transient transfection of Cre to circumvent the 
toxic phenotype resulting from prolonged Cre expression, demonstrating this as 
a useful method. The aim of this work is to recycle floxed drug resistance 
cassettes following gene deletion, or to integrate floxed constructs containing an 
add-back gene in array with a drug resistance marker to facilitate excision of the 
gene and markers following induced Cre expression (Kim et al. 2013).  
A limitation to this approach is the absence of a tet-inducible system in 
Leishmania to induce expression of the Cre enzyme. This was despite a previous 
effort to regulate expression in L. donovani (Yan et al. 2001), where background 
activity was high and expression varied depending on the RNA polymerase 
mediated gene expression. A recent study by Kraeva et al (2014) generated a 
Leishmania mexicana cell line expressing the TetR and T7 polymerases from the 
ribosomal locus which may resolve this issue, but was unavailable at the start of 
this project. The integration of a cassette into the tubulin locus containing a 
catalase enzyme, upstream T7 promoter region and tetO facilitates expression 
of the enzyme in the presence of tetracycline. The reverse orientation of this 
cassette aims to reduce background expression of a catalase enzyme marker 
from L. pyrrhocoris in the absence of tetracycline, and based on immunoblotting 
in the absence of tetracycline regulation of the protein is stringent. Such a 
system represents a useful method to induce Cre recombinase activity in L. 
mexicana, however as demonstrated previously in T. brucei there can be 
deleterious side-effects of uncontrolled and leaky Cre expression which may 
arise when utilising this system. In addition, this cell line has undergone three 
separate transfections to select for integration and expression of the inducible 
machinery and the regulatable enzyme, leaving only blasticidin deaminase 
(BLA), the phleomycin resistance gene (PHLEO) and puromycin acetyltransferase 
(PAC) selectable markers for integration of floxed gene and reporter gene 
cassettes. In the absence of any toxic side-effects of Cre expression, this 
methodology would represent a useful method for Cre mediated gene excision.  
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As an alternative to regulating cre expression in Leishmania, we looked to a 
conditional version of Cre developed in 2003 (Jullien et al). In this work the 
authors separated the Cre enzyme into two inactive fragments fused to FK506-
binding protein (FKBP12) and the binding domain of the FKBP12-rapamycin 
associated protein (FRB). Treatment with rapamycin therefore dimerises the Cre 
(diCre) subunits to reconstitute recombinase activity, and the expression of Cre 
as non-functional subunits is an elegant method to alleviate any side-effects of 
overexpression of active, cytotoxic Cre. Induction of diCre activity through 
rapamycin treatment of rat fibroblasts was detectable in vitro through loss of a 
floxed spacer region, resulting in promoter transfer to the 5’ end of a beta-
galactosidase cassette and highly efficient induction of X-gal positive cells. In 
addition, the low background activity of this assay demonstrates that diCre 
induction is very tightly regulated. Importantly, the functionality of diCre in vivo 
(Jullien et al. 2007) has implications for the utilisation of this system for 
deletion of genes during infection, a desirable property for researchers 
interested in regulating genes involved in pathogenesis. To this end, the system 
represents a desirable tool for use in molecular parasitology, where there is a 
paucity of systems to conditionally regulate essential genes in a disease context. 
Our collaborator Markus Meissner recognised the potential for this system and 
utilised it to great effect in Toxoplasma gondii to investigate the role of proteins 
thought to be necessary for cellular invasion (Andenmatten, Egarter & Jackson 
2012). Since this study, the rapid nature of diCre mediated gene excision has 
been utilised to efficiently excise drug selectable markers during the course of 
the forty eight hour Plasmodium falciparum erythrocytic life cycle (Collins et al. 
2013). This study utilised a strategy to excise the floxed 3’UTR of a target gene 
in order to ablate the poly-adyenylation site (PAS), yet down regulate gene 
expression was unsuccessful due to an alternative PAS. A more successful 
strategy involved integrating a floxed version of the apical membrane antigen 1 
(PfAMA1) coding sequence which was successfully excised following diCre 
activation, thereby preventing invasion of erythrocytes by the merozoites (Yap 
et al. 2014). This complementation method of a floxed target gene represents 
the most efficient method for gene deletion. The high levels of diCre mediated 
gene excision and protein loss presented in these studies demonstrates the 
efficiency of the system in the organisms, indicative of the potential for 
efficient activity in Leishmania. In terms of kinetoplastids, only one study to 
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date has been published using diCre for the removal of drug selectable markers 
in T. cruzi (Kangussu-Marcolino et al. 2014), however the absence of an 
appropriately designed and conducted method to ablate endogenous genes in 
this study does not address the lack of useful techniques to manipulate gene 
expression in this organism.  
3.1.4 Research aims 
We aimed to design a robust, targeted and flexible approach to induce deletion 
of endogenous genes in Leishmania mexicana using the diCre system. In 
particular, we were concerned with adapting this system to induce deletion of 
genes essential to parasite survival due to the lack of a conditional gene deletion 
system for such genes in Leishmania. Therefore we will: 
1. Design a Gateway based cloning strategy to generate diCre and floxed 
gene vectors to replace endogenous target genes 
2. Apply this strategy to generate an L. mexicana line expressing diCre from 
the CRK3 locus and a floxed green fluorescent protein transgene at the 
ribosomal locus  
3. Test the efficiency of diCre mediated recombination by loss of a GFP 
expression in promastigotes and amastigotes 
3.2 Results 
3.2.1 Design of a DiCre expression construct for L. mexicana 
Two elements are necessary in order to carry out diCre mediated site-specific 
recombination; sufficient expression of the dicre coding sequence and a loxP 
flanked copy of the target gene of interest. Previous studies have conferred 
diCre expression through transient plasmid transfection (Yap et al. 2014), by 
integrated expression to generate a diCre ‘parental’ line at multiple loci 
(Andenmatten, Egarter & Jackson 2012) or in array with the floxed gene (Collins 
et al. 2013). These studies were carried out in haploid, apicomplexan parasites, 
therefore in the context of the diploid Leishmania expression of the diCre by 
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integration and subsequent replacement of a target gene was deemed a 
practical strategy.  
We obtained the in silico dicre sequence from our collaborators in order to 
design and synthesise an appropriate vector for diCre expression. The dicre 
construct encodes each subunit separately, with each open reading frame 
encoding a 5’MAPKKKRKVV eukaryotic nuclear localisation signal (NLS) peptide 
(Kalderon et al. 1984). The N-terminal domain residues 19-59 of Cre (Cre59) are 
coupled to the FK506-binding protein (FKBP12) by a 15 amino acid linker, and 
the C-terminal domain residues 60-343 of Cre (Cre60) are linked to the binding 
domain of the FKBP12-rapamycin-associated protein (FRB) via a 12 amino acid 
linker. Due to the poly-cistronic expression of genes by PolII in Leishmania, there 
is no requirement to include promoter regions into an expression vector. 
However, appropriate gene flanks must be introduced to a transgene cassette to 
confer the necessary splice acceptor site (SAS) and poly adenylation sites (PAS) 
for trans-splicing and polyadenylation to generate mature messenger RNA. To 
confer stable expression of diCre in both promastigotes and amastigote forms, 
each encoded polypeptide was flanked with 198bp 5’ and 3’actin (LmjF.04.1230) 
or beta-tubulin (LmjF.08.1230). Annotated mapping of the splice and poly-
adenylation sites are only available from TriTrypDB for Leishmania major, 
showing the appropriate splice sites 73bp and 75bp upstream of the coding 
sequence (CDS) respectively. The synteny between different species of 
Leishmania allows efficient expression of transgenes from vectors containing 
regulatory flanks derived from L. major (Misslitz et al. 2000). In order to select 
drug resistant clones following transfection and integration of the construct, a 
blasticidine resistance cassette was incorporated downstream of dicre. To confer 
stable expression of the marker, the cassette was flanked by 300bp regions 
derived from the 5’ and 3’ arms of the dihydrofolate reductase-thymidylate 
synthetase (DHFR-TS) gene from L. major (Goyard & Beverley 2000), and this 
region was flanked by multiple cloning sites to exchange the drug resistance 
cassette if required in the future. Following this in silico design process, the 
construct was synthesised (Figure 3:1a.). 
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Figure 3:1- Schematic depicting the design of the L. mexicana diCre expression construct. 
Panel a. represents the original, synthesised construct encoding each dicre subunit and the 
blasticidine resistance marker (bsd) flanked with regulatory regions to confer expression by 
transplicing (red circle) and polyadenylation (AAA). Panel b. represents the optimised diCre vector 
with extended 3’ actin flank to confer the appropriate polyadenylation signal and enhance 
expression of the FKBP12-Cre59 subunit. Also shown is the strategy for restriction enzyme 
mediated replacement of the resistance cassette. 
 
The synthesised construct was flanked with 5’ and 3’ arms of homology from the 
flanking regions of the crk3 gene locus (detailed in section 3.2.3), allowing 
transfection and homologous recombination to replace the first crk3 allele. 
Integration and replacement was confirmed by PCR, however following poor 
detection of the FKBP12-Cre59 subunit by immunoblotting, analysis of the 
available gene expression data from TriTrypDB revealed the primary site of 
regulation to be 585bp downstream of the actin stop codon. This is not present 
in the synthesised vector, so in order to create an ‘optimised’ expression vector 
additional 650bp fragment was inserted through mutagenesis of the original 
vector to insert BamHI and NotI sites, PCR amplification of the extended 
fragment containing these sites and subsequent ligation (Figure 3:1b.). This 
optimised construct was used for all future experiments.  
3.2.2 Design of a loxP construct for L. mexicana 
In order to regulate the expression of a gene using diCre site-specific 
recombination, the target gene must be flanked by loxP sites. The design 
rationale is the integration of a gene of interest (GOI) into a floxed multiple 
cloning site (MCS) by restriction enzyme cloning, a practical strategy which has 
been utilised by others to effectively excise a number of genes through diCre 
mediated recombination (Andenmatten et al. 2012, Yap et al. 2014). In contrast 
to the diCre vector, in silico design and synthesis of a small (1.1kbp) loxP vector 
5’actin nls-fkbp12-cre59 5’β-tub3’actin nls-frb-cre60 5’dhfr 3’dhfrbsd3’β-tub
5’actin nls-fkbp12-cre59 5’β-tubExtended 3’actin nls-frb-cre60 3’β-tub
XbaI
SacI
SmaI
KpnI
5’dhfr 3’dhfrsat
5’dhfr 3’dhfrhyg
5’dhfr 3’dhfrbsd
BamHI NotI
a.
b. AAA
AAA
AAA
AAA
AAA
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backbone was constructed, allowing other elements to be incorporated through 
restriction digest cloning (Figure 3:2a). This backbone consisted of a SAS from 
the established pGL631 transgene expression construct (Misslitz et al. 2000) 
upstream of a MCS. The addition of 6x hemagglutinin (HA) downstream of the 
MCS to confer a C-terminal epitope tag to the expressed gene of interest (GOI), 
thereby facilitating subsequent expression monitoring through western blotting 
or immune fluorescence. The inclusion of unique restriction sites flanking this 
tag allows 6xHA replacement by other epitope tags, such as the GFP coding 
sequence at the N or C-terminal of the GOI. A 3’ flank conferring a PAS from the 
vector pGL631 was included downstream of the GOI, and two locations flanked 
by restriction sites formed the template for which a puromycin resistance 
cassette (Figure 3:2b) and an mCherry cassette (Figure 3:2c) could be cloned in 
by restriction digest.  
 
Figure 3:2- Schematic depicting the construction of a loxP vector. a. The in silico designed 
and synthesised vector backbone ready for restriction digest cloning of; b. the puromycin 
resistance cassette from pGL631, and c. the HASPB18-mCherry expression cassette from 
pGL1893. d. The final vector ready for gene of interest (GOI) insertion by restriction digest 
mediated cloning for loxP site flanking (blue arrows). The 6xHA can be readily exchanged with 
other epitope tags such as GFP. Mutagenesis of the XhoI site to the 5’CDS of mCherry facilitates 
the replacement of HASPB18-mCherry with other reporter cassettes.   
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Following synthesis of a loxP backbone, drug resistance and fluorescent gene 
cassettes were PCR amplified from pGL631 and pGL1893 respectively and 
inserted through restriction digest cloning to generate the full-length loxP vector 
(Figure 3:2d). The loxP vector contains a loxP flanked GOI site with a C-terminal 
6xHA sequence, a puromycin resistance cassette and an mCherry reporter with 
an N-terminal hydrophilic acylated surface protein B (HASPB18) domain for 
membrane trafficking (Denny et al. 2000). Mutagenesis was also performed to 
exchange the XhoI restricition site from upstream to downstream of the SAS 
regulating mCherry expression in order to replace this cassette with the open 
reading frame of an alternative reporter. The result is a construct that once 
transfected into Leishmania mexicana permits puromycin selection of clones 
with expression of a conditionally regulatable target gene. Induction of diCre 
mediated site specific recombination will excise the gene, resulting in 
detectable protein loss through immunoblotting with an antibody raised against 
the protein tag. An mCherry cassette was included to assist phenotypic analysis 
by fluorescent microscopic imaging or flow cytometry analysis. 
3.2.3 A flexible method for homologous flank addition 
In contrast to previous studies utilising diCre in haploid organisms, the 
implementation of a flexible system for gene replacement of the diploid (and 
sometimes polyploid) Leishmania poses a challenge. An advantage of genetic 
manipulating of Leishmania is the well established protocol for transfection and 
replacement of a target gene through recombination of homologous flanks (Cruz 
et al. 1991), therefore the replacement of one allele with the diCre cassette and 
the second with a floxed gene of interest represents a feasible strategy. 
However, the addition of gene homologous flanks to these constructs by 
restriction enzyme cloning represents a laborious cloning method, one which 
would impede the utilisation of diCre for targeting multiple genes. An 
alternative cloning methodology is Gateway recombination, whereby the 
addition of att sites on different constructs enables enzyme mediated 
recombination and linkage in a manner more conducive to high-throughput 
cloning. As such, we utilised the Multisite Gateway three-fragment vector 
construction kit for the addition of gene homologous flanks the diCre and loxP 
vectors by sub-cloning each construct into a pDONR221 vector. PCR amplification 
of between 0.5-1kbp of 5’ and 3’ flanks surrounding a target gene from gDNA 
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with oligos containing the appropriate att sites generates amplicons which can 
be recombined into pDONR vectors in a reaction catalysed by BP clonase (Figure 
3:3). The incorporation of unique restriction sites (such as PacI and PmeI) into 
these oligos enables the transfection fragment to be digested following flank 
addition. Finally, these individual elements can be cloned into a single vector by 
an LR clonase mediated reaction, thereby flanking the diCre and loxP vectors 
with the appropriate homologous DNA sequences to allow gene replacement by 
PacI and PmeI digest and subsequent transfection.  
 
 
Figure 3:3- Pipeline of Gateway mediated addition of target gene homologous flanks to 
diCre and loxP vectors. 1. Primers (blue arrows) containing appropriate att sites and 5’ PacI or 
3’PmeI unique restriction sites amplify a 0.5-1kbp region up and downstream of the gene. 2. BP 
clonase catalysis the insertion of these flanks into their appropriate vectors. 3. The resulting 5’,3’ 
and diCre or loxP vectors are recombined into a pDEST vector by LR clonase 4. The final vector is 
linearised by PacI and PmeI digest for 5. transfection into L. mexicana. This method enables 
flanking of both the floxed gene of interest (GOI) expression cassette and diCre expression 
cassette. 
3.2.4 Functional analysis of diCre activity 
By utilising the Gateway system, the ‘non-optimised’ diCre construct was 
flanked by 500bp regions of homology from the gene encoding the L. mexicana 
cdc-2 like protein kinase CRK3 (A detailed description of the process and 
rationale of regulating CRK3 expression is the topic of Chapter 4). Integrative 
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replacement of CRK3 by diCre at this locus was conducted to establish whether 
expression of diCre from an endogenous gene locus as opposed to the ribosomal 
locus would be sufficient to induce efficient gene loss. Blasticidin selection 
yielded a number of surviving clones, with protein extracts prepared from six of 
these to detect expression of the diCre subunits. Immunoblotting with polyclonal 
antibodies against residues in the FRB and FKBP12 domains resulted in good 
detection of expression of the 46kDa FRB-Cre60 subunit, but no detection of the 
smaller FKBP12-Cre59 (Figure 3:4b). This may be as a result of its size or more 
rapid degradation; however optimisation to confer stability to this subunit by 
rapamycin treatment to induce diCre complex formation did not improve 
detection. By in silico expression analysis of the actin gene, it was discovered 
that the lack of a poly-A site within the 3’flank of Cre59 may result in reduced 
expression of the protein. Therefore the optimisation shown in Figure 3:1 was 
carried out to extend the flank and confer this site. In order to circumvent the 
problematic Western blotting process, a cell line was generated by integration of 
a loxP flanked GFP open reading frame from the ribosomal locus: [SSU GFP Flox]. 
This line was strongly fluorescent as confirmed through fluorescence microscopy 
(Figure 3:4a) and was used as negative control to investigate growth and 
fluorescence following rapamycin treatment. Transfection of this line with the 
diCre-CRK3 construct resulted in the heterozygous experimental line 
(Δcrk3::DICRE/CRK3 [SSU GFP Flox]) retaining high levels of GFP expression and 
replacement of CRK3 as confirmed by PCR analysis.  
 
3.2.5 diCre conditional deletion of GFP in promastigotes 
Experimental (Δcrk3::DICRE/CRK3 [SSU GFP Flox]) and control ([SSU GFP Flox]) 
cultures were seeded at 1x106 promastigotes/ml with increasing rapamycin doses 
to identify any cytotoxic effects of rapamycin treatment and establish the 
optimal dose for diCre activity. There was no effect on the growth of the control 
or experimental parasites over 5 days even at the highest dose of 250nM (Red 
plotted lines in Figure 3:4c), a dosage of around twenty times less than the L. 
major inhibitory IC50 of 4.9±0.5μM (Madeira da Silva et al. 2009). In conjunction, 
Wt L. mexicana seeded at 5x105 cells/ml were treated with zero, 100nM, 500nM 
and 1µM doses of rapamycin to investigate any effect on growth or the cell cycle 
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(Figure 3:4d.), resulting in a minor growth rate reduction at 1µM treatment but no 
detectable effect on the cell cycle.  
 
Figure 3:4- Growth rate of L. mexicana promastigotes following rapamycin treatment. Panel 
a. is a representive image of green fluorescent protein expression by the Δcrk3::DICRE/CRK3 
[SSU GFP 
Flox
] experimental line. b. Analysis of diCre expression from the CRK3 locus by western 
blotting of protein extracted from 3 clones grown in the presence (+) or absence (-) of 50nM 
rapamycin using an anti-FRB antibody and EF1a loading control. c. Experimental 
Δcrk3::DICRE/CRK3 [SSU GFP 
Flox
] or control [SSU GFP 
Flox
] L. mexicana promastigotes were 
seeded at 1x10
6
 cells/ml and incubated in the presence or absence of between 1 to 250nM 
rapamycin. Cell density was determined at 24 hour intervals and the mean result of between 1-3 
counts per sample shown (Error shown as SD). d. Wild-type L. mexicana were seeded at 5x10
5 
cells/ml and incubated in the presence or absence of between 0-1000nM rapamycin. Cell density 
was determined every 24 hours and the mean triplicate value is plotted (Error shown as SD). At 72 
hours DNA content analysis was conducted by methanol fixation and PI staining. Flow cytometry 
analysis of 100,000 cells per group and graphical representation of the DNA content of each 
population is shown.  
Gene excision efficiency was investigated by PCR amplification of the floxed GFP 
locus following 120 hours in culture. Analysis shows amplification of a smaller 
0.6kbp amplicon following treatment and therefore GFP excision at all but the 
lowest dilutions, with no background diCre activity in the untreated 
experimental sample (Figure 3:5a.). Amplification of the excised fragment is not 
a quantitative measure of loss as small amplicons are preferentially amplified, 
consequently Southern blotting of these genomic DNA was conducted, 
demonstrating highly efficient loss of floxed GFP above 50nM treatment (Figure 
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3:5b.). Flow cytometry at day 5 demonstrates an equal loss of fluorescence in all 
samples treated with greater than 50nM of rapamycin, however this reduction in 
protein expression is not as pronounced as the relative DNA loss (Figure 3:5c). 
Western blotting confirms efficient protein loss by immunoblotting of protein 
extracts 5 days following treatment with 100nM rapamycin using a monoclonal 
anti-GFP antibody (Figure 3:5d.). This slower loss of protein is likely due to the 
stability of GFP, in conjunction with the high levels of expression from the 
ribosomal locus as a reservoir of protein to be degraded and mature mRNA 
transcript to be expressed in the absence of the gene coding sequence. These 
data demonstrate that expression of diCre from the CRK3 locus is sufficient to 
efficiently excise the GFP transgene at rapamycin concentrations above 25nM, 
and importantly that no background diCre activity can be detected in the 
absence of ligand. 100nM rapamycin was selected as sufficient dose to induce 
efficient diCre activity and gene loss in promastigotes whilst having no effect on 
in vitro growth or cell cycle progression.  
 
Figure 3:5- DiCre inducible loss of GFP expression in promastigotes. a. Experimental 
Δcrk3::DICRE/CRK3 [SSU GFP 
Flox
] or control [SSU GFP 
Flox
] L. mexicana promastigotes were 
seeded at 1x10
6
 cells/ml and incubated in the presence or absence of between 1 to 250nM 
rapamycin. Genomic DNA was extracted at day 5 post rapamycin treatment from each 
experimental and control treatment group. Loss of floxed GFP was detected by PCR amplification 
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of the floxed GFP region which reduces in size from a 1.45KBp to a 0.69KBp amplicon using the 
primers shown in the lower schematic. b. 3µg gDNA was digested overnight with SacI and SpeI 
restriction enzymes and the digested DNA resolved on a 0.7% agarose gel followed by overnight 
transfer of resolved DNA to a Hybond-N membrane. Floxed GFP loss by Southern blotting was 
determined using a GFP CDS probe to detect a 3.1kBp digested genomic fragment as depected on 
the lower schematic. c. Flow cytometry analysis of promastigotes at 5 days post treatment. d. GFP 
loss by immunoblotting of protein extracted from cells 120hr post 100nM treatment with anti-GFP 
Ab with EF1-alpha loading control.  
 
3.2.6 diCre conditional deletion of GFP in amastigotes 
In order to test if diCre activity could be used in amastigotes, the experimental 
line (Δcrk3::DICRE/CRK3 [SSU GFP Flox]) was inoculated into Balb/c footpads and 
amastigotes extracted following 2 months infection. Lesion derived amastigotes 
retained high levels of green fluorescence (Figure 3:6c) and were subjected to 
0nM, 250nM, 500nM or 1µM rapamycin treatment in Schneider’s medium. Cells 
were then washed and used for 1:2 in vitro infection of bone-marrow derived 
macrophage extracted from Balb/c mice. The rationale for this ‘pre-treatment’ 
method was to determine whether diCre activity in amastigotes is efficient after 
24 hours to allow infection of macrophages in the absence of the immuno-
modulatory rapamycin.  
By gDNA extraction at day 5 post infection and PCR amplification using primers 
amplifying a 1.44kBp floxed GFP retained fragment, the amplification of 0.65Kbp 
fragments are indicative of efficient floxed GFP excision at all rapamycin 
treatment concentrations (Figure 3:6a). In contrast, the loss of GFP intensity is 
not as pronounced as in the promastigote study (Figure 3:5c) where rapamycin 
treatment results in ~90% loss of fluorescence intensity. In addition, it was more 
difficult to quantify by flow cytometry because of the presence of macrophage 
cellular debris in the amastigote pre-gate (Figure 3:6b). Microscopic analysis of 
live amastigotes during macrophage infection reveals a very variable rate of GFP 
loss between individual cells (Figure 3:6c), some of which have undergone 
complete loss (white arrows) and some retaining strong fluorescence. This is 
independent of the rapamycin treatment, leading again to the conclusion that 
the integration of floxed GFP and subsequent high level of GFP expression from 
the ribosomal locus requires a long incubation period for the cells to undergo 
GFP degradation and transcript loss, coupled with the transfer of cytosolic 
protein between cells during division. This may be particularly true of lesion-
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derived amastigotes which undergo replication and protein turnover at a 
reduced rate compared with axenic or macrophage-derived amastigotes (Kloehn 
et al. 2015). Despite the reduced rate of protein loss, these data demonstrate 
the functionality of conditional deletion in amastigotes and their retention of 
diCre expression and activity following in vivo infection and recovery.  
 
Figure 3:6- DiCre induced loss of GFP in amastigotes. a. PCR amplification of gDNA purified 
five days post macrophage infection to detect floxed GFP excision. Samples run alongside a 1Kb+ 
DNA ladder (L). b. Flow cytometry analysis of GFP fluorescence intensity loss; (left) events were 
pre-gated on an amastigote gate based on forward (size) and side (granularity) scatter. Blue plots 
represent the contaminant cellular ‘debris’ in this gate as a result of macrophage lysis following 
infection and amastigote preparation. A gate was drawn based on the untreated sample green 
fluorescent expression and used to quantify loss of GFP as a % (right) based on two biological 
replicates (Error indicates SD). c. Representative images of live cell imaging at days 5 post 
infection with GFP and DAPI nuclear DNA staining. Non-fluorescent amastigotes are indicated with 
white arrows.  
 
3.2.7 Stationary phase induction of GFP FLOX loss 
A potential utilisation of the diCre system is to induce deletion of a virulence 
factor or essential gene in promastigotes by rapamycin treatment for a short 
period of time, followed by infection into murine hosts to investigate the host-
pathogen interactions or resulting parasite burden. To establish whether such an 
‘ex vivo’ strategy would be experimentally viable, a comparison between the 
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dynamics of GFP loss over time in replicating, log-phase and quiescent, 
stationary phase promastigotes was established (Figure 3:7a). Genomic DNA was 
extracted following between 1 and 20 hours 50nM rapamycin treatment and PCR 
analysis conducted to investigate the rate of floxed GFP excision. Amplification 
of a pronounced 1.44kBp fragment demonstrates that the loss of GFP is 
inefficient at this dose after 20 hours for stationary cells and requires a higher 
dose or incubation time. In contrast, in the dividing population floxed GFP 
efficiency of excision was higher, with amplification of a 0.69kBp fragment at 20 
hours post treatment indicative of highly efficient rates of floxed GFP loss. The 
higher cell density of the stationary population is a likely contributing factor to 
this reduced rate of excision, with the high concentration of cells and therefore 
diCre complexes diluting the rapamycin ligand relative to the sparser logarithmic 
cultures. With this consideration, an ‘ex vivo’ pilot trial was conducted to 
establish the stability of diCre inducible gene loss over the course of an 
infection. Inducible deletion of GFP was induced by a higher dose rapamycin 
treatment (150nM) of stationary phase promastigotes for 24 hours, followed by 
inoculation into the ear pinna of Balb/c mice with an uninduced control sample. 
Amastigotes were recovered from the draining, cervical lymph nodes 6 months 
post infection, grown as promastigotes in culture for genomic DNA extraction. 
Analysis shows highly efficient deletion, as confirmed by PCR (Figure 3:7b) and a 
90% loss of GFP fluorescence compared with the uninduced control (Figure 3:7c). 
These preliminary data establish the potential of conditional deletion in 
promastigotes resulting in loss of the encoded protein during in vivo infection. 
This study establishes that 50nM is sufficient to induce efficient levels of gene 
deletion in cells seeded at between 5x105 to 7.5x106 cells/ml in 20 hours, with 
no deleterious effect on growth. 
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Figure 3:7- ‘Ex vivo’ diCre conditional deletion of GFP. a. Floxed GFP gene loss in log-stage 
(L) or stationary (S) promastigotes following treatment with 50nM rapamycin over the course of 
hours. Panel b. GFP deletion retention after 6 months murine infection by PCR amplification of 
gDNA extracted from lesion derived parasites at the GFP locus. Panel c. shows % loss of green 
fluorescent protein following diCre induction and in vivo infection by FACS (between 50,000 and 
100,000 events each population).  
 
 
3.3 Discussion 
Development of a robust, flexible and conditional method to conduct gene 
deletion in Leishmania has been established. Conditional deletion of the green 
fluorescent protein coding sequence demonstrates the efficacy of the diCre 
system in both the promastigote and amastigotes lifecycle stages, with induction 
stringently controlled in the absence of the rapamycin ligand. The efficiency of 
the system and our targeting strategy represents an advantageous method for 
essential gene targeting in both the in vitro and in vivo contexts.  
3.3.1 diCre in L. mexicana: efficacy and advantages over current 
molecular tools 
There have been no previous reports of Cre recombination in Leishmania. 
Previous attempts to utilise constitutive or conditionally expressed Cre has 
resulted in toxicity and ‘leakiness’ in T. brucei (Barrett et al. 2004), so a similar 
method of conditional Cre expression in Leishmania may also result in 
deleterious side effects resulting from leaky expression. DiCre expression in 
Leishmania mexicana has no effect on promastigote growth or amastigote 
infectivity before or after induction with rapamycin and is therefore a practical 
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method to regulate Cre-mediated recombination. In addition, active diCre 
mediates levels of excision >90% by analysis of the reduced GFP intensity over 
the course of in vitro (Figure 3:5) or ‘ex vivo’ (Figure 3:7) induction. Efficient 
excision of the GFP transgene is a proof of principle for development of 
inducible deletion of endogenous genes encoding important proteins for survival 
and virulence. A key aspect of making the diCre cloning process conducive for 
targeting such genes is the use of Gateway recombination to add homologous 
flanks and facilitate target gene replacement with the diCre sequence. The 
expression of the diCre subunits from this endogenous gene locus must therefore 
be sufficient to induce loss of the target gene. Importantly, these experiments 
show that replacement of one CRK3 gene with the diCre sequence confers 
expression of the proteins at a level sufficient for inducible deletion in both 
promastigote and amastigote life cycle stages. The method to replace both 
copies of a gene with a loxP flanked gene for complementation and the second 
by diCre integration remains a viable and flexible strategy, one which was 
utilised in the following chapter. These findings are promising as they address a 
limitation in the current molecular toolkit; the ability to conditionally induce 
loss of an essential gene.  
The induction of diCre mediated gene loss is rapid and efficient, however the 
subsequent time required for protein and transcript degradation may be a factor 
in slowing the rate at which a phenotype can be detected following essential 
gene deletion. A more rapid approach to regulate protein expression involves 
linkage of a target protein with a regulatory destabilisation domain (DD) based 
on a modified FKBP domain, whereby protein stability and therefore activity is 
conferred by Shld-1 addition (Banaszynski et al. 2006). An advantage of this 
method is the rapid nature of induction, with DD-YFP stability by Shld-1 ligand 
treatment occurring within 8 hours, and conversely rapid protein degradation 
within around 2 hours occurs once the ligand is removed (Madeira da Silva et al. 
2009). Loss of ddGFP is therefore far more rapid than by diCre mediated gene 
deletion, as cells must be left for five days to ablate the protein despite 
undergoing rapid floxed GFP deletion. The authors used the DD method to 
regulate stability of UDP-galactopyranose mutase (UGM), a protein encoded by 
GLF involved in linkage of the membrane bound surface protein 
liphophosphoglycan (LPG). By complementation of a GLF deletion line with a 
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ddGLF vector, the authors were able to regulate LPG expression in a tightly 
controlled manner, resulting in sensitivity to complement mediated lysis in the 
absence of Shld-1 ligand. However, GLF and LPG null mutants are viable as 
promastigotes in vitro and as this study is the only publication where the dd 
domain is used in Leishmania it appears that the method is not conducive to 
essential gene regulation. Personal communication with colleagues who have 
used the system for regulation of essential Leishmania proteins reveals that 
there remains background retention of a non-regulated, wild-type protein. This 
is likely due to retention of an extra copy of the gene which does not contain 
the domain indicates that linkage of the FKBP regulatory domain to the encoded 
protein may ablate the activity of the product, even in the presence of the 
stabilising agent. As a result, there may be strong selective pressure on those 
parasites retaining an additional copy of the gene, leading to drug resistant 
Leishmania with only partial regulation of protein expression. An advantage of 
floxed gene complementation is that it may circumvent this selective pressure 
due to the lack of any FKBP-like exogenous protein domain. By this method there 
will be weaker selective pressure on parasites with altered ploidy, resulting in 
the majority of transfectants expressing the protein from the floxed gene 
resulting in more stringent regulation. The diCre strategy may therefore 
represent an improved method to regulate gene and down-stream protein 
expression, albeit with a delayed deletion phenotype. 
High-throughput methodologies for regulating the expression of whole families of 
proteins is a desirable and powerful tool. We have endeavoured to make the 
diCre/loxP cloning process as amenable as possible, however the necessity to 
integrate these constructs is a limiting factor in terms of the time required to 
generate and select clonal lines. The lack of necessary Dicer-like and argonaute 
proteins prevents the small inhibitory RNA mediated degradation of transcript 
and the use of RNA interference in most species of Leishmania. Since the 
discovery of a functional RNA interference pathway in T. brucei (Ngô et al. 1998) 
and the development of an inducible method for generating stem-loop construct 
to generate double stranded RNA guides for siRNA targeting of specific genes (Shi 
et al. 2000), this method has been used extensively to study gene function. 
There are no limitations based on gene copy variation by this method, as the 
siRNA mediates targeted degradation of mRNA to knockdown expression, 
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therefore one round of transfection is sufficient to generate a conditional line. 
The development of Gateway cloning methods has accelerated the rate at which 
RNAi stem-loop constructs can be cloned to target gene families, as exploited by 
application to the 190 protein kinase ‘kinome’ (Jones et al. 2014). The pooling 
of such clones produces specific protein family libraries for high-throughput 
screening to identify ‘hits’ based on loss or prevalence of particular genes in a 
population following altered environmental conditions such as differentiation 
(Jones et al. 2014; Mony et al. 2014) or in vivo infection. DiCre mediated 
deletion represents a system which is far less conducive to such high-throughput 
application, however there is an absence of a conditional RNAi method in 
Leishmania. The absence of the RNAi pathway in the L. (Leishmania) subgenus is 
an impediment to the utilisation of RNAi to dissect gene function. Despite the 
retention of a functional RNAi pathway in the L. (Viannia) subgenus, there is no 
method for conditional regulation of RNAi mediated transcript degradation as 
current ‘stem-loop’ constructs lack any inducible promoters for regulation.  
The average time frame to generate such RNAi lines of ~1 week is very rapid 
compared with the roughly two and a half months required for the generation of 
a diCre inducible line. However, the relatedness of kinetoplastids is such that 
75% of coding gene sequences are shared between African trypanosomes and 
Leishmania (Subramaniam et al. 2006). Therefore any ‘hits’ derived from such 
tractable, high-throughput studies can be used to form concise hypotheses with 
which to utilise diCre in the study of the Leishmania homologues, and would be 
particularly attractive when knockdown results in a severe phenotype associated 
with essential protein loss. RNAi is not a perfect tool, indeed a limitation of the 
system is the variation in transcript down-regulation, and also knockdown in the 
absence of tetracycline due to the ‘leakiness’ of TetR mediated control (Tu & 
Wang 2004). DiCre has no such background activity as excision in the absence of 
rapamycin was not detected and consistently induces loss of GFP through 
efficiently induced site-mediated recombination and represents a useful strategy 
with which to dissect the function of genes and their encoded protein in a tightly 
regulated manner.  
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3.3.2 The use of rapamycin and Leishmania TOR 
Rapamycin is the ligand necessary for diCre induction, but genomic analysis 
reveals that Leishmania have three homologues of the mammalian target of 
rapamycin (mTOR) gene (Madeira da Silva & Beverley 2010). mTOR is a 
serine/threonine kinase functioning as a master regulator of many cellular 
processes through separate signal transduction pathways. An important function 
of mTOR is in complex formation with Raptor and mLST8 (mTORC1) to mediate 
biological processes such as translation and autophagy (Ballou & Lin 2008). 
Studies of the processes controlled by the mTORC1 complex have been 
amendable through rapamycin treatment, whereby the compound binds the 
FKBP12 protein. This rapamycin-FKBP12 complex then binds the FRB region of 
the mTOR protein, obstructing active site mediated phosphorlyation of substrate 
and ‘weakening’ of the mTORC1 complex (Yip et al. 2010). This allosteric 
inhibition has enabled the study of pathways down regulated as a result of 
mTORC1 complex inhibition, however other mTOR activities are not inhibited by 
rapamycin such as mTORC2 complex formation (Ballou & Lin 2008). The presence 
of mTOR homologues in Leishmania with conserved motifs such as HEAT and FRB 
domains raises the issue of rapamycin as a ligand for diCre induction. mTOR 
binding by rapamycin is dependent on a Serine residue at position 2035, with 
mutagenesis of this site to any residue other than an Alanine preventing FKBP12-
rapamycin binding (Chen et al. 1995). L. major and L. mexicana TOR1 
(LmjF.36.6320 and LmxM.36.6320) contain tryptophan residues at this site, 
thereby conferring resistance to rapamycin inhibition. The two remaining TORs, 
TOR2 (LmjF.34.4530 and LmxM.34.4530) and TOR3 (LmjF.34.3940 and 
LmxM.34.3940) both contain functional alanine residues at this site, however 
little is known about the activity of these mTOR homologues. Gene deletion of 
TOR3 results in normal Leishmania major promastigote growth and 
differentiation but attenuation in vivo, and a null mutant of TOR2 could not be 
generated as indicative of essentiality (Madeira da Silva & Beverley 2010). In 
addition to mTOR homologues in Leishmania, a BLAST search identifies three 
FKBP12 homologues encoded by LmxM.22.1430, LmxM.19.1530 and 
LmxM.36.0230. A tryptophan residue at position 59 is associated with binding of 
rapamycin to FKBP12 (Choi et al. 1996), and interestingly this residue is 
conserved in all encoded Leishmania FKBP12. The effect of rapamycin treatment 
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on each of these proteins is a potential concern in the context of deletion 
activity, but in contrast rapamycin treatment has been shown to enhance 
amastigote proliferation during intracellular infection of macrophage (Pinheiro 
et al. 2009; Jaramillo et al. 2011). Considering the relatively low dose used for 
rapid diCre induction (100-200nM), and the absence of cell cycle defects and 
only a marginal growth reduction with a high (1µM) dosage (Figure 3:4), 
rapamycin treatment does not result in any detectable, deleterious side-effects 
in promastigotes.  
3.3.3 Implications for in vivo conditional deletion 
Previous studies on genes associated with virulence and in vivo maintenance of 
parasite survival rely on the survival of null mutant parasites as promastigotes in 
vitro, therefore if a protein is essential for survival in both promastigotes and 
amastigotes the study of in vivo infectivity is severely limited. Currently, the use 
of plasmid shuffle has allowed the N-Myristoyltrnsferase (NMT) protein to be 
identified as essential to L. donovani amastigotes survival in vivo by retention of 
the plasmid encoding NMT and a toxic TK in array throughout murine infection 
(Paape, personal communication). The lack of regulation of this system is a 
limitation which prevents NMT expression from being manipulated to investigate 
further host-parasite dynamics, such as the resulting immune response to 
infection with null mutant parasites. Proteins such as NMT are potential targets 
for drug inhibition, therefore diCre mediated ‘ex vivo’ excision may represent a 
method to study the immune response and outcome of infection with conditional 
null mutants. The nature of diCre deletion is such that a gene is ablated but 
transcript and protein can remain as a pool in the population; this is exemplified 
by the retention of GFP in many of the lesion derived amastigotes despite 
efficient GFP loss. This in vitro caveat may benefit the ‘ex vivo’ deletion 
strategy as deletion will not result in reduced protein expression immediately, 
thereby allowing infection to be established by metacyclic promastigotes with 
appropriate protein retention and translation from mRNA, but which are no 
longer able to transcribe the gene following differentiation and expansion as 
amastigotes. If inducible loss of the gene prevents establishment of infection, 
the protein expressed is therefore essential for amastigotes survival. A limit of 
this approach will be the efficiency of floxed gene deletion over the 24 hour 
time period; if the target gene is essential, there will be an outgrowth of cells 
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retaining the gene. As demonstrated in this study, when a gene is not essential 
for survival the rate of deletion remains constant over the course of infection 
(Figure 3:7b. & c.), therefore if the subsequent outgrowth population retain the 
full ‘floxed’ gene this is indicative of the selective pressure on this population in 
vivo. Gene deletion by active diCre occurs rapidly and consistently at treatments 
above 25nM, however the starting cell concentration must be taken into account 
when calculating excision as a similar dose in stationary cells results in poor 
excision. This study establishes that 50nM is a sufficient concentration for 
induction of gene deletion within 20 hours by seeding promastigotes to 5x105 to 
7.5x106 cells/ml (Figure 3:7). 
A desirable strategy for the validation of Leishmania proteins as therapeutic 
targets is the regulation of proteins essential to parasitic survival during 
infection. This is particularly important when a gene has been identified as 
essential in vitro thereby hindering research into its role in immune evasion or 
host manipulation in an in vivo context (Barrett et al. 1999). RNAi has been 
utilised to carry out such investigation in T. brucei, whereby knockdown is 
induced during murine infection by doxycyclin treated drinking water to induce 
degradation of the target transcript. By monitoring the resulting parasitaemia 
the outcome of knockdown and therefore essentiality of the target protein can 
be established (Abdulla et al. 2008). Direct in vivo regulation of Leishmania 
essential genes would be a significant tool for identifying proteins which would 
represent useful therapeutic targets; inducible deletion would result in loss of 
protein expression as a proxy of drug inhibition. Studies into host-Leishmania 
interactions would also benefit greatly by inducible deletion to bypass the early 
immune response to infection of null mutant metacyclics and examine the 
influence of the target virulence or regulatory factor in amastigotes directly. By 
deletion induction, analysis of the host immunobiology such as immune cell 
recruitment, activation and cytokine expression would lend itself to establishing 
the outcome of gene deletion in the context of the immune response. The 
dissection of host pathogen interactions by this method would expand our 
working knowledge and aid vaccine design (Kumar & Engwerda 2014).  
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4 Inducible deletion of the gene encoding the 
essential cdc2-like kinase, CRK3 
4.1 Introduction 
4.1.1 Essential genes as promising drug targets 
Since the establishment of transfection and homologous recombination to 
conduct gene deletion in Leishmania (Cruz & Beverley 1990), proteins have been 
identified which are essential to the survival of the parasites. Essentiality can 
manifest itself in a variety of ways; a lethal phenotype in all life-cycle stages, a 
conditional lethal phenotype whereby cell death is induced upon an alteration in 
growth conditions such as nutrient availability, or essentiality in one life cycle 
stage but not the other (Barrett et al. 1999). The identification of the latter is 
currently limited to the generation of viable, null mutant procyclic 
promastigotes which are subsequently unable to establish infection as 
amastigotes in a mouse or in vitro macrophage. By adhering to one of these 
conditions, a gene can be established as essential to virulence and therefore 
provisionally identified as a drug target. Barrett et al (1999) expand these 
criteria further by highlighting the fact that although removal of a gene results 
in a lethal phenotype, drug inhibition of the target protein may have no curative 
effect in a disease context. This is an important consideration if the encoded 
protein functions as a structural rather than catalytic component of an active 
complex, for example.  
By these criteria, the inherent essentiality of the protein is not sufficient to 
establish it as an appropriate drug target until active and catalytic sites confirm 
the protein as suitable for inhibition by chemicals or small molecules. In the 
absence of a conditional method to regulate gene expression, the analysis of 
genes as potential drug targets has relied on progressively advanced techniques 
such as recombinant protein activity assays (Gomes et al. 2010), mutant yeast 
complementation (Wang et al. 1998) and plasmid shuffle (Morales et al. 2010; 
Dacher et al. 2014). Recombinant protein assays are particularly useful for 
inhibitor screens because of their application in high-throughput inhibitor 
screens to identify loss of enzymatic activity (Walker et al. 2011) to enable 
testing of more specific inhibitors in intracellular parasite assays (Rachidi et al. 
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2014). Through mutagenesis of the encoding DNA sequence, particular residues 
can be identified as active sites required for the correct function of the protein, 
thereby validating such regions for targeted inhibition of catalytic function by 
pharmacological inhibition. In an established recombinant system yielding high 
concentrations of active protein, the mutation of multiple residues is an 
amenable method to establish residues which compose active sites that 
represent targets for drug inhibition. Yet in such large scale screens, there can 
be issues with relating loss of enzyme activity with parasite killing once these 
compounds are applied to in vitro cultures due to off-target or non-specific 
effects of the inhibitors (Paape et al. 2014). There is no guarantee that 
enzymatic inhibition of recombinant complexes directly translates to in vitro 
efficacy of the same compound once applied to an intracellular screen. This 
dichotomy between assays represents a limitation with such studies, and ideally 
a more targeted means to uncover the phenotype by loss of the protein in vitro 
would better establish that protein as a therapeutic candidate. 
We are compromised in our ability to study and validate drug targets encoded by 
essential genes by the lack of a method to conditionally regulate their 
expression in Leishmania. Functional analysis of proteins encoded by essential 
genes by inducible gene deletion is a desirable tool in Leishmania, as it would 
allow the phenotypic validation of proteins as drug targets, particularly if 
utilised in a disease context. In conjunction with existing screening methods, 
knowledge of the phenotype resulting from inducible deletion would facilitate 
the testing of lead compounds and their validation as specific inhibitors; in this 
context, drug inhibition of a target protein in viable Leishmania should mimic 
the phenotype manifest by inducible gene deletion, such as arrest at a defined 
cell cycle checkpoint. By this method, the specificity of the inhibitor and the 
necessary dose required to elicit inhibition at a level equivalent to gene loss 
could be identified. 
4.1.2 CRK3 as a drug target in Leishmania 
Protein kinases mediate regulation of cellular function through phosphorylation 
of a diverse range of proteins to mediate cellular processes necessary for 
survival. As a result of this powerful regulatory activity, protein kinases 
represent useful therapeutic targets in a disease context; in mammalian cells, 
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kinase inhibition is particularly associated with anti-cancer treatment, whilst in 
parasitic protozoans the ability to repress kinase activity represents a promising 
avenue in preventing cell division, differentiation and survival (Naula et al. 
2005) during infection. A subset of protein kinases with particular importance in 
mediating the cell cycle are the cyclin dependent (CDK) protein kinases. Studies 
into the role of CDKs, such as cdc2 in S. pombe and mammalian cells 
demonstrate the essentiality of active CDK-cyclin complexes in regulating 
regimented cell cycle progression through mitosis (Gutiérrez-Escribano & Nurse 
2015). There is an established repertoire of approved, therapeutic kinase 
inhibitors for human use (Jänne et al. 2009), with CDK inhibition representing a 
promising therapeutic route to prevent tumour growth in human cancer. 
Compounds such as flavopiridol, olomoucine, roscovitine and kenpaullone exhibit 
a range of CDK inhibitory activities, and subsequent testing as anti-cancer agents 
for human use has been conducted (Cicenas & Valius 2011). 
Compounds which inhibit CDK activity such as indirubins function by competitive 
binding in the ATP binding pocket (Leclerc et al. 2001), with application of the 
use of such compounds in humans laying the foundation for similar CDK inhibition 
in trypanosomatids; the basis of such work was the discovery of homologues of 
mammalian CDKs, termed CDK related protein kinases (CRKs). These were first 
identified in L. mexicana by immunoblotting of cell extracts with a monoclonal 
antibody raised against the cdc2 conserved, 16 amino acid PSTAIR box (Mottram 
et al. 1993) implicated in cyclin binding. Western blotting detected the presence 
of multiple proteins in a range of molecular weights, suggestive of the 
expression of multiple CRKs. By cloning and sequencing, the LmmCRK1 protein 
kinase was identified by conserved structural components such as the PSTAIR 
domain and conserved phosphorylation sites found in CDC2. Protein kinase 
activity was confirmed in promastigote forms by immunoprecipitation and 
subsequent kinase activity assay. Later investigation revealed the essential role 
of CRK1 in mediating the cell cycle of L. mexicana by the failure to generate a 
null mutant cell line (Mottram et al. 1996), however the inability to complement 
a yeast cdc2 mutant by expression of lmmcrk1 was indicative of diversity from 
the yeast homologue (Mottram et al. 1993). In contrast, yeast complementation 
by a second CRK discovered in both L. mexicana (Grant et al. 1998) and L. major 
termed CRK3  was able to recover a yeast cdc2 mutant (Wang et al. 1998), 
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indicative of a closer homologous function to cdc2. However further analysis of 
LmxCRK3 demonstrates the diverged function of this CRK relative to its yeast 
homologue. Sequence analysis showing a 54% identity with mammalian cdc2 
implicates a sufficient divergence for specific targeting of the Leishmania CRK 
(Grant et al. 1998). LmxCRK3 is essential for growth of promastigotes by the 
selection of drug resistant cells with altered ploidy following replacement of the 
coding sequence with drug resistance markers.  
To be active, CRK3 must form a complex with a regulatory subunit cyclins (CYCs) 
and be de-phosphrylated at the ATP binding pocket and phosphorylated at the T-
loop residue (Grant et al. 2004). In the absence of a reverse genetic technique 
to conditionally delete CRK3 in L. mexicana, the use of CDK inhibitors, in this 
case flavopiridol, is an appropriate method to inhibit CRK3 activity. Flavopiridol 
treatment of promastigotes results in cell cycle arrest in G2/M (Hassan, 2001). 
RNAi of TbCRK3 which has ~78% sequence identity to LmxCRK3 in the closely 
related T. brucei results in arrest at the G2/M stage, however the resulting 
phenotypes differ depending on whether induction is carried out in bloodstream 
or procyclic forms (Tu & Wang 2004). A cell cycle arrest in G2/M resulting from 
flavopiridol treatment of L. mexicana procyclic promastigotes may be indicative 
of a shared function of active CRK3 in mediating the transition over mitosis 
between different species of kinetoplastids. Yet the inhibition of the mitotic 
activity of LmxCRK3 by competitive binding of flavopiridol to the ATP binding 
site may not be specific, as the presence of 12 predicted CRKs this compound 
may not be inhibitory to CRK3 alone.  
To be a useful drug target, the activity of a Leishmania protein must be 
inhibitory in the mammalian infective amastigote stage. Promisingly, treatment 
of L. donovani and L. mexicana infected murine macrophage with CDK inhibitors 
from an indirubin-based chemical library resulted in impaired parasite viability 
(Grant et al. 2004). Five indurubin kinase inhibitors which also showed inhibitory 
activity towards CRK3His were validated by this screen and subsequently tested 
against L. mexicana axenic amastigotes and promastigotes by in vitro growth 
curve analysis. However, only two of these compounds resulted in impaired 
growth as a result of impaired cell cycle regulation. CRK3 is active in both life 
cycle stages (Grant et al. 1998), but the absence of a mechanism to regulate 
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essential gene expression renders phenotypic assessment of gene deletion in 
both life cycle stages unfeasible. The cell cycle arrest phenotype by indurubin 
treatment is indicative of CRK inhibition in both life cycle stages, however the 
study was unable to identify the selectivity of such compounds towards CRK3. To 
facilitate a larger screen of possible anti-leishmanial compounds specifically 
targeting CRK3, recombinant CRK3:CYC complexes were expressed and used for 
functional analysis of protein kinase activity (Gomes et al. 2010) and high-
throughput inhibitor screening (Walker et al. 2011). 
A variety of cognate cyclins of have been identified in eukaryotic organisms, 
with 11 identified in L. major (Naula et al. 2005). Of these, CYC6 (Walker et al. 
2011) and the Leishmania specific CYCA pair with LmxCRK3 to form active 
protein kinase complexes which phosphorylate downstream mitotic regulators 
(Gomes et al. 2010). Active, recombinant L. major CRK3:CYCA complexes are 
phosphorylated at the T-loop residue T178 by a CDK activating kinase (CAK). Use 
of a yeast derived CAK, Civ-1 was utilised in activity assays, however Civ-1 
mediated phosphorylation at this site enhances but is not essential for kinase 
activity as measured by phosphorylation of histone-H1 substrate (Gomes et al. 
2010). Mutation of this T-loop residue to a glutamic acid in the P. falciparum 
homologue of cdc2 (PfPK5) mimics phosphorylation and increases histone-H1 and 
casein phosphorylation 5-10 fold (Graeser et al. 1996), but interestingly in 
Leishmania, T178E mutagenesis of LmxCRK3 inhibits functional rescue in S. 
pombe (Wang et al. 1998) and ablates CRK3:CYCA recombinant protein kinase 
activity (Gomes et al. 2010). These findings are in partial agreement with cdc2 
mutant yeast recovery experiments with S. pombe (Gould et al. 1991), whereby 
mutagenesis of the corresponding T-loop residue at position 167 to glutamic acid 
results in an intermediate recovery of colony growth. These studies highlight the 
importance of this T-loop residue in the mediating protein kinase activity and 
implicate it as potentially viable site for targeted chemical inhibition in 
Leishmania. Importantly, treatment of recombinant CRK3:CYCA with CDK 
inhibitors flavopiridol and indirubin-3’-monoxime were shown to inhibit histone-
H1 kinase activity at similar IC50 concentrations as previously determined by the 
same assays using purified CRK3His (Hassan et al. 2001, Grant et al. 2004). These 
concurrent data provide further evidence that the cell cycle arrest and growth 
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attenuation resulting from CDK inhibitor treatment of L. mexicana is a result of 
impaired CRK3 activity. 
The role of CRK3:CYC6 in mediating the Leishmania cell cycle transition through 
mitosis is implicated by RNAi of CYC6 in T. brucei (Hammarton et al. 2003). As 
established by TbCRK3 RNAi (Tu & Wang 2004), there are differences in the 
phenotypic outcome by RNAi of CYC6 between bloodstream and procyclic forms, 
indicative of stage specific protein kinase activity. Again, the absence of a 
method to regulate CRK3 expression in L. mexicana prevents such stage-specific 
dissection, however the block in the cell cycle at G2/M suggest a similar role in 
cell cycle regulation in the related Leishmania as shown by CDK inhibitor 
treatment.  
The preparation of active, recombinant CRK3:CYC6 kinase complexes enabled a 
high-throughput screen to identify selective inhibitors of kinase activity with no 
such inhibition of a range of recombinant, human CDK:CYC complexes (Walker et 
al. 2011). High throughput chemical screens were conducted using two separate 
compound libraries; the first screen utilised a diverse, 25,000 compound Lexicon 
library, with initial screening confirming CRK3 specificity by counter screening 
against mammalian CDK2:Cyca. This yielded 12 potent azupurines (IC50 values 
<11µM) against CRK3:CYC6, but further counter screening against a range of 
mammalian CDK:CYC complexes revealed inhibitory activity against the 
mammalian protein kinase CDK4:CYCD1 complex at IC50 values <30µM. The lack 
of Leishmania selectivity is an impediment in terms of therapeutic use, with the 
additional caveat of low potency against L. major amastigotes (IC50 values 
>50µM). Despite this, these results allowed structural modelling of the binding 
site of these azupurines to elucidate this lack of selectivity. Interestingly, the 
authors describe an acceptor-donor-acceptor (A-D-A) binding motif, where 
hydrogen bonds are formed between the azupurines and backbone residues 
present in both CRK3 and CDK4. The potency of these compounds to either the 
human or Leishmania CDKs was hypothesised to be a result of structural 
differences within the azupurine scaffold.  
To explore this further, an additional 23 azupurine derivatives were synthesised 
with altered chemical structure of the azupurine backbone, and screened 
against recombinant CRK3:CYC6. Such changes varied the efficacy of CRK3:CYC6 
116 
 
inhibition, with the likelihood that the presence of a benzene ring results in 
complimentary binding to the hydrophobic pocket present in CRK3. Screening of 
these compounds against promastigotes and amastigotes showed little growth 
inhibition, and despite the employment of a second BioFocus SFK48 kinase-
focused inhibitor screen there remained a disagreement between recombinant 
protein inhibition and anti-parasite activity as commonly seen in such screening 
experiments (Paape et al. 2014). Despite an absence of potent anti-parasite 
compounds, such work demonstrates how a high-throughput screening process is 
important for elucidating specific structure-activity relationships (Bell et al. 
2012). An additional screen using multiple chemical series aimed at finding 
specific CRK3 inhibitors was conducted in parallel with this one (Cleghorn et al. 
2011), with the data gathered from such study lending itself to practical design 
of Leishmania specific inhibitors of CRK3 and other potential therapeutic targets 
(Hutton et al. 2014).  
A common disparity arising from such screens is specific inhibition of 
recombinant complexes but inefficient anti-parasitic activity when utilising the 
same compound. This can also be the case in reverse, where parasite killing is 
efficient at low doses of compound but recombinant activity is unaffected. The 
difficulty in establishing and validating an essential protein by chemical 
inhibition is exemplified by this duality. In order to establish a protein as a 
‘useful’ drug target, we must utilise reverse genetic techniques to conditionally 
regulate expression of the parasitic gene. An important consideration is that the 
treatment of leishmaniasis is initiated only once the disease manifests itself in 
the form of a cutaneous lesion, or following diagnosis of the visceral form 
following symptoms such as fever or cachexia (Herwaldt 1999), at which stage 
the parasites have differentiated into replicative amastigotes. Demonstration of 
the essentiality of a protein during this life cycle stage is crucial. However, 
current molecular techniques to regulate the expression of essential genes such 
as CRK3 in any life cycle stage do not currently exist. In addition, downstream 
analysis of the resulting immune response yields useful information into the 
outcome of disease clearance following inoculation of null mutant Leishmania 
lines into appropriate murine models (Alexander et al. 1998, Buxbaum et al. 
2003). The resolution of infection by development of an appropriate Th1 immune 
response to Leishmania null mutants has implications on the development of 
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protective immunity from subsequent infection. These experiments are 
dependent on the deletion of genes which are not essential in promastigotes; 
therefore an absence of a conditional system to regulate genes which are 
essential at all life cycle stages prevents such analysis. An in vivo infection 
model which encompasses the inducible deletion of an essential gene to monitor 
the resultant parasite burden by bioluminescence expression, in addition to 
phenotyping of the resulting immune response to inducible null mutant parasite 
infection represents a crucial model for drug target validation.  
4.1.3 Research Aims 
The body of work discussed in this chapter provides strong evidence that CRK3 
represents a useful target for pharmacological inhibition. To further establish if 
this is the case, we aim to utilise the diCre inducible deletion system to 
conditionally regulate CRK3 expression in order to: 
1. Generate a conditional deletion L. mexicana line to enable phenotypic 
analysis by of CRK3 deficient promastigotes. 
2. Test functional recovery and specificity of floxed CRK3 deletion by 
complementation with a CRK3 transgene, and conduct complementation 
to define the activity of a CRK3T178E mutant in promastigotes. 
3. To investigate the essentiality of protein kinase activity by conditional 
deletion of floxed CRK3 in the mammalian infective, amastigote stage. 
4. To investigate the essentiality of protein kinase activity during murine 
infection by conditional deletion of floxed CRK3 in stationary phase, 
bioluminescent reporter promastigotes and subsequent infection of 
BALB/c mice. 
5. Develop a model to study the recruitment of innate immune cell 
populations to both infection site and draining lymph node by infection 
with conditional null mutant, bioluminescent reporter L. mexicana. 
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4.2 Results 
4.2.1 Generation of a CRK3 conditional deletion cell line 
Application of the diCre system for targeted gene replacement of L. mexicana 
was designed to be as flexible as possible in order to target a variety of genes, 
without laborious and time-consuming preparatory cloning. The diCre construct 
and loxP vectors were therefore sub-cloned into the pDONR221 Gateway vector 
containing att recombination sites to facilitate the flanking of appropriate 5’ 
and 3’ homologous flanking regions of a target gene of interest through LR 
clonase mediated recombination (see section 3.2.3 for more information). By 
Gateway recombination, the constructs were flanked by 500bp CRK3 flank 
amplicons containing the appropriate att sites and PacI and PmeI restriction sites 
for restriction digest to linearise the integration cassettes for homologous 
recombination.  
Following generation of vectors flanked by these homologous sequences, the 
CRK3 coding sequence was inserted into the loxP vector by PCR amplification 
from wild-type genomic DNA using oligonucleotides containing 18bp of gene 
homology and conferring a NdeI restriction enzyme site at the 5’ end, a SpeI site 
at the 3’ end in the absence of a ‘Stop’ codon. Integration of this amplicon 
upstream of a GFP coding sequence by restriction digest mediated ligation into 
pGL2315 resulted in a floxed, CRK3-GFP expression cassette (Figure 4:1a). CRK3 
expressed with a C-terminal protein fusion tag is enzymatically functional 
(Hassan et al. 2001, Grant et al. 2004, Gomes et al. 2010), therefore the 
expression of the floxed CRK3 linked to a C-terminal GFP was utilised to examine 
protein loss by immunoblotting in the absence of an available CRK3 antibody. 
Each CRK3 copy was replaced by consecutive transfection and selection using the 
diCre construct and the floxed, CRK3 expression cassette respectively (Figure 
4:1a). Each vector contains an encoded drug resistance marker conferring either 
blasticidin or puromycin resistance to enable drug selection of integrated clones 
following transfection. Generation of a CRK3 heterozygote, termed 
Δcrk3::DICRE, was identified by PCR amplification of genomic DNA extracted 
from six blasticidin resistant clones (Figure 4:1b). 5’ and 3’ 940b and 950bp 
amplicons were obtained by amplification with diCre specific primers and 
primers binding outwith the integration site, demonstrating replacement of the 
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first CRK3 allele. Clone F was used for replacement of the second CRK3 allele by 
transfection with the floxed CRK3 construct generated multiple double drug 
resistant clones. Genomic DNA was extracted from eight clones, and PCR 
amplification of the 5’ and 3’ CRK3 flanking regions of expected size was 
conducted using pairs of oligonucleotides which bind outside the locus 
integration site, and within the diCre sequence, floxed CRK3 vector or the CRK3 
gene in the opposite orientations (Figure 4:1b). By this method, clones 2 and 8 
were demonstrated as lacking both CRK3 copies by replacement. By conventional 
nomenclature for Leishmania (Clayton et al. 1998), this cell line was termed 
Δcrk3::DICRE/Δcrk3::CRK3FLOX .  
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Figure 4:1- Establishment of a CRK3 inducible deletion L. mexicana cell line. a. Schematic 
representing the diCre and floxed CRK3 replacement strategy. Homologous recombination was 
facilitated by Gateway flanking of both diCre and loxP vectors with crk3 5’ and 3’ 500bp 
homologous regions to mediate transfection and replacement of both alleles b. Transfection of 
wild-type L. mexicana with the diCre construct; integration was confirmed by PCR amplification of 
genomic DNA extracted from six clones with primers (OL) binding outwith the integration site (grey 
arrows) and within the diCre coding sequence (blue arrows) to amplify 950bp amplicons. A single 
blasticidin (BSD) resistant clone F with diCre integrated at the crk3 locus was subsequently 
transfected with the loxP construct to replace the remaining endogenous crk3 allele with a floxed 
CRK3 fused to a 3’ GFP tag, thereby generating a diCre mediated conditional deletion line: 
Δcrk3::DICRE/ Δcrk3::CRK3
FLOX.
 PCR amplification of genomic DNA extracted from two blasticidin 
and puromycin (PUR) clone 2 and 8 drug resistant lines with oligonucleotides binding out with the 
integration site (grey arrows), within the crk3 coding sequence (grey arrows), within the loxP vector 
(blue arrows) and diCre sequences (red arrows). See materials and methods for OL sequences. 
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4.2.2 Conditional deletion of CRK3 in promastigotes using 
inducible diCre 
Based on our previous data demonstrating the efficient loss of floxed GFP 
following diCre induction by treatment of logarithmically growing promastigotes 
with 50nM rapamycin, we deemed this dose sufficient to induce efficient 
excision of floxed CRK3. The loss of an essential gene should result in the 
cessation of growth, therefore to investigate this growth curves were generated 
by seeding promastigote cultures at 5x105 cells/ml and gene deletion induced by 
50nM rapamycin treatment alongside an untreated control for each clone. 
Growth was measured over the course of 7 days, demonstrating a severe growth 
defect in those cells treated with rapamycin (Figure 4:2). By day 7, growth of the 
induced cells had recovered, therefore to investigate whether this was a result 
of selective pressure for cells retaining an extra copy of CRK3 or as a result of 
inefficient diCre induction, the cultures previously treated with rapamycin were 
seeded once more at 5x105 cells/ml concentrations and either treated with 
rapamycin once more (redose) or allowed to grow (recovery).  
A pronounced growth defect was achieved by re-dosing, indicating that the 
recovery population was likely a result of inefficient diCre activation. 
Subsequent conditional gene induction experiments were conducted with 100nM 
rapamycin to address this possible issue of inefficient diCre mediated gene 
excision.  
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Figure 4:2- Promastigote growth following diCre mediated floxed CRK3 excision. Clones 2 
and 8 were seeded as promastigotes at 5x10
5 
cells/ml cultures and grown in the presence or 
absence of 50nM rapamycin (Rap) for 7 days. Cell counts were obtained at 24 hour intervals to 
monitor growth and a representative growth curve was plotted. After 7 days growth the rapamycin 
treated cells were seeded at 5x10
5 
cells/ml as indicated by the red, dotted line in the presence 
(Redose) or absence (Recovery) of 50nM rapamycin and growth monitored by cell counting every 
24 hours for four days. Error shown as standard deviation of the mean between 1 and 3 replicates 
dependent on the concentration of cells due to the haemocytometer detection limit of 1x10
5 
cells/ml. 
Data in the previous chapter showed no promastigote toxicity of rapamycin even 
at 500nM treatment indicating that promastigotes were insensitive to treatment 
with rapamycin, which is in agreement with other studies (Madeira da Silva et al. 
2009). The growth arrest phenotype is therefore likely due to the loss of floxed 
CRK3. To investigate the rate of floxed CRK3 excision, cells were once more 
seeded at 5x105 cells/ml in either the presence or absence of 100nM rapamycin, 
and genomic DNA extraction performed at 24 hour and 48 hour time points. The 
genomic DNA was analysed by PCR amplification using oligonucleotides binding 
either side of a 3.4Kbp region outwith the floxed site (Figure 4:3a upper panel). 
Once diCre activity is induced and the floxed fragment excised, the resulting 
amplicon is 1.36Kbp in size, therefore facilitating a rapid analysis of gene loss. 
Gene deletion as detected by this method occurred efficiently within 24 hours 
for both clones, with no larger fragment being visible by agarose gel separation 
(Figure 4:3a lower panel). In addition, the absence of a 1.36Kbp amplicon in 
either of the untreated clones reveals the tight regulation of diCre mediated, 
floxed CRK3 excision.  
Days Post Treatment
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To confirm the PCR analysis that loss of floxed CRK3 was efficient within 24 
hours post rapamycin induction, Southern blotting was conducted using genomic 
DNA extracted from clone 2 procyclic promastigotes grown in the presence or 
absence of rapamycin for 24 and 48 hours. A wild-type L. mexicana genomic DNA 
control was included. Restriction digest with NruI resulted in excision of a 
6.2Kbp fragment containing the floxed CRK3 sequence, or a 2.4Kbp wild-type 
fragment containing endogenous CRK3. Digested DNA was subsequently resolved 
by agarose gel electrophoresis and hybridised with a chemiluminescent CRK3 
open reading frame probe. A 6.2Kbp fragment containing the CRK3 ORF was 
detected in the untreated control at 24 hours, and with the rapamycin treated 
group showing partial retention of the gene at this time point. The 6.2Kbp 
fragment was not detected by Southern blotting of the 48 hour rapamycin 
treated genomic DNA (Figure 4:3b). The inclusion of a Wt gDNA control 
demonstrates the specificity of the probe, however the presence of a band at 
>2.4Kbp is likely a result of incomplete restriction digestion.  
Interestingly, Southern blotting of the 24 and 48 hour rapamycin treated samples 
yields a ~3Kbp CRK3 retained fragment; diCre recombination results in the 
circularisation and therefore loss of a floxed target, therefore detection of a 
fragment at this size may be an indication that the floxed CRK3 coding sequence 
is retained as an episome. The circular DNA should be around 2Kbp in size, 
therefore the detection of a larger ~3Kbp fragment may be due to poor gel 
resolution due to its circularisation. The lower chemiluminescent signal of the 
equally sized fragment at the later, 48 hour time point relative to the 24 hour 
induced line suggests that this ‘episome’ is lost over time.  
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Figure 4:3- DNA and transcript analysis of floxed CRK3 excision. a. (upper) A schematic 
representation of the strategy utilised to investigate CRK3 loss by a change in size following PCR 
amplification with primers binding upstream of the 5’ CRK3 integration flank (grey) and within the 
puromycin resistance cassette. (lower) Genomic DNA extracted from clones 2 and 8 at 24 and 48 
hours after rapamycin treatment was used for PCR amplification and amplicons resolved on an 
agarose gel. b. (upper) A schematic representation of the size change of the NruI restriction digest 
fragment upon integration and replacement of the endogenous wild-type L. mexicana (Wt) locus by 
the floxed CRK3 cassette. (lower) Southern blot analysis of wild type and clone 2 cell lines 
following growth in the presence or absence of rapamycin. 5µg of DNA was digested with NruI and 
resolved by agarose gel electrophoresis, transferred to a nylon membrane and hybridised with a 
chemiluminescent CRK3 open reading frame probe. c. Real-time PCR analysis of cDNA generated 
from RNA extracted at 48 and 72 hours post rapamycin treatment of clone 2 promastigotes. Fold 
increased expression of transcript is quantified relative to a 0 hour treatment control.  
Inducible deletion of floxed CRK3 is rapid and tightly regulated based on these 
data, therefore the distinct growth arrest phenotype exhibited 48 hours post 
rapamycin mediated induction is attributed to a loss of active CRK3. Western 
blotting of promastigotes cell extracts grown in the absence or presence of 
rapamycin with an anti-GFP antibody were problematic due to the aberrant 
growth and morphology of the induced cells. Real-time PCR was instead utilised 
to compare the level of CRK3 transcript expressed 48 and 72 hours post 
treatment between induced and uninduced lines showed a 7 and 11 fold increase 
in CRK3 specific transcript in the induced lines respectively (Figure 4:3c). Such a 
contrary finding suggested the possibility of CRK3 overexpression by 
circularisation as an episome. This was assessed by conditional complementation 
of this line with a CRK3 as a transgene, yielding a cell line insensitive to floxed 
CRK3 gene deletion and establishing gene deletion as the reason for growth 
arrest (Figure 4:6).  
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The pronounced growth arrest phenotype upon CRK3 conditional deletion was 
investigated further by DNA content analysis. Δcrk3::DICRE/Δcrk3::CRK3FLOX 
clone 2 promastigotes were grown in the presence or absence of 100nM 
rapamycin for 120 hours, resulting in a reduced growth rate by 48 hours post 
diCre induction and growth arrest by 96 hours (Figure 4:4a). Cells were then 
extracted at 72 and 96 post treatment, fixed with methanol and stained with 
propidium iodide (PI) and DNA content analysis conducted by flow cytometry to 
identify the proportion of parasites at each cell cycle stage (Figure 4:4b). As 
anticipated, loss of CRK3 resulted in the accumulation of cells in the G2/M phase 
(4N) of the cell cycle by 72 hours, with an increasing proportion of >4N by 96 
hours in which population multinucleated cells were identified (Figure 4:4c). 
Taken together, these demonstrate a block in G2/M and the accumulation of 
cells with a high DNA content which are unable to undergo division, confirming 
the requirement of active CRK3 in mediating the transition through G2/M. 
Interestingly there is an accumulation of a <0N population, usually indicative of 
a population of anucleated ‘zoids’ which lack a nucleus yet retain a kinetoplast. 
The proportion of <0N cells with low DNA content increased from 72 to 96 hours, 
and due to the defined population peak it is likely this population represents 
anucleated zoids rather than a result of cell death and DNA degradation as 
demonstrated previously (Grant et al. 2004).  
 
Figure 4:4- DNA content analysis of CRK3 inducible deletion promastigotes. a. Clone 2 cells 
were seeded as promastigotes at 1x10
5 
cells/ml cultures and grown in the presence or absence of 
100nM rapamycin (Rap) for 5 days (error shown as SD, N=3). Cell counts were obtained at 24 hour 
intervals to monitor growth and a representative growth curve was plotted. b. At 72 and 96 hours, 
cells were fixed and stained with propidium iodide for FACS analysis of 100,000 cells on a 
MacsQuant flow cytometer. Arrows indicate the positions of the 2N content of cells representing G1 
phase cells (ii) and 4N content representing G2 (iii) peaks in untreated controls. An additional peak 
of low DNA content associated with increased incidence of <2N zoids (i) in the population c. 
Graphical representation of the DNA content of each population based on the flow cytometry plots  
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To confirm the accumulation of multi-nucleated, G2/M stalled cells and 
anucleated zoids by floxed CRK3 deletion, DNA staining by DAPI treatment and 
microscopic analysis was performed on cells 96 hours post rapamycin treatment 
(Figure 4:5). Conditional deletion of CRK3 in promastigotes resulted in cells that 
had undergone repeated rounds of flagellar synthesis in the absence of 
cytokinesis. In addition, these cells were generally larger than the uninduced 
control cells and some are observed as multi-nucleated (>2N1K), therefore it 
appears that the cells continued to undergo the growth and flagellar growth 
normally associated with synthesis and G2 stage of the cell cycle, but were 
blocked in their ability to undergo mitosis, preventing appropriate cell division.  
 
Figure 4:5- Morphology and nuclear staining of promastigotes after CRK3 deletion. Images 
of cells grown in the presence (top) or absence (bottom three rows) of 100nM rapamycin for 96 
hours. Cells (clone 2) were fixed and stained with DAPI in Fluoromount solution to detect nuclear 
and kinetoplast content. The expression of HASPB-mCherry red fluorescent protein (RFP) from the 
loxP vector backbone allowed red-fluorescence detection from the membrane and flagella. Scale 
bar 5µm. 
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The presence of anucleated L. mexicana promastigotes following indirubin 
treatment has been demonstrated previously (Grant et al. 2004), and cells with 
a similar phenotype were also identified by microscopy following inducible 
deletion of CRK3 (Figure 4:5). The presence of such cells indicates that 
cytokinesis is not entirely blocked in the absence of mitosis, an explanation for 
the expanding <2N population resulting from loss of CRK3. These data show that 
loss of CRK3 results in the blocking of cells in the G2/M stage of the cell cycle, 
resulting in continued protein synthesis as demonstrated by the accumulation of 
multiple flagella on individual cells, as well as an increased cell size. This cell 
cycle arrest and resulting phenotype is indicative of the efficacy of diCre 
mediated gene excision, and forms the basis for further probing of CRK3 function 
in promastigotes. 
4.2.3 Inducible complementation assays by CRK3 deletion 
The ability to conditionally regulate expression of CRK3 enables the 
identification of residues that are essential for protein kinase activity. This 
approach involves complementation of the inducible deletion line with an 
exogenous gene copy, which can be mutated to identify active sites once 
expressed as protein. Conditional gene deletion of the floxed gene copy induces 
expression of only the mutant transgene, enabling phenotype dissection. By 
application to CRK3, the floxed CRK3 copy should be sufficient to maintain 
progression through the cell cycle until excised by rapamycin activation of diCre, 
probing whether mutated CRK3 protein activity functionally recovers growth, or 
results in a block in G2/M as a consequence of impaired protein kinase activity. 
Cell lines were generated by transfection of the Δcrk3::DICRE/Δcrk3::CRK3FLOX 
cell line (now referred to as the ‘parental flox’ line) with a wild-type CRK3 
sequence (Δcrk3::DICRE/Δcrk3::CRK3FLOX [SSU CRK3]) or a T178E mutated version 
(Δcrk3::DICRE/Δcrk3::CRK3FLOX [SSU CRK3T178E]) into the 18S ribosomal small 
subunit (SSU) using a modified version of the pRib vector conferring neomycin 
resistance. Previous studies generating CRK3 mutants for use in yeast recovery 
(Wang et al. 1998) and recombinant protein activity assays (Gomes et al. 2010) 
show loss of kinase function by mutation of this T-loop residue. Previous 
attempts to investigate the essentiality of this residue in situ were unfeasible 
due to the essentiality of CRK3, therefore we utilised conditional 
complementation to conduct such work.  
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Three clones per transfection were selected that were resistant to puromycin, 
blasticidin and G418 and tested for their sensitivity to floxed CRK3 deletion by 
growth in the absence or presence of 100nM rapamycin by cell counting over the 
course of 5 days. Growth curves in the absence or presence of rapamycin were 
analogous between each clone tested, therefore representative growth curves 
were prepared from a single clone from each cell line (Figure 4:6b). Loss of floxed 
CRK3 in the mutant T178E expressing line resulted in a growth arrest by 72 
hours, a delay comparable with that previously seen in the parental flox line 
where a pronounced difference between rapamycin treated and untreated cells 
is evident by 48 hours. In contrast the growth arrest phenotype induced by loss 
of floxed CRK3 in the Δcrk3::DICRE/Δcrk3::CRK3FLOX line was recovered by 
complementation with the wild-type CRK3 transgene, as evidenced by growth in 
the presence of rapamycin. Recovery of growth by complementation 
substantiates the previous evidence that CRK3 activity is essential for cell cycle 
progression in promastigotes. To ensure the resultant phenotypes were as a 
result of floxed CRK3 loss, genomic DNA extraction and subsequent PCR 
amplification of the floxed CRK3 gene locus was conducted to confirm gene loss, 
with amplification of a smaller 1.36Kbp fragment following 24 hours post 
rapamycin treatment for both cell lines (Figure 4:6c). 
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Figure 4:6- Generation of mutant and wild-type CRK3 inducible complementation lines. a. 
Schematic representation of the process of generating complementary lines by integration into 
ribosomal locus of the CRK3 inducible deletion line with constructs containing a wild-type or T178E 
mutant CRK3 transgene in a vector conferring resistance to G418. b. 3 clones per cell line were 
confirmed as G418 resistant. A single clone for the T178E mutant (lower) and wild-type 
complementary line (upper) were seeded as promastigotes at 1x10
5 
cells/ml cultures and grown in 
the presence or absence of 100nM rapamycin (Rap) for 5 days (error shown as SD, N=3). Cell 
counts were obtained at 24 hour intervals to monitor growth and a representative growth curve was 
plotted. c. PCR validation of floxed CRK3 gene deletion; (upper) schematic for amplification of the 
CRK3 locus, with expected sizes before and after excision. (lower) Amplification of gDNA extracted 
from cells grown in the presence or absence of rapamycin at 24 and 48 hours for each cell line. d. 
Doubling time values in hours of each cell line during the first 48 hours of logarithmic growth.  
These data confirm that the growth phenotype resulting from floxed CRK3 
excision in the parental flox line is a result of loss of protein expression, as 
opposed to an overexpression from a functional episome. In the absence of 
rapamycin treatment, both wild-type and mutant complemented cell lines grow 
at reduced rates compared with the parental flox cell line (Figure 4:6d). A growth 
defect might be anticipated following overexpression of the inactive CRK3T178E 
mutant as this could have a dominant-negative phenotype, however the more 
severe growth reduction of the wild-type complemented line suggest 
overexpression of CRK3 from the ribosomal small subunit is deleterious to the 
cells. Despite a less pronounced effect on growth, the CRK3T178E complemented 
promastigotes appeared reduced in cell size and lack flagella prior to rapamycin 
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treatment. This curious phenotype may be indicative of a metabolic stress from 
overexpression of the inactive T178E, with loss of flagellum and reduced cell 
size compensating for a dominant negative stress. The loss of growth by 72 hours 
post induction compared with 48 hours in the parental flox line was likely a 
result of the reduced growth rate of the cells, resulting in the growth arrest 
phenotype to take longer to manifest.   
DNA content analysis was performed to establish whether expression of the 
inactive CRK3T178E mutant results in arrest at G2/M, and to confirm the standard 
progression of the CRK3 complemented line through the cell cycle (Figure 4:7a-
d). Both cell lines were grown in the presence or absence of rapamycin for 96 
hours, with cells fixed and stained with PI at hours 72 and 96 for DNA content 
analysis by flow cytometry. In the wild-type complementation line, floxed CRK3 
excision had no detectable effect on the cell cycle compared with the uninduced 
control (Figure 4:7a & b). However, a standard flow cytometry profile with a 
large proportion (~70%) of cells at 2N was not seen; instead there was a large 
proportion (25-30%) of >4N cells, with a roughly equal 4N population 
independent of time or treatment. The slow growth of this cell line as a result of 
CRK3 overexpression may be influencing the flow cytometry profile. Despite this, 
these data demonstrate that the attenuated growth obtained by inducible Cre 
excision of floxed CRK3 is complemented by expression of wild-type CRK3 as a 
transgene.  
Analysis of the CRK3T178E complementation line yielded a DNA content profile 
which better fitted the established cell cycle distribution, with a larger 
proportion (~40%) of 2N cells at both time points  (Figure 4:7c & d). Floxed CRK3 
deletion resulted in the reduction of this population to ~15%, with an increased 
abundance of 4N and >4N cells (~70% in total) at both time points. These 
populations represent cells which are cell cycle arrested at G2/M, and these 
data are in agreement with the proportion of parental flox cells blocked in G2/M 
as indicated by the 4N and >4N populations (~60% in total) at 72 hours post 
induction (Figure 4:4c). These data indicate that the CRK3T178E mutant is unable to 
mediate cell cycle progression. Inducible deletion of floxed CRK3 in the 
Δcrk3::DICRE/Δcrk3::CRK3FLOX parental strain resulted in a <0N population of 
~25% by 96 hours post induction, whereas the mutant complementation line had 
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a <0N population of around 10%. This discrepancy may explain the reduced 
proportion of 4N and >4N cells blocked in G2/M as the induced parental flox line, 
as the production of anucleated zoids by cytokinesis in the absence of mitosis is 
reduced by the slower growth rate of these CRK3T178E expressing cells.     
 
Figure 4:7- DNA content analysis of inducible complementation lines. a. Complemented 
CRK3 and b. CRK3T178E mutant cells were seeded at 1x105 cells/ml in the presence or absence 
of 100nM rapamcyin. After 72 and 96 hours, cells were fixed and stained with propidium iodide for 
flow cytometry analysis of 100,000 cells on a MacsQuant flow cytometer. Arrows indicate the 
positions of the 2N content of cells representing G1 phase cells (ii) and 4N content representing G2 
(iii) peaks in untreated controls. An additional peak of low DNA content associated with increased 
incidence of <2N zoids (i) in the population Graphical representation of the DNA content of c. 
CRK3 and d. CRK3T178E complemented cell lines based on the flow cytometry plots. e. CRK3 
and f. CRK3T178E complemented cell lines were fixed and stained with DAPI in Fluoromount 
solution to detect nuclear and kinetoplast content. Scale bar 5µm. 
 
To further investigate the morphology and DNA content of these complemented 
cells, fluorescence microscopy was performed on cells stained with DAPI after 
growth in the absence or presence of 100nM rapamycin for 96 hours. Analysis of 
wild-type complemented cells revealed no difference between induced and 
uninduced, with cells mainly exhibiting 1N1K karyotypes  (Figure 4:7e). In 
contrast, loss of floxed CRK3 in the CRK3T178E expressing line results in the 
appearance of aberrant cells with increased cell size and multi-nucleation 
(Figure 4:7f). Such morphology was indicative of a block in G2/M and impaired 
cytokinesis, with an overall increased cell size indicative of the continued 
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growth and protein expression in preparation for mitosis. These data 
demonstrate that the growth cycle defect following loss of floxed CRK3 can be 
recovered by expression of a CRK3 transgene, and that mutation of the T-loop 
residue at position 178 to a glutamic acid ablates kinase function in L. mexicana 
promastigotes.    
4.2.4 Conditional deletion of CRK3 in lesion-derived amastigotes 
The lack of a molecular tool for conditional regulation of essential genes in the 
replicative, mammalian infective amastigote stage Leishmania is a major 
impediment to the validation of molecular targets which represent useful drug 
targets, as the inability to generate a null mutant in promastigotes is not 
necessarily an indication that the activity of the encoded protein is essential for 
amastigotes. DiCre is functional in amastigotes as determined in chapter 3 by 
conditional deletion of floxed GFP. To establish whether CRK3 activity is 
essential for amastigote replication, the Δcrk3::DICRE/Δcrk3::CRK3FLOX clone 2 
cell line was isolated from the footpads of infected BALB/c mice two months 
after inoculation. An amenable property of L. mexicana over other species is the 
ability to culture the parasite as axenic amastigotes (Bates 1994) in acidic, 
serum supplemented Schneider’s Drosophila medium, therefore the isolated 
amastigotes were cultured in the presence or absence of 200nM rapamycin and 
growth measured by cell counting at 24 hours post treatment, then twice more 
at 48 hour intervals (Figure 4:8a). Floxed CRK3 deletion by treatment with 
rapamycin resulted in a dramatically reduced growth rate relative to uninduced 
amastigotes. To investigate whether these cells were arrested in the cell cycle 
at G2/M as observed following conditional deletion of CRK3 in promastigotes, 
DNA content analysis was conducted at 72 hours (Figure 4:8b). In contrast to 
G2/M stalling, the resulting profile was instead indicative of arrest in the G1 
phase of the cell cycle. To determine the effect on cellular morphology and 
nuclear content, DAPI staining of live cells (Figure 4:8c) showed aberrant 
amastigotes with rounded morphology and fragmented DNA content.  
To demonstrate that rapamycin treatment was inducing excision of floxed CRK3, 
the experiment was repeated by isolation of Δcrk3::DICRE/Δcrk3::CRK3FLOX 
lesion-derived amastigotes and subsequent growth measured in the presence or 
absence of 200nM rapamycin for 5 days (Figure 4:8d). Antibiotic selection with 
133 
 
puromycin and blasticidin was included as an additional factor to investigate 
whether diCre activity and therefore the efficiency of gene excision was 
enhanced by selection for those parasites retaining the diCre and floxed gene 
cassettes. A distinct growth arrest phenotype was manifest by cell counting at 
day 5 post treatment, with little difference in terms of antibiotic selection 
between treatment regimes. The growth rate of both induced and uninduced 
was dramatically reduced compared with the previous experiment (Figure 4:8a), 
with lesion derived amastigote growth rate highly variable between four 
independent experimental replicates. By genomic DNA extraction at day 5 post 
treatment, PCR analysis indicated the loss of floxed CRK3 and the retention of 
diCre activity in the absence of antibiotic selection (Figure 4:8e). Such findings 
have important implications for the utilisation of diCre inducible deletion of 
essential genes in vivo, as the application of antibiotics in mice for parasite 
selection is not feasible. A previous experiment utilising lesion-derived 
Δcrk3::DICRE/Δcrk3::CRK3FLOX amastigotes extracted from a different mouse also 
exhibited growth arrest and conditional deletion of floxed CRK3 by PCR analysis 
following treatment with 100nM rapamycin for 5 days (data not shown). 
Together, these data showed that integration of the diCre and floxed gene into 
the endogenous gene locus confers sufficient floxed gene expression for the 
maintenance of infection, whilst continuing to express the diCre molecular 
machinery at a level sufficient for inducible gene deletion throughout infection. 
Despite conditional deletion of CRK3 in at least two independent experiments, 
the growth arrest at G1, coupled with the aberrant morphology by rapamycin 
treatment of Δcrk3::DICRE/Δcrk3::CRK3FLOX cannot solely be attributed to loss of 
CRK3; rapamycin treatment inhibits the growth of wild type, lesion-derived L. 
mexicana amastigotes (Figure 4:8d). This inherent sensitivity to rapamycin 
necessitates an alternative dosage regime of amastigotes, with a 24 hour dosage 
period a potential alternative to dissect the outcome of gene deletion from the 
effect on growth by rapamycin treatment.  
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Figure 4:8- Conditional deletion of CRK3 in amastigotes and the increased sensitivity to 
rapamycin treatment. a. Δcrk3::DICRE/Δcrk3::CRK3
FLOX  
amastigotes were seeded at 1x10
6
 
cells/ml in the presence or absence of 200nM rapamycin and counted at 24, 72 and 120 hours post 
treatment (SD, N=3). b. DNA content analysis on 100,000 cells at 72 hours post treatment; i. 
represents <2N population, ii. indicates cells 2N content cells in G1 and iii. cells with 4N content at 
G2 prior to mitosis. c. DAPI staining microscopy of live amastigotes at 72 hours post treatment. d. 
The experiment in panel (a) was repeated with the Δcrk3::DICRE/Δcrk3::CRK3
FLOX  
line (Exp) 
grown in the presence or absence of 10µg/ml puromycin and blasticidin for antibiotic resistance 
selection (Selection) with a seperate wild-type (Wt) L. mexicana rapamycin treatment control. 
Growth curves were prepared by counting the experimental line at 120 hours post induction, whilst 
the wild-type cells were cunted at 72 and 96 hours post treatment. e. PCR amplification of gDNA 
extracted at 120 hours post treatment (right) using the strategy detailed in the schematic (left).  
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4.2.5 Conditional deletion of CRK3 in stationary phase 
promastigotes to assess activity in vivo  
A major obstacle in drug target identification is our inability to conduct 
inducible deletion of an essential gene to establish the requirement of the 
expressed protein during infection of a murine host. Active CRK3 is essential to 
mediate cell cycle progression through mitosis in dividing promastigotes, 
however to further identify CRK3 as a potential drug target we must conduct 
deletion of CRK3 in an in vivo context. The use of an in vivo imaging system 
(IVIS) is a longitudinal, non invasive method to track the burden of transgenic L. 
mexicana expressing a bioluminescent protein, therefore floxed CRK3 
conditional deletion promastigotes were generated which express a more 
sensitive red-shifted luciferase (RE9H) compared with renilla and conventional 
firefly luciferases (McLatchie et al. 2013).  
 
Figure 4:9- Generation of a CRK3 inducible deletion line expressing red-shifted luciferase. a. 
Red-shifted luciferase expression was measured in two G418r clones as logarithmically (log) 
growing and stationary phase with a [SSU RE9H] transgenic L. mexicana line as a positive control 
(+Control). Cells were washed in 1xPBS and 1x10
6 
cells/well added to individual wells in a 96 well 
plate in duplicate (N=2, error is SE of the mean). Bioluminescence was detected using a Pherestar 
plate reader at 0, 30 and 60 minutes post luciferin addition. b. Sensitivity to CRK3 deletion is 
exhibited by both clones as measured by growth curves prepared by seeding promastigotes at 
1x10
5 
cells/ml cultures and grown in the presence or absence of 100nM rapamycin (-/+Rap) for 5 
days (error shown as SD, N=3). Cell counts were obtained at 48 hour intervals to monitor growth 
and a representative growth curve was plotted. c. Integration of the RE9H expression construct at 
the ribosomal locus was investigated by PCR amplification using primers binding upstream of the 
5’SSU integration site and in the reverse orientation from the RE9H coding sequence to amplify a 
2.2KBp fragment (upper). PCR amplification of genomic DNA extracted from both clones and a 
wild-type L. mexicana negative control (wt) was conducted and the amplified products resolved on 
an agarose gel.   
The parental flox, inducible CRK3 deletion line (Δcrk3::DICRE/Δcrk3::CRK3FLOX ) 
was transfected with the pRib vector previously utilised for CRK3 integration into 
the 18S ribosomal RNA locus (Figure 4:6a) to generate the 
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Δcrk3::DICRE/Δcrk3::CRK3FLOX [SSU RE9H] cell line (subsequently referred to as 
‘bioluminescent parental flox line’). Transfection of this construct yielded two 
G418 resistant clones which were tested for bioluminescent protein expression 
and the retention of inducible deletion of CRK3 by diCre mediated 
recombination following rapamycin treatment. Both clones exhibited high levels 
of red-shifted luciferase expression relative to an L. mexicana line expressing 
RE9H from the SSU ([SSU RE9H) which was included as a positive control. Clone 1 
had ~5 fold higher expression and clone 2 had >10 fold higher expression 
compared with the positive control during logarithmic stage growth at all time 
points. The clones were then tested for their ability to undergo inducible 
deletion of CRK3 by growth in the presence or absence of 100nM rapamycin for 
96 hours (Figure 4:9b), with rapamycin resulting in growth arrest by 48 hours post 
treatment as previously demonstrated in the parental flox line (Figure 4:2). 
Integration of the bioluminescent gene into the 18S locus was checked prior to 
use in vivo. To confirm integration of these constructs, genomic DNA was 
extracted from each clone and PCR amplification using primers binding upstream 
of the 5’SSU flank and within the RE9H coding sequence were used to amplify a 
2.2Kbp fragment (Figure 4:9c). Such an amplicon was absent in clone 2, and in 
conjunction with the extremely high expression of RE9H by plate reader assay 
these data implicate the expression of the gene from an episome, or by 
integration elsewhere in the genome. Expression of the reporter cassette from 
an episome is retained during in vitro culture by the presence of drug selective 
pressure, however once inoculated into mice the episome and therefore gene 
expression can be lost. In contrast, amplification of clone 1 genomic DNA 
resulted in the expected size of amplicon, thereby confirming integration and 
establishing the suitability for this cell line to be utilised for in vivo measures of 
parasite burden. 
To circumvent the sensitivity of amastigotes to rapamycin treatment and test 
the hypothesis that CRK3 activity was essential for amastigotes during murine 
infection, a strategy was conducted which involved the induction of diCre 
activity in stationary phase promastigotes for 24 hours followed by subcutaneous 
infection of BALB/c footpads. Previous attempts to induce diCre activity in 
stationary phase promastigotes for deletion of floxed GFP by treatment with 
50nM rapamycin for 20 hours was inefficient (Figure 3:7a), with the higher 
137 
 
number of cells in stationary phase cultures necessitating a higher rapamycin 
concentration to deliver an adequate dose of rapamycin to each cell. Therefore 
a concentration of 1µM was used. This high dose of rapamycin had no detectable 
effect on the cell cycle profile of log-stage promastigotes, and only a marginal 
effect on the overall growth of wild-type L. mexicana promastigotes (Figure 
3:4c) and was deemed sufficient to induce deletion in the absence of any 
deleterious side effects. To ensure that rapamycin treatment had no effect on 
infectivity, L. mexicana [SSU RE9H] were cultured to stationary phase and dosed 
in an identical manner prior to infection to act as a treatment control. Both the 
bioluminescent parental flox line (experimental) and treatment control lines 
were grown to stationary phase by seeding cultures at a reasonably high cell 
density (2x106 cells/ml) for 4 days. The doubling time of this cell line was such 
that stationary phase (~1.6x107 cells/ml) was achieved within two days. After 3 
days culturing, experimental and control lines were split and cultured in the 
presence or absence of 1µM rapamycin for 24 hours. After 24 hours the cells 
were washed twice in 1xPBS and 2x106 cells inoculated into the footpads of four 
Balb/c mice per treatment group. Genomic DNA extraction of the stationary 
phase promastigotes following the 24 hour incubation was conducted to enable 
PCR amplification of the CRK3 locus. This showed efficient loss of CRK3, with a 
small percentage retaining the floxed gene (Figure 4:10a).  
IVIS imaging of the bioluminescence signal from the footpads of infected mice at 
5 weekly time points yielded levels of flux far higher than background, with 
region of interest values (ROI) obtained from those mice infected with the 
untreated experimental and treatment control groups being higher relative to 
the rapamycin treated experimental line by week 1 post infection (Figure 4:10b). 
Imaging over the course of 5 weeks shows the steady increase in parasite burden 
in those mice infected with the treatment control and experimental cell which 
have not undergone CRK3 deletion, with the exception of a single 
Δcrk3::DICRE/Δcrk3::CRK3FLOX [SSU RE9H] – rap infected mouse which had no 
detectable signal by week 5 (mouse removed from subsequent analysis in Figure 
4:10c resulting in a sample size of 3). In contrast to the high bioluminescent 
signal detected from these mice, a low level of light was emitted from mice 
infected with cells lacking CRK3. However, the flox ROI values obtained were 
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above the background signal (~5x103 photons/sec/cm2) suggesting the survival of 
a dramatically reduced number of cells compared with the uninduced group.  
The steady increase in bioluminescent signal from mice infected with the 
treatment control group showed that rapamycin alone is not deleterious to the 
establishment of infection, and instead results from a loss of active CRK3. The 
low signal obtained from mice infected with the CRK3 inducible deletion 
corroborates the evidence obtained by PCR analysis (Figure 4:10a) that a small 
population of cells retain the floxed gene and therefore remain viable. Imaging 
at 9 weeks post infection revealed an increased bioluminescent signal across all 
treatment groups, with an increased ROI value of 1x106 photons/sec/cm2 in the 
previously low intensity conditional deletion group. A likely explanation for this 
later recovery was the establishment of infection by those parasites that had not 
responded to rapamycin induction to undergo CRK3 deletion. To test this, these 
‘recovery’ amastigotes were purified from each footpad at 10 weeks post 
infection and cultured in vitro as promastigotes to obtain sufficient cell 
concentrations for genomic DNA extraction and PCR analysis of CRK3 loss (Figure 
4:10d). By PCR amplification alongside positive and negative control DNA from a 
previous floxed CRK3 deletion experiment and resolution of the resulting 
amplicons by agarose gel electrophoresis, each extracted population has 
complete retention of the floxed CRK3 in the genome. Taken together, the 
attenuation of infection over 5 weeks by gene deletion and the later 
establishment of infection by a small population of amastigotes retaining floxed 
CRK3 validates that active CRK3 is essential for the maintenance of virulence in 
vivo. 
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Figure 4:10- Inducible deletion of CRK3 in stationary phase promastigotes results in 
attenuated virulence in vivo. a. (left) A schematic representation of the strategy utilised to 
investigate CRK3 loss by PCR amplification (right) Genomic DNA extracted from rapamycin treated 
and untreated experimental cells after 24 hours was used for PCR amplification and amplicons 
resolved on an agarose gel. b. Representative images of the bioluminescent signal obtained from 
the footpads of mice infected with L. mexicana retaining CRK3 (left), deficient in CRK3 (middle) or 
bioluminescent control cells pre-treated with rapamycin at 1, 3 and 5 weeks post infection. Region 
of interest (ROI) values (photons/second/cm
2
) are shown below each image. c. The mean ROI 
value for each treatment group (N=3-4, error bars denote the standard deviation around the mean) 
at each week imaged. A significant difference in bioluminescent signal (*= P-value of <0.05 and **= 
P-value of <0.005 by unpaired T-test and 2-way ANOVA) is observed between experimental 
uninduced and induced replicates at week 5 and 9 P.I. d. Amastigotes were extracted from the 
footpads of each mouse (Sample 1-4) infected with the induced experimental group and grown in 
culture. Genomic DNA was extracted from each expanded promastigote population and used for 
PCR amplification alongside +/-  gDNA as controls for floxed CRK3 loss or retention (as schematic 
in a). Amplicons were resolved on an agarose gel. 
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4.2.6 Analysis of immune cell recruitment following L. mexicana 
infection; implications for in vivo study of CRK3 
The use of non-invasive imaging to measure bioluminescent parasites during in 
vivo studies of parasite burden is beneficial both in terms of reducing the 
number of mice required for conducting experiments, and in the ability to 
monitor the course of infection longitudinally in a single mouse. The results from 
the previous section demonstrate that when coupled to an inducible method of 
essential gene deletion, this combination represents a powerful method to 
establish the candidate gene as encoding an important drug target for 
maintaining infection. However, a further aim of this project was to expand this 
model even further by combining in vivo imaging techniques, inducible gene 
regulation and the subsequent analysis of immune cell recruitment by flow 
cytometry of the infection site and draining lymph node. By this method, a gene 
can be identified as essential and the resulting influence on the immune 
response established. Such study has implications on the resolution of infection, 
but also on the immunity to subsequent infection. The purpose of the study 
presented here was to establish a model to investigate immune cell recruitment 
at the infection site and draining lymph node (dLN) during a late stage ear 
infection with bioluminescent reporter L. mexicana, as a reference point for 
further study using the diCre inducible system to delete essential or virulence 
factor genes. 
Prior to the adaptation of the diCre conditional deletion system in L. mexicana, 
a model to study innate cell recruitment at the inoculation site and draining 
lymph node was established by generation of wild-type L. mexicana reporter 
lines. By transfection with pGL2217 or pGL2234, constructs were integrated into 
the ribosomal locus conferring expression of either firefly luciferase (LUC) or 
red-shifted luciferase (RE9H) respectively (utilised in section 4.2.4.). Drug 
resistant clones were selected and bioluminescence expression measured for 
four clones each per transfection at both logarithmically growing and stationary 
phase growth (Figure 4:11a). LUC bioluminescence was consistently higher than 
RE9H at both growth stages, however the red-shifted light emitted by RE9H 
results in more sensitive detection during in vivo imaging. A single, highly 
expressing clone from each group was inoculated into the footpad of a single 
Balb/c mouse each to allow direct comparison using the IVIS. By 1 month post 
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infection, the signal detected from the footpad infected with the [SSU RE9H] 
reporter line infected was ~5 fold higher when compared with the footpad 
infected with the [SSU LUC] reporter line (Figure 4:11b), with a higher signal also 
detected from the region corresponding to the draining popliteal lymph node. 
Parasite burden was not directly measured however, therefore this increased 
signal may have derived from an increased parasite burden in the footpad. 
Despite this lack of investigation, the increased detection sensitivity of RE9H 
over LUC2 (McLatchie et al. 2013) led to the purification and application of this 
line in the development of an in vivo infection model.  
 
Figure 4:11- Generation of a bioluminescent L. mexicana line for determining parasite 
burden in vivo. a. Expression of LUC or RE9H determined by in vitro measures of light from 5x10
6 
logarithmically growing or stationary promastigotes by a Pherestar plate reader. b. Region of 
142 
 
interest (ROI) measures from the footpads and draining lymph nodes of Balb/c mice infected with 
selected clones from each bioluminescent reporter line. c. Representative images of the 
bioluminescence signal detected using an IVIS from C57BL/6 mice infected in the ear pinna with 
the RE9H reporter line. Detection was weekly after week 2 post infection over the course of 12 
weeks. d. The individual ROI values plotted over the course of 12 weeks post infection for 3 mice 
infected in the ear pinna with the RE9H reporter line and e. grouped analysis showing the average 
ROI value (error bars represent the standard error of the mean, N=3).   
Amastigotes were extracted from the lesions caused by infection with both 
reporter lines, differentiated to promastigotes in vitro and stored as low passage 
stabilites. The [SSU RE9H] reporter line was used for subsequent infection of 
5x104 stationary phase promastigotes by intradermal injection into the right ear 
pinna of six C57BL/6 mice to monitor parasite burden in the ear over the course 
of 3 months infection (Figure 4:11c). Immune cell extraction was conducted by 
homogenising the ear and cervical lymph nodes and purifying the resident cells 
for phenotypic analysis by flow cytometry at the 3 month end time point. Left 
ears were inoculated with the vehicle 1xPBS as a ‘sham’ needle injury control, 
with ear and dLN resident populations quantified using naïve controls. Of the six 
mice inoculated, two (mouse 1 and 2) exhibited consistently increasing 
bioluminescent signal detection from the ear, whilst the signal from mouse 3 
gradually increased until week 10 when the signal begins to drop in intensity 
(Figure 4:11d). The loss of signal from the remaining 3 mice which maintained low 
levels of flux detection was likely a result of the inoculation route, as infection 
into the ear pinna is a difficult procedure. As such, this model requires a higher 
sample size to control for the variability introduced from the infection route. 
Grouped analysis of the three mice shows an average increase in burden over 
time (Figure 4:11e), demonstrating the establishment of long term infection in 
these mice.  
The infiltration of monocytes and in particular monocyte derived dendritic cells 
(mo-DC) into Leishmania infection sites has been implicated in the development 
of appropriate immunity against L. major in C57BL/6 mice (Petritus et al. 2012). 
In contrast, infection of these mice with L. mexicana results in reduced 
recruitment of mo-DC, impaired inducible nitric oxide synthase (iNOS) 
production in infected cells and their reduced migration to the draining lymph 
nodes for antigen presentation to T-cells relative to L. major infections (Petritus 
et al. 2012). The influence of these cells in driving an appropriate Th1 
inflammatory immune response is an important aspect of host-mediated 
immunity to Leishmania infection. By inducible deletion of an essential gene or 
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virulence factor from L. mexicana during in vivo infection, the recruitment of 
these cell subsets to the infection site and draining lymph node represents a 
useful population to quantify in the context of infection resolution by an 
appropriate immune response.  
Previous work (Goundry, 2015 Thesis) demonstrates the potential of studying 
monocyte subset as indicators of an appropriate immune response by utilisation 
of in vivo imaging to compare the parasite burden of C57BL/6 mice infected with 
LUC expressing L. major deficient in the genes encoding inhibitors of serine 
peptidases (ISP2/3). The loss of ISP2/3 virulence factor expression of these 
mutant reporter lines prevents parasite-mediated immunosuppression, resulting 
in an early recruitment of mo-DC to the infection site compared to wild-type and 
the accelerated resolution of lesions. These data implicate the efficacy of a 
similar approach by in vivo inducible gene deletion to establish the regulated 
gene as encoding an essential or immune modulating factor.  
To establish the ‘baseline’ number of such cells at week 12 post infection, the 
red-shifted luciferase reporter expressing L. mexicana infected mice (Figure 
4:11b-d) were culled and the immune cell populations at the ear infection site 
and the draining cervical lymph nodes extracted. Based on a published gating 
strategy (Ribeiro-Gomes et al. 2012), the extracted immune cells were 
phenotyped by staining with fluorescent antibodies against a variety cell surface 
markers and detect viable, innate immune leukocyte populations expressing 
CD45 and the leukocyte antigen CD11b (Hickstein et al. 1987) by flow cytometric 
analysis. This subset was further phenotyped by gating in respect to CD11c+ and 
MHCII surface receptor expression to detect Ly6G+ neutrophils, infiltrating Ly6C+ 
monocytes (Gordon & Taylor 2005), monocyte-derived dendritic cells and 
monocyte-derived macrophage (mo-MΦ) and Ly6C- skin or lymph node resident 
DC and MΦ (Figure 4:12). Both infected and sham ears and draining lymph nodes 
were extracted for analysis, with an equal number of ears and cervical lymph 
nodes used for immune cell extraction from uninfected, naïve mice as a non-
inoculated control.  
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Figure 4:12- Immune cell populations at the infection site 3 months post infection. Ear 
derived dermal cells extracted from infected, PBS inoculated and naïve ears were analysed by flow 
cytometry. Representative gating on mouse 3 shown. Populations were pre-gated as single, 
viability stain negative, CD45+, CD11b+. Gating against Ly6C and Ly6G expression (top) allows 
quantification of a distinct neutrophil population as Ly6C+/Ly6G+, Ly6G-/Ly6C+ infiltrating 
monocytes (right) and Ly6G-/Ly6C- (left) skin resident populations. Quantification of dermal 
Dendritic cell (DC) and dermal macrophage (MΦ) populations by MHCII and CD11c expression 
(left, middle and lower). Quantification of inflammatory monocyte (Inf. Mono), monocyte derived DC 
(mono DC) and monocyte derived MΦ populations by MHCII and CD11c expression (right, middle 
and lower). N=3, error shown as standard deviation around the mean. 
CD11b+ innate immune cell recruitment to ears infected with L. mexicana were 
around 100 fold higher relative to PBS and naïve treatments by three months 
post infection (Figure 4:12 upper panel), with a corresponding increase in the 
number of neutrophils and infiltrating Ly6C+ monocytes. The observable increase 
in ear vascularisation and lesion development at this time point was indicative of 
an increased recruitment of CD11b+ cells, such as neutrophils to the infection 
site. An equal number of neutrophils were recruited to ears of C57BL/6 infected 
as compared with a published study examining neutrophil recruitment to L. 
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major infected ears after only 14 days (Ribeiro-Gomes et al. 2012), suggesting an 
impaired level of recruitment for disease resolution.  
A trend towards an increased Ly6C+/Ly6G- infiltrating monocyte population in 
infected ears was observed in this study, with the most pronounced increase in 
cell numbers relative to non-infected controls being the moDC population (Figure 
4:12 bottom right panel). Previous experimentation identified the impaired 
recruitment of mo-DC at 14 days post infection C57BL/6 mice infected with L. 
mexicana compared to L. major, with around 7.5x103 cells being identified 
(Petritus et al. 2012). The identification of an average 1.49x103 moDC quantified 
at 3 months post infection demonstrated the low levels of recruitment at this 
chronic stage of infection. These data establish a basis for investigating the 
recruitment of monocytes and in particular moDC to the infection site. The use 
of parasites expressing RE9H allows a comparison between parasite burden at 
the infection site with immune cell recruitment following gene deletion of a 
potential drug target.  
Migration of antigen presenting cells to the draining lymph node to induce the 
differentiation of naïve T Cells to Th1 effector cells is a crucial stage in the 
development of an appropriate immune response to Leishmania infection 
(Carvalho et al. 2012). Migration of moDC to the dLN is impaired in C57BL/6 
infected with L. mexicana (Petritus et al. 2012; Hurrell et al. 2015a), therefore 
recovered migration of such cells following inducible deletion of an essential or 
virulence factor in L. mexicana represents a functional confirmation of the 
recovery of an appropriate immune response. The use of an ‘innate’ antibody 
strategy to investigate the recruitment of mo-DC in the draining lymph node was 
established for future use of C57BL/6 mice expressing the Kaede photo-
switchable protein (Tomura et al. 2008). This method would enable cells from 
the infection site to be photo-switched, thereby inducing the expression of 
green fluorescence to red fluorescence in order to track dissemination from the 
infection site to the draining lymph node.  
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Figure 4:13- Immune cell populations at the cervical lymph node 3 months post infection. 
Cervical lymph node derived cells draining from the ear of infected, PBS inoculated and naïve mice 
were extracted and analysed by flow cytometry. Representative gating on mouse 3 shown. 
Populations were pre-gated as single, viability stain negative, CD45+, CD11b+. Gating against 
Ly6C and Ly6G expression (top) allows quantification of a distinct neutrophil population as 
Ly6C+/Ly6G+, Ly6G-/Ly6C+ infiltrating monocytes (right) and Ly6G-/Ly6C- (left) lymph node 
populations. Quantification of lymph node resident dendritic cell (DC) and lymph node migratory 
DC populations by MHCII and CD11c expression (left, middle and bottom). Quantification of 
inflammatory monocyte (Infl. Monocytes), monocyte derived DC (mono DC) and monocyte derived 
MΦ populations by MHCII and CD11c expression (right, middle and bottom). N=3, error shown as 
standard deviation around the mean. 
 
To establish a basis for future application of Kaede expressing mouse models and 
in vivo inducible gene deletion in L. mexicana, immune cells from in the 
cervical, dLN were extracted, stained with an ‘innate’ antibody screen and 
phenotyped by flow cytometry (Figure 4:13). Quantification of the number of 
innate cell at this site identified an overall 5 fold increase in the number of 
CD11b+ cells relative to non-infected LNs, with an increase in both Ly6C+ 
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myeloid cell numbers and Ly6C- resident populations (Figure 4:13, upper panel). 
Further phenotypic analysis of the populations showed a trend towards increased 
moDC recruitment in infected mice, however this was highly variable. A general 
trend towards increased numbers of Ly6C- DC and MO populations was observed, 
indicative of the expansion of the lymph nodes relative to uninfected controls 
however the recruitment of Ly6C+ infiltrating monocytes remained 
comparatively low throughout (Figure 4:13, middle and lower panels). 
4.3 Discussion 
4.3.1 Establishment of CRK3 as a validated drug target 
The data presented in this chapter establishes that the inducible excision of 
essential genes in L. mexicana is a viable method for conditional null mutant 
generation by application to conditional deletion of the gene encoding the 
essential cdc2-like protein kinase (CRK3). CRK3 was previously proposed to be 
essential for promastigote growth by the inability to generate a null mutant line 
(P Hassan et al. 2001), thereby forming the basis for future study into the 
potential of this protein kinase as a drug target. Essentiality alone cannot be 
taken as a proof that a protein represents a validated drug target (as reviewed 
in section 4.1.2), however the production of active, recombinant CRK3/Cyclin 
complexes with which to conduct activity assays with CDK inhibitor screens 
(Walker et al. 2011) and probe active site residues (Gomes et al. 2010) 
demonstrate CRK3 activity can be inhibited with small molecules inhibitors and 
mutation of key residues. A limitation to such an approach is the lack of 
correlation between active protein kinase complex inhibition in vitro and in situ 
parasite cytotoxicity, as evidenced by previous screens of CRK3 inhibitors (Grant 
et al. 2004). A recent plasmid shuffle based methodology (Dacher et al. 2014; 
Morales et al. 2010) enables the generation of ‘partial null mutants’ with which 
activity can be probed directly in promastigotes (discussed in chapter 1.2), 
however this method not been applied to CRK3. Instead, the method of 
conditional complementation with a CRK3T178E mutant has confirmed this as a 
key residue for mediating CRK3 function in L. mexicana promastigotes directly, 
implicating the inhibition of CRK3 activity in situ by chemical blocking of this 
active site. Our previous inability to regulate expression of CRK3 in vivo was a 
major limitation in establishing whether CRK3 activity was essential for 
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mediating the cell cycle of amastigotes. By deletion in stationary phase cells and 
subsequent infection, the attenuation of CRK3 deficient L. mexicana in vivo 
indicates the protein kinase as essential for amastigote replication (see section 
4.3.3 for further discussion).  
In order to confirm that the cell cycle arrest phenotype demonstrated in 
promastigotes was specifically due to loss of CRK3 rather than an artefact of 
rapamycin treatment or overexpression from the circularised fragment, a 
complementation was carried out through overexpression of CRK3His from the 
ribosomal locus. These cells no longer arrest once deletion is induced with 
rapamycin thereby confirming the specificity of gene deletion, however 
overexpression gives rise to cells with increased DNA content (Figure 4:4b) and a 
comparatively slow growth rate. In addition to cyclin binding and T178 
phosphorylation, S. pombe cdc2 mutant functional rescue by L. mexicana CRK3 
confirms dephosphroylation of T14/15A conserved residues is necessary for 
activity (Wang, 1998). Phosphorylation of T14/15A residues is thought to occur 
through negative regulation by wee1 kinase and positive regulation by a CDC25 
phosphatase homologue (Gomes, 2010) therefore an overall abundance of CRK3 
may impair the normal interactions with these regulators, resulting in 
uncoordinated mitosis thereby slowing growth. Previous study has shown that 
cells lacking endogenous CRK3 but complemented with CRK3 expression from a 
pTEX vector retain a normal cell cycle profile (Hassan, 2001) therefore our 
phenotype is likely an artefact of ribosomal overexpression. To address this we 
are currently developing vectors to facilitate integration into the beta-tubulin 
locus, thereby conferring lower expression of our complemented gene. This 
methodology represents an excellent method to identify and probe active sites 
within a protein.  
Taken together, these findings establish CRK3 as a validated drug target in L. 
mexicana and demonstrates that the use of diCre will enable novel insights into 
essential gene function.  
4.3.2 CRK3 is a mitotic regulator in promastigotes 
Conditional gene deletion of floxed CRK3 results in growth arrest after 48 hours 
in L. mexicana promastigotes. Active CRK3 has been previously implicated in the 
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regulation of mitosis in L. mexicana promastigotes, with DNA content analysis 
following treatment with the CDK inhibitor flavopiridol indicative of cell cycle 
arrest in the G2 phase of the cell cycle (P Hassan et al. 2001). The conclusion 
that CRK3 mediates only the G2/M phase was deemed unsuitable, as absence of 
a block at a different cell cycle boundary such as G1/S could be explained by a 
differential inhibition of CRK3 in complex with a G1/S specific cyclin. Inducible 
deletion of floxed CRK3 results in a block at the G2/M phase of the cell cycle 
(Figure 4:4b and c), thereby confirming the previous finding that active CRK3 in 
the promastigote stage controls the G2/M transition. Loss of CRK3 results in the 
accumulation of enlarged, multi-flagellated cells (Figure 4:5 middle panels). This 
phenotype is indicative of an impaired mitotic regulation, whereby cells 
continue to synthesise organelles such as the flagellum and continue kinetoplast 
duplication in the absence of cytokinesis. In addition to continued protein 
synthesis, the increased nuclear DNA content of these cells is indicative of 
impaired mitosis, where re-initiation of G1 in the absence of cytokinesis results 
in the accumulation of nuclear DNA. It appears that these abnormal cells can 
eventually undergo cytokinesis by the observation that of one such daughter 
cells becoming 0N1K yet retaining two flagella (see bi-flagellated zoid in the 
lower panel of Figure 4:5). Such an interesting phenotype demonstrates the 
severe impairment in cell cycle regulation that loss of CRK3 induces, thereby 
confirming previous data that CRK3 was inhibited by flavopiridol treatment of 
promastigotes (P Hassan et al. 2001) leading to arrest at G2/M. RNAi of the 
syntenic orthologue of CYC6 in T. brucei results in growth arrest within 48 hours 
of induction and the accumulation of zoids and cells in G2/M in procyclic forms 
(Hammarton et al. 2003). This analogous phenotype is shown in our study 
through CRK3 inducible excision, therefore it is likely that LmxCRK3 pairs with 
CYC6 to mediate mitosis (Walker et al. 2011). 
The accumulation of cells with an increased DNA content and anucleated zoids 
by CRK3 inducible deletion were previously observed following flavopiridol 
(Hassan et al. 2001) and indirubin treatment of L. mexicana promastigotes 
(Grant et al. 2004). The increased abundance of such aberrant cells likely results 
from the impairment of normal cell division, whereby loss of CRK activity results 
in an unequal sharing of nuclear DNA between daughter cells resulting in a single 
2N1K cell and a 0N1K zoid. RNAi knockdown of the syntenic ortholog of CRK3 in 
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Trypanosoma brucei procyclic forms also results in G2/M arrest and zoid 
formation (Tu & Wang 2004) with the accumulation of such aberrant cells 
rationalised by the lack of a checkpoint controlling mitosis to cytokinesis in the 
procyclic form (Ploubidou et al. 1999). The accumulation of zoids by CRK3 
deletion and the same phenotype by indurubin treatment of promastigotes 
demonstrates the absence of a similar checkpoint for regulating premature 
cytokinesis in the absence of mitosis and implicates CRK3 as the target for 
indurubin inhibition. Yet the observation that indurubin treatment also results in 
the development of elongated cells (Grant et al. 2004) was not evidenced by 
CRK3 deletion, thereby indicating that indurubin is also likely to inhibit other 
kinases as evidenced by its role in glycogen synthase kinase 3 (GSK3) inhibition 
(Leclerc et al. 2001).  
4.3.3 CRK3 is essential for amastigote growth in vivo 
In amastigotes, the effect of floxed CRK3 deletion could not be dissected from 
the inhibitory effect that rapamycin has on the growth of L. mexicana 
amastigotes (Figure 4:8). CRK3 activity is essential for replication of amastigote in 
vivo as determined by their attenuation by stationary phase, floxed CRK3 
deletion and subsequent murine infection, but the utilisation of conditional gene 
deletion represents an important tool for dissecting the activity of a protein 
between life cycle stages. Previous RNAi of TbrCRK3 resulted in disparate 
phenotypes depending on transcript down-regulated in either bloodstream or 
procyclic forms (Tu & Wang 2004). A differential role for CRK3 in mediation of 
the cell cycle by the formation of an alternative protein kinase complex, such as 
CRK3:CYCA with an alternative regulatory function is therefore possible. Protein 
expression assays of the CYCA homologue L. donovani Cyc1 demonstrates an 
increased abundance during S-phase (Banerjee et al. 2006). In addition, histone 
phosphorylation by an active LdCYC1:CRK3 complex (Maity et al. 2011) are 
suggestive of S-phase kinase activity. Our initial observation of a G1/S cell cycle 
arrest in amastigotes by treatment with rapamycin (Figure 4:8) implicated the 
differential regulation by a CRK3:CYCA mediated protein kinase activity. 
However, this block in G1/S is likely due to rapamycin mediated inhibition 
instead. Despite the technical issues diCre conditional deletion represents an 
important method to dissect the function of an essential gene in amastigotes. 
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The process by which the conditional null phenotype can be assessed therefore 
requires optimisation to allow sufficient gene deletion in the absence of 
rapamycin mediated cell arrest. In place of a constant incubation of amastigotes 
in the presence of rapamycin, a possible improvement may be to treat the lesion 
derived cells for 24 hours with a sufficient dose to activate diCre mediated 
recombination. By removal of the rapamycin from the culture medium after this 
incubation period, the cells should recover their normal cell cycle progression. 
An additional improvement would be the use of rapalogs which may have 
reduced binding specificity to L. mexicana mTOR or FKBP12 homologues, thereby 
inducing diCre activity in the absence of inhibitory effects on cellular regulation. 
CRK3 protein kinase activity is dependent on its pairing with cognate, partner 
cyclins, therefore conditional deletion of CRK3 could potentially result in the 
accumulation of cells arrest in a stage other than G2/M if a different partner 
cyclin is necessary for activity. The dissection of such pathways has important 
implications for dissecting the role of other protein kinases in different life cycle 
stages.   
4.3.4 Inducible mutant transgene complementation: a robust 
method for identifying active sites 
Inducible complementation of an essential, but mutated transgene to recover 
activity and growth was developed to establish the essentiality of 
phosphorylation of the CRK3 T-loop residue. T178E mutagenesis of LmxCRK3 
inhibits functional rescue in S. pombe (Wang et al. 1998) and ablates kinase 
activity with recombinant CRK3T178E:CYCA (Gomes et al. 2010). The activity of 
CRK3T178E has not been studied directly in Leishmania due to experimental 
constraints, therefore we utilised a conditional complementation approach to 
investigate the necessity of the phosphorylation of the T178 residue in L. 
mexicana promastigotes (Figure 4:6). The residue was identified as essential by 
excision of floxed CRK3 in the CRK3T178E complementation line, leading to cell 
cycle arrest in G2/M and zoid formation. Cell cycle arrest at 72 hours is later 
than the 48 hour arrest observed by conditional deletion of floxed CRK3 in the 
parental flox line, with a lower proportion of zoids when analysed by flow 
cytometry at 72 and 96 hours post induction. This result is likely attributed to 
the reduced growth rate of the complemented line relative to the parental flox 
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line, thereby leading to a delay in the onset of the arrest phenotype by slower 
cell division and protein turnover.  
Interestingly with this cell line both induced and uninduced cells have 
dramatically reduced flagella length and are immotile (Figure 4:7f). This 
phenotype is likely due to a partial dominant negative effect due to 
overexpression of CRK3T178E, resulting in impaired cell function, but maintenance 
of the cell cycle due to sufficient floxed CRK3 expression and activity. The 
reduced flagellar size and growth are phenotypes mirrored by the generation of 
L. major deficient in ATG5, a gene encoding a key component of the autophagic 
pathway (Williams, 2012). The reduced size and growth of these cells is likely a 
result of their impaired ability to salvage material through the autophagic 
pathway, imparting selection on the parasites to reduce energy through 
flagellum regression. The partial dominant negative effect of CRK3T178E may also 
result in metabolic stress in these cells, therefore inducing a compensatory 
response by flagellar loss. Another explanation may be the involvement of 
mitogen-activated protein (MAP) kinases, CDK-like kinases which respond to 
changes in environmental stress. Reduced cell size and flagellum length is a 
result of gene deletion of LmxMPK3 and LmxMKK in promastigotes (Erdmann, 
2006) (Wiese, 2003), however the involvement of this signalling cascade is 
unlikely. The G2/M arrest phenotype of this cell line resulting from floxed CRK3 
loss confirms the essentiality of T-loop residue phosphorylation to facilitate 
cyclin binding for the formation of an active complex to subsequently regulate 
progression through mitosis. These data establish this complementation assay as 
a rational approach for active site investigation.  
4.3.5 Technical considerations for conditional deletion of 
essential genes by diCre mediated recombination 
The generation of a Δcrk3::DICRE/Δcrk3::CRK3FLOX cell line was aided by the 
production of gene replacement cassettes with an optimised Gateway cloning 
protocol (detailed in Figure 3:3). Gene replacement was also efficient, with the 
first round of gene replacement by the diCre construct yielded four blasticidin 
resistant clones out of six tested with diCre integrated into the CRK3 locus. 
Subsequent replacement of the remaining CRK3 allele by the floxed CRK3 
expression construct yielding four clones out of ten puromycin/blasticidin 
153 
 
resistant lines with both alleles replaced. Such amenable cell line generation 
holds promise for the utilisation of diCre as a method to regulate expression of a 
variety of essential genes, however the approach to delete the first gene copy 
by diCre replacement may not be advisable for the replacement of genes where 
replacement of a single copy results in altered ploidy (Martínez-Calvillo et al. 
2005). In this circumstance, replacement of the first allele by loxP would be a 
preferable strategy to avoid such gene copy variation by initial ‘add back’ of the 
gene, followed by subsequent replacement with diCre. Even this approach may 
be limited for certain genes such as that encoding the Leishmania metacaspase 
(MCA), where gene expression is tightly regulated and deletion of a single allele 
leads to altered ploidy even in the presence of an integrated transgene (Ambit 
et al. 2008). Despite such potential complications, the efficacy of the diCre 
inducible deletion strategy for targeting essential genes is evidenced by the data 
presented in this chapter. In conjunction, the application of the system to 
induce deletion of a gene encoding an essential protein for cell cycle progression 
in L. major by our collaborator corroborates this (Damasceno, unpublished data). 
Floxed CRK3 is consistently excised by 24 hours post rapamycin treatment (Figure 
4:3; Figure 4:8; Figure 4:10). Despite repeated attempts to detect loss of CRK3 by 
GFP tagging, protein extraction and SDS-page resolution and subsequent 
immunoblotting with an anti-GFP antibody, no detection of the CRK3-GFP fusion 
protein was obtained. Conditional complementation of CRK3 as a transgene 
integrated at the 18S ribosomal locus yielded clones which grow at a reduced 
rate, but which were insensitive to loss of floxed CRK3 (Figure 4:6). This 
experiment infers that growth arrest resulted from loss of CRK3 expression 
despite an absence of Western blot confirmation. In addition, diCre mediated 
inducible gene deletion of a protein essential for cell cycle progression by our 
collaborator (Damasceno, unpublished data) results in the loss of the target 
protein as detected by immunoblotting with an antibody specific to the target 
protein. We can therefore infer that loss of floxed CRK3 results in loss of CRK3 
protein and the inactivity of the cells.  
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4.3.6 Evaluation of the use of diCre inducible deletion as a tool 
for phenotypic screening of drug targets in vivo  
By deletion of floxed CRK3 in stationary phase promastigotes, the activity of the 
encoded protein kinase has been demonstrated as essential to the maintenance 
of infection in the susceptible murine BALB/c model. This finding demonstrates 
that diCre mediated conditional deletion will have important application to the 
study of other such proteins which have been implicated as essential by gene 
deletion in promastigotes. Prior to this study, the identification of essential 
genes in vivo was by the generation of mutant lacking both endogenous copies of 
the gene by complementation with the transgene expressed from an episome. 
The retention of the transgene in the absence of antibiotic selection following 
infection into a murine host (Wang et al. 2005) is the criteria for essentiality. 
There may be limitations to this approach, such as a more subtle selective 
advantage by expression of the protein as opposed to an essential function. To 
address this, expansion of this method to induce negative selection of such an 
episome by expressing the gene in array with a toxic thymidine kinase and in 
vivo ganciclocvir treatment (Paape, manuscript in preparation) further supports 
the requirement of the encoded protein for infectivity. Yet although this 
optimisation renders the method more robust, the inability to ablate the target 
gene and therefore dissect the resulting host immune response, or directly 
measure the parasite burden resulting from gene loss is a severe limitation. 
In contrast, the application of this diCre technique can be applied to directly 
confirm essentiality in a more robust manner, with gene deletion directly 
resulting in impaired virulence and burden as measured by comparisons of in 
vivo bioluminescence relative to a non-induced control (Figure 4:10). A rapamycin 
treated, wild-type background [SSU RE9H] cell line established infection of mice 
following high dose rapamycin treatment, indicating that rapamycin treatment 
does not attenuate growth in vivo. The attenuated growth therefore results from 
deletion of the essential gene. More subtle side effects of CRK3 deletion during 
the 24 hour treatment window which may alter aspects of cellular regulation 
influencing infection, such as metacyclogenesis were not explored. Such effects 
are unlikely however, as the proven insensitivity of promastigotes to rapamycin 
(Madeira da Silva et al. 2009), in conjunction with inducible deletion of CRK3 
inducing a growth arrest phenotype in replicative promastigotes after ~48 hours 
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of growth (Figure 4:2) substantiate this method as a practical strategy. The 
recovery of in vivo growth by week 10 post infection as measured by an 
increased bioluminescent signal from the footpads of mice infected with 
rapamycin treated, floxed CRK3 line resulted from a subset of cells not 
undergoing conditional deletion. The necessity to amplify these populations by 
in vitro culture has the potential to enrich the population of cells retaining the 
gene, however the presence of these original cells in the cultures used for 
genomic DNA extraction would enable the detection of gene loss due to the 
sensitivity of PCR. In addition, the preferential amplification of the smaller, 
‘excised’ fragment suggests that an absence of such an amplicon is an indication 
that none of the recovered cells retained floxed CRK3. In future, such 
experiments should utilise the axenic amastigotes media for enrichment of 
lesion-derived amastigotes to address this. Despite this consideration, this study 
demonstrates that attenuation of L. mexicana in vivo is a direct result of an 
absence of active CRK3, and by this method, the large body of evidence that this 
protein kinase represents a validated drug target has been confirmed by such 
experimentation.  
4.3.7 A model for monitoring L. mexicana burden in vivo and 
phenotype the immune response to infection 
The use of red-shifted luciferase expressing, bioluminescent reporter parasites 
represents a practical and powerful strategy to monitor parasite burden in vivo 
over the course in infection, and has already been applied to establish sensitive 
drug screening models for T. brucei (McLatchie et al. 2013) and T. cruzi (Lewis 
et al. 2014). The generation of LUC expressing Leishmania for measuring 
parasite burden by bioluminescent signal was first conducted in 2005 (Lang et 
al.), and has been applied for drug screening in murine models of cutaneous 
(Fortin et al. 2014) and visceral forms of the disease (Michel et al. 2011). 
However, the use of an RE9H based model for the study of Leishmania infection 
is preferable due to its enhanced tissue penetration and the subsequent 
increased detection sensitivity relative to LUC for the determination of parasite 
buden in vivo (Figure 4:11a). The establishment of such a model to measure 
parasite load by the proximate bioluminescent signal from the ears of C57BL/6 
mice indicates that low dose infections are detected at early time points, before 
visible lesion development or vascularisation had occurred (Figure 4:11b). 
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However, the signal strength from infected ears generally increased throughout 
infection in only half of the infected mice, as the signal from half of the mice 
reduced to very low levels. This disparity may be due to variable doses of 
infectious parasites being inoculated into the ear pinna, as this infection route is 
technically difficult, however ear inoculation was chosen because it represents a 
practical site for downstream application of 2-photon microscopy.    
By immune cell extraction and purification from ears (Figure 4:12) and draining, 
cervical lymph nodes (Figure 4:13) at three months post infection with the [SSU 
RE9H] reporter line, a methodology was established to quantify and analyse the 
recruitment of CD11b+ leukocytes at this chronic stage. The rationale for this 
model was the established experimental findings that CD11b+ cell recruitment to 
the infection site is higher in resolving L. major infections of C57BL/6 mice, with 
a subset of infiltrating, inflammatory monocyte derived cells being implicated in 
the development an appropriate Th1 CD4+ T cell response (Petritus et al. 2012). 
Phenotyping of a subset of monocytes which express the DC marker CD11c after 
de novo differentiation from inflammatory monocytes at the site of recruitment 
reveals an increased accumulation of monocyte-derived dendritic cells (mo-DC) 
(León et al. 2007) to the infection site of L. major mice relative to L. mexicana 
infected mice. These cells exhibit very low levels of iNOS production in the 
context of an L. mexicana infection, an antimicrobial response necessary for the 
clearance of Leishmania parasites (Alexander et al. 1998) and a further 
indication of the deficient immune response to L. mexicana relative to L. major. 
By quanitification of leukocyte populations in the ear during chronic infection, 
the levels of recruitment to a wild-type infection were established. 
The migration of mo-DC to the draining lymph node for antigen presentation and 
CD4+ Th1 differentiation is also a key step in generating a Th1 response (Hurrell 
et al. 2015b). This migration is impaired however, as evidenced by adoptive 
transfer of monocytes into the infection site at 2 weeks post infection results in 
reduced dLN migration in L. mexicana infected mice relative to L. major 
(Petritus et al. 2012). The isolation and phenotyping of low levels of leukocytes 
in the draining lymph node (Figure 4:13) established a basis for the tracking of 
migration from infection site to dLN by Kaede (Tomura et al. 2008) reporter 
mouse infection and photo switching of the ear cells, or FITC painting. The 
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expansion of this model to include conditional gene deletion in L. mexicana will 
yield novel insights into the resolution of infection in the context of parasite 
burden and generation of an appropriate immune response.  
4.3.8 L. mexicana conditional gene deletion for In vivo 
application: implications for multiple disease models 
The initial strategy for the establishment of an in vivo model to measure 
parasite burden and immune cell recruitment was the application of L. mexicana 
conditional gene deletion by rapamycin treatment of chronically infected mice. 
This technique would allow the validation of the deleted gene as a ‘druggable‘ 
target and phenotype the resulting immune response to identify the 
development of a resolving infection. By gene deletion of CRK3 and monitoring 
of parasite burden in vivo we have established the protein kinase as essential for 
maintaining infection; however we are currently unaware of how deletion of 
CRK3 influences the resulting immune response.  
The persistence of a small population of parasites expressing CRK3 was able to 
drive subsequent re-infection in Balb/c mice after a period of 10 weeks; we may 
have hypothesised that the attenuation of the majority of cells would result in 
an appropriate Th1 response to prevent outgrowth of the remaining amastigotes 
retaining a copy of CRK3. The recovery of latent L. major infections in C57BL/6 
infections has been demonstrated by the inhibition of appropriate iNOS 
mediated parasite killing (Stenger et al. 1996), therefore the recovery of 
parasite growth is likely a result of impaired immunity by the inherent 
disposition towards a Th2 mediated, humoral response in BALB/c mice (Rosas et 
al. 2005). BALB/c infection therefore represents an ‘immuno-compromised’ 
model of Leishmania infection. In the context of chronic infection and drug 
target validation, this would be an appropriate model for in vivo diCre activation 
and subsequent conditional gene deletion; loss of the gene would need to result 
in a pronounced effect on in vivo viability if the encoded factor is to be 
identified as a useful drug target. This is particularly important in the context of 
HIV co-infection, where immune compromised individuals would require an 
extremely efficient rate of drug mediated leishmania toxicity to prevent or treat 
the relapse of infection (Okwor & Uzonna 2013).  
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The treatment of infected mice with rapamycin or analogues of rapamycin 
(rapalogs) to induce gene deletion during in vivo infection would therefore be an 
excellent basis in the identification of genes encoding practical drug targets, 
particularly when coupled with the bioluminescent reporter parasites and the 
IVIS to monitor resulting parasite burden in vivo. The control of such 
experimentation would have to be stringent as a result of treatment with the 
immunoinhibitory compound rapamycin (Araki et al. 2011), as treatment may 
result in an altered immune response and influence the rate of attenuation. In 
addition, the bioavailability of rapamycin in vivo is poor (Rouf et al. 2009), 
therefore such a strategy may be experimentally challenging and is discussed 
further in chapter 6. The application of in vivo deletion to an essential L. 
mexicana gene during BALB/c infection is a powerful model to validate a drug 
target, but is not suitable for monitoring the outcome of appropriate immunity. 
With such considerations in mind, an appropriately controlled study represents a 
powerful tool to screen potential anti-leishmanial drug targets in vivo.  
In contrast to BALB/c mice which are susceptible to infection with L. major and 
L. mexicana, C57BL/6 mice are only attenuated in a Th1 response by L. 
mexicana mediated immune modulation, therefore the attenuation of L. 
mexicana by gene deletion could potentially result in the induction of an 
appropriate immune response to target those remaining viable cells which retain 
the gene. In this respect, C57BL/6 infection represents an acute model to 
establish the outcome of gene deletion on infection resolution by an appropriate 
immune response. The application of the stationary phase conditional gene 
deletion and subsequent infection of C57BL/6 mice would enable the resulting 
immune response to be contextualised in regards to innate cell recruitment, and 
the subsequent development of adaptive and memory responses. The current 
antibody screen used to identify infiltrating moncoytes could be expanded to 
identify T helper cell differentiation and effector function. Additional 
components could be applied to the model depending on the biological outcome 
being tested, such as the use of photo-switchable Kaede mice (Tomura et al. 
2008) to establish the effect of gene deletion on immune dissemination to the 
the draining lymph node. The application of this method would allow novel 
insights into the function of essential genes, the loss of which may induce an 
appropriate immune response early in infection. In addition, application to 
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encoded virulence factors would enable direct comparisons between the 
resulting immune response to cells expressing or lacking the target gene, 
thereby establishing the role of the encoded protein in mediating host-pathogen 
interactions.  
The application of such multi-factorial studies would be important for 
establishing the resulting phenotype by inducible gene deletion in both the 
context of immune response, and by parasite burden to further validate the 
encoded parasite factors as essential for the maintenance of infection.  
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5 The role of repressor of differentiation protein 
kinase 1 in Leishmania mexicana 
5.1 Introduction 
5.1.1 Leishmania differentiation: from vector to host and back 
again 
Differentiation between life cycle stages is an essential process for transmission 
and survival of Leishmania. To infect, survive and replicate between the 
contrasting environments of host and vector, Leishmania undergoes 
morphological and biochemical differentiation (Alexander et al. 1999). The 
transition to each of these stages must be tightly regulated in order for the 
parasite to complete its complex life cycle, with environmental changes such as 
pH variation and temperature shifts forming the basis for differentiation 
‘sensing’ to occur. Such extracellular cues are received by specific receptors and 
transduced into an appropriate cell response by a signalling cascade to drive 
cellular differentiation, a chain of events which represent an essential process 
for maintenance of infection and life cycle transition. The mechanisms 
regulating this process are little understood, but signal transduction is likely 
mediated by post-transcriptional regulation by protein phosphatases and kinases, 
in particular the mitogen activated protein kinases (MAPK). These kinases are 
activated in response to environmental cues such as pH, temperature and 
nutritional stress in a signalling cascade which mediates transcriptional 
regulation and gene expression (Dacher et al. 2014). A body of evidence is 
establishing the role of MAPKs in regulating a number of cellular processes by 
phosphorylation of a range of substrates in the nucleus or cytosol (Kuhn & Wiese 
2005). The relevance of these kinases in regulating differentiation is notable by 
their stage-specific activity; overexpression analysis of three such kinases 
(LmjPK4, 7 and 10) reveals an increase in kinase activity following exposure to 
34°C and increased pH, mimicking the inoculation into the host and intracellular 
survival (Morales et al. 2007). A proteomics approach has further identified 
LmaMPK10 as an amastigote specific phosphoprotein (Morales et al. 2008). In 
addition, expression of the MAPK kinase homologue LmxPK4 is highest in 
promastigotes undergoing division and differentiation to amastigotes, with 
kinase activity highest at 40°C indicative of enhanced activity following 
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inoculation into the warm blooded host (Kuhn & Wiese 2005). The generation of 
an LmaMPK4 null mutant has been unobtainable (Wang et al. 2005), but a recent 
plasmid shuffle approach has identified key residues necessary for the protein 
kinase activity by a partial complementation approach and validated the 
essentiality of the protein in promastigotes (Dacher et al. 2014). The retention 
of the gene on an episome during murine infection also further demonstrates the 
requirement for active LmaPK4 in amastigotes, suggestive of a crucial role in 
regulation of differentiation at all life cycle stages. Stage specific activity has 
again been identified by gene knockout of MPK1 in L. mexicana (Wiese 1998) to 
establish the necessity of LmxMPK1 protein kinase activity for amastigote 
proliferation and maintenance of infection.  
Collectively, these studies are establishing MAP kinases as important transducers 
of extracellular cues in the context of disease maintenance, yet despite this 
expanding knowledge no studies have established a MAP kinase which directly 
regulates the differentiation of amastigotes to procyclic promastigotes. The 
premature entry of amastigote forms to avirulent procyclic promastigotes 
represents an important stage where stringent control must be exerted to 
prevent premature differentiation and maintain infection, but little is known 
about the chief regulators of this process. MAPK mediated signalling pathways 
are likely implicated in this, as exemplified by LmxMPK3 (Erdmann et al. 2006) 
and LmxMPK9 (Bengs et al. 2005). Both genes are expressed exclusively in 
dividing or differentiating promastigotes and can be efficiently deleted in 
promastigotes resulting in altered flagellar biosynthesis. The effect on flagellar 
development has implications regarding the regulation of amastigote to 
promastigote transition, yet this phenotype is not strong enough to exert a 
deleterious differentiation phenotype such as seen by LmxMAPK1 deletion 
(Wiese 1998). This represents an important finding in preventing life cycle 
progression, with disruption of differentiation acting as a transmission blocker. 
An LmxMAPK2 null mutant has also been generated with amastigote attenuation 
and morphological disorders in the promastigote stage (Wiese 2007), however 
this phenotype is not as pronounced as the effect of TbMAPK2 depletion. Such 
powerful mediation of the cell cycle by a single protein is a desirable outcome in 
the study of regulatory factors, yet other than LmxMAPK1, no protein has yet 
been identified which can induce a more pronounced impairment on 
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differentiation between Leishmania life cycle stages. This may be in part the 
essentiality of many MAPKs (Morales et al. 2010) which prevents phenotypic 
analysis by the absence of a method to conditionally regulate essential gene 
expression in Leishmania. The diCre strategy discussed in Chapters 4 and 5 
would lend itself to analysis of amastigote to promastigote differentiation, 
either in vitro with axenic amastigotes in culture or during in vivo infection. As 
discussed in Chapter 1.4, protein kinases are crucial regulators of cellular 
processes and represent important targets for drug inhibition, therefore the 
identification of protein kinases controlling differentiation during host infection 
would be of great interest both as drug targets. 
5.1.2 A role for Repressor of differentiation kinase 1 (RDK1) in L. 
mexicana differentiation? 
A body of knowledge is being generated on the role of signal transduction and 
regulation of differentiation in T. brucei. This is in part a result of the more 
amenable methods to manipulate this organism, particularly by RNA interference 
of target gene transcripts. Differentiation has been studied in depth in ‘Stumpy’ 
cells, the quiescent, transmissible stage of the parasite whereby differentiation 
is regulated by quorum sensing in a density dependent manner. TbMAPK5 has 
previously been identified as a regulator of stumpy differentiation, as BSF MAPK5 
null mutants undergo stumpy generation prematurely both in vitro and in vivo 
resulting in impaired growth (Pfister et al. 2006). Interestingly, deletion of the 
L. mexicana homologue also impairs growth in vivo (Wiese 2007), yet the 
apparent lack of an established quiescent, ‘stumpy-like’ transmissible stage 
amastigote prevents direct comparison of such a phenotype in Leishmania. 
Application of RNAi to a genome wide screen has allowed RNAi target sequencing 
(Rit-seq) to induce protein knock down of T. brucei transfected with the genome 
fragment RNAi library (Mony et al. 2014). By this method, a number of protein 
kinases were identified and implicated in the quorum sensing pathway that 
results in stumpy differentiation. Of particular interest was the involvement of a 
never-in-mitosis A (NIMA) related kinase (NEK) in signal transduction. The role of 
NEK kinases in differentiation was expanded following a more concise, kinase-
wide RNAi screen conducted by Jones et al. (2014). Knockdown of NEK 12.2 in 
bloodstream forms resulted in the induction of procyclic form differentiation, as 
identified by high levels of procyclin expression in the absence of heat shock and 
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the repositioning of the kinetoplast indicative of procyclic differentiation (Jones 
et al. 2014). In addition, this protein kinase was essential to the growth of the 
parasites, with RNAi resulting in a lethal phenotype. Due to its mediation of 
procyclic differentiation, this protein kinase was termed repressor of 
differentiation kinase 2 (RDK2). Interestingly, a related protein kinase may be 
expressed in Leishmania as evidenced by a gene with a high degree of DNA 
sequence identity (~63%) and genomic synteny to the LmxM.30.2960. Such a 
gene would represent an interesting target to conditionally regulate in 
Leishmania, as we may postulate that the loss of protein activity may induce a 
similar differentiation phenotype. To explore this, a null mutant could first be 
established by drug cassette replacement. RNAi of RDK2 results in a rapid lethal 
phenotype, therefore a shared function in Leishmania would be detrimental to 
the parasite. As such, conditional regulation by the diCre system represents a 
novel and robust approach to circumvent the current limitations on essential 
gene deletion (detailed in chapters 4 and 5). However the location of this gene 
on chromosome 30 obstructs knockout by either method, as this chromosome is 
associated with high copy number due to chromosomal duplication (Rogers et al. 
2011). As such, at least four rounds of transfection and drug selection would be 
necessary to delete the gene. However, the Jones screen revealed another 
bloodstream to procyclic repressor of differentiation, termed RDK1. RNAi of this 
kinase induced procyclic differentiation in about 20% of cells with differentiation 
enriched to 38% by pretreatment of cells with 8-pCPT-cAMP and 27°C cold shock. 
An interesting property of this protein kinase is its sequence identity with STE11-
like MAP kinase kinase kinases, which in conjunction with its localisation on the 
cell surface implicates RDK1 in initiating a MAPK signalling cascade following 
uptake by the Tsetse fly. As with RDK2, RDK1 has a syntenic orthologue in L. 
mexicana which represents an interesting target for gene deletion to investigate 
its role in differentiation. In conjunction, the gene encoding RDK1 
(LmxM.31.0810) is likely diploid due to its location on chromosome 31 and was 
deemed amenable to deletion by replacement of drug selectable markers.  
5.1.3 Utilising the diCre system to study LmxRDK1 function in 
vivo 
We postulate that if LmxRDK1 is regulating differentiation with a similar 
mechanism to TbRDK1 that the active kinase would be involved in suppressing 
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the differentiation and early entry of mammalian infectious amastigotes to the 
sand fly infectious proliferative promastigotes. The induction of procyclic 
differentiation following RNAi of RDK1 in bloodstream form T. brucei at 37°C has 
important implications for the maintenance of infection, as this demonstrates 
the induction of inappropriate differentiation even in the absence of 
extracellular cues such as cold-shock or cis-aconitate treatment (Jones et al. 
2014). In Leishmania, the procyclic promastigotes are non-infectious in vivo 
(Sacks & Perkins 1984) as they lack a thickened glycocalyx  composed of 
elongated lipophosphoglycan (LPG) and the metalloprotease gp63 (Alexander et 
al. 1999), therefore RDK1 inhibition in vivo could result in down regulation of 
these virulence factors. The loss of virulence factor expression may enhance 
recognition and clearance of the parasites by the mammalian immune response. 
In conjunction, as metabolism is altered dramatically between amastigotes and 
promastigote life cycle stages (Kloehn et al. 2015) the induction of promastigote 
metabolism in vivo would be deleterious to parasite survival. TbRDK1 expression 
on the cell surface implicates it directly in the signalling of extracellular cues 
which are subsequently transduced by proteins such as the MAPKs in a signalling 
cascade. The increasing body of evidence for the regulation of life cycle 
differentiation by MAPK mediated signalling, in addition to the upstream signal 
transduction potential of RDK1 implicates a role as an important regulator of 
differentiation and therefore virulence in L. mexicana. These data suggest that 
RDK1 might play a potentially powerful role in regulating differentiation in vivo. 
By in vivo conditional deletion of RDK1, this hypothesis could be explored. The 
development of the diCre conditional gene deletion system represents a novel 
method to conduct gene deletion in axenic amasitogotes, or during the course of 
in vitro macrophage or murine infection. By in vivo application the infection 
dynamics of lesion size and immune cell recruitment following loss of RDK1 can 
be investigated.  
5.1.4 Research aims 
We aim to utilise the diCre system to conditionally regulate RDK1 expression 
during murine infection. Gene knockout by replacement of both RDK1 copies 
with drug resistance cassettes will first be conducted to establish the 
essentiality of the gene in both life-cycle stages, followed by generation of a 
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conditional deletion line. The role of RDK1 in controlling the life cycle 
differentiation of L. mexicana will be investigated by: 
1. Attempted generation of an LmxRDK1 null line.  
2. Phenotype analysis of null mutants if generated, including murine 
infection with the LmxRDK1 null line to determine whether infection can 
be maintained in vivo. 
3. If null mutants cannot be generated, the creation of a diCre mediated 
inducible knockout line with which to regulate RDK1 expression. 
4. Phenotype analysis of innate immune recruitment by ear infection of 
C57BL/6 mice following RDK1 inducible deletion to probe immune cell 
recruitment and disease maintenance in vivo. 
5.2 Results 
5.2.1 In silico Trypanosome/Leishmania RDK1 structural 
homology analysis 
The coding sequences for TbRDK1 (Tb11.01.5650) and LmxRDK1 (LmxM.31.0810) 
were downloaded from TriTrypDB, translated to protein sequences and aligned 
to identify sequence conservation (Figure 5:1). Pfam and TMHMM prediction 
analysis revealed sequence identity between three transmembrane domains and 
a single protein kinase domain at the N and C-terminus of the protein 
respectively. These transmembrane domains in T. brucei RDK1 are functional as 
a myc-tagged RDK1 was detected in the membrane and cell surface by protein 
fractionation and IFA labelling (Jones et al. 2014). These conserved 
transmembrane domains suggest LmxRDK1 might be embedded in the cell 
membrane to transduce extracellular cues by a similar mechanism to TbRDK1.  
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Figure 5:1- Schematic showing the alignment of L. mexicana and T. brucei RDK1 protein 
sequences. Black, horizontal lines indicate the region of the corresponding protein being mapped, 
with gene identification shown at left. Vertical, pink bars demonstrate sequence conservation 
between proteins. Highlighted domains were predicted by Pfam mapping and are annotated as 
protein kinase domains (red), active sites where substrate is either bound or phosphorylated (grey) 
and transmembrane domains (blue). 
 
There are differences between the sequences, with RDK1 in Leishmania 
containing an additional 171 amino acids compared with T. brucei RDK1. The 
overall amino acid conservation between the sequences is around 28% and non-
conserved extensions occur mainly at the N-terminal region and around 50 amino 
acids before the predicted kinase domain, thereby contributing to the low 
degree of conservation between sequences. However, analysis of the kinase 
domain reveals a relatively high 50% identity between the residues, suggestive of 
a conserved protein function at this region. In addition, the highly conserved 
mapping of active sites identified by the Pfam domain search implicates a shared 
protein kinase activity. Downstream cell signalling is likely to be a result of a 
RDK1 mediated phosphorylation of a MAP kinase signalling cascade, with 
conservation in this region suggestive of a homologous kinase activity towards 
MAPKs in Leishmania. Overall, the conservation of predicted transmembrane and 
catalytic domains implicates a role in differentiation of RDK1, therefore 
targeted replacement of the gene was conducted to establish the function of 
LmxRDK1. 
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5.2.2 Generation of an RDK1 null mutant 
The 4.1kbp RDK1 open reading frames were replaced by the integration of gene 
resistance cassettes. The strategy for attempted generation of an L. mexicana 
RDK1 null mutant is shown in Figure 5:2. Constructs were created for the 
replacement of the RDK1 gene with puromycin and hygromcyin drug resistance 
markers. PCR amplification of 500bp 5’ and 3’ flanks directly up and downstream 
of RDK1 was conducted with primers containing appropriate attB sites to 
facilitate Gateway mediated insertion into pDONR vectors (explained in more 
detail in Chapter 3). Puromycin, blasticidin, nourseothricin and hygromycin drug 
resistance vectors were created by flanking the gene resistance cassettes with 
RDK1 homologous arms by Gateway cloning. Only the puromycin and hygromcyin 
resistance constructs were used for subsequent transfection of wild-type L. 
mexicana.  
Puromycin resistant clones were generated by transfection of the resistance 
cassette and replacement of RDK1 confirmed by PCR amplification. Only 
amplification of clone 6 gDNA yielded a 1.13Kbp amplicon of expected size 
(Figure 5:2b upper), therefore this heterozygote for RDK1 (Δrdk1::PACr ) was 
subsequently transfected with the hygromycin resistance cassette. A single clone 
(clone 4) was confirmed to have both RDK1 alleles replaced by drug selection 
markers as evidenced by two 1.13Kbp amplicons by PCR amplification of genomic 
DNA with primers specific to the RDK1 locus and the resistance cassettes (Figure 
5:2b lower). To confirm loss of RDK1, genomic DNA of clone 4 
Δrdk1::PACr/Δrdk1::HYGr and clone 6 Δrdk1::PACr gDNA was used for Southern 
blotting (Figure 5:2c & d.). By restriction digest and probing with a 3’ RDK1 
flank, the lack of a 8.2Kbp fragment containing the RDK1 coding sequence 
established clone 4 as an RDK1 null mutant (Δrdk1).  
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Figure 5:2- Replacement of RDK1 with drug resistant cassettes. Panel a. The strategy for 
replacement of RDK1 by homologous recombination of the puromycin (PAC) and hygromycin 
(HYG) resistance cassettes flanked 5’ and 3’ homologous flanking regions (FR). Panel b. 
Integration of drug resistance cassettes at the RDK1 locus checked by PCR amplification. Genomic 
DNA was extracted from each of five puromycin and hygromycin resistant clones alongside a Wt 
control, followed by amplification with a forward primer binding upstream of the 5’ flank and a 
primer binding within the PAC (P), HYG (H) or RDK1 (Wt) coding sequences in the reverse 
orientation. A longer exposure of the gel reveals the presence of a Wt amplicon for all clones with 
the exception of clone 4. Panel c. (upper) depicts the strategy used for restriction enzyme digestion 
of genomic DNA by SacI to excise an 8.2KBp fragment if RDK1 is retained. (lower) Genomic DNA 
was extracted from the Wt control, PAC integrated heterozygote and the subsequent PAC/HYG 
integrated clone 4. The DNA was digested by SacI and resolved on a 0.8% agarose gel, followed 
by transfer to a nitrocellulose membrane. The transferred, digested DNA was hybridised with a 
500bp 3’FR chemiluminescent probe, allowing detection of each predicted DNA fragment (c.) by 
the development of X-Ray film following addition of a chemiluminescent substrate. 
 
 
5.2.3 Murine infection by RDK1 deficient L. mexicana 
Δrdk1 in vitro, was comparable to growth of wild-type L. 
mexicana. Neither Δrdk1::PACr nor Δrdk1::PACr/Δrdk1::HYGr clones had 
aberrant morphology, with the only observable difference to wild-type being a 
slight elongation of the cells (data not shown). These observations were to be 
expected as the hypothesis was that RDK1 is a repressor of differentiation in the 
amastigote stage, therefore to test the hypothesis that RDK1 inactivity would 
result in the induction of differentiation and therefore attenuation in vivo, the 
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Δrdk1 line was inoculated into the footpads of Balb/c mice. Parasite burden was 
measured by footpad size over the course of 6 weeks, identifying the growth of 
footpad lesions at an equal rate to wild-type infection (Figure 5:3). 
 
Figure 5:3- Infectivity of Δrdk1 to mice. 2x10
6
 stationary phase Δrdk1 stationary phase 
promastigotes were inoculated into the footpads of Balb/c mice and footpad size measured using a 
calliper (n=2, mean lesion size +/- S.E.). An L. mexicana wild-type control infection is included as a 
reference (n=1) and lesion size calculated by subtracting the measured footpad size from the initial 
size at week 1 post infection.  
 
Viable Δrdk1 amastigotes were isolated from the footpad lesions. Purified 
amastigotes had a normal cell morphology and size as observed by light 
microscopy and were capable of differentiation to procyclic promastigotes 
within 24 hours of in vitro culture in supplemented HOMEM media, providing 
further evidence that cellular signalling and appropriate control of 
differentiation was in operation in this mutant.  
5.3 Discussion 
5.3.1 RDK1 is not essential for L. mexicana differentiation 
We expected deletion of LmxRDK1 to result in a phenotype akin to removal of an 
essential virulence factor, whereby growth and survival during murine infection 
would be attenuated. The generation of a Δrdk1 L. mexicana cell line enabled 
the testing of this hypothesis, yet integration of puromycin and hygromycin 
resistance cassettes at this locus was infrequent as determined by PCR analysis 
(Figure 5:2b). Difficulties in gene replacement can indicate essentiality of a 
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gene (Ambit et al. 2008), however this was not the case as a single clone was 
isolated in which both copies of RDK1 were replaced (Figure 5:2b and c). The 
low frequency of gene replacement may therefore be a result of the large size of 
the 4Kbp gene. Despite the difficulties in generating this null line, RDK1 deletion 
yields viable promastigotes with an absence of altered ploidy to retain an extra 
copy of the gene, therefore it is not essential to growth and survival of 
promastigotes in culture, a trait shared by previously established virulence 
factor knockout lines (Wiese 1998, Buxbaum et al. 2003, Denise et al. 2003, 
Castanys-Muñoz et al. 2012). In contrast to the attenuated infectivity of these 
knockout mutants, RDK1 depletion yields L. mexicana which remain infective in 
Balb/c mice (Figure 5:3). There remains some minor experimental disparities 
between this study and those published examples; burden monitoring in vivo by 
lesion size was conducted for a longer time scale of between 8 and 70 weeks, 
and in the case of the Δcpb trial (Buxbaum et al. 2003b) which ran for 18 weeks 
this longer time frame was crucial for identifying the subsequent lesion size 
reduction and reduced parasite burden manifested from 6 weeks post infection. 
Balb/c remain the most susceptible line to L. mexicana infection due to the 
polarised Th2 response, yet the susceptibility of this line may mask more subtle 
phenotypes such as impaired differentiation. The CPB study utilised C3H mice 
which are susceptible to L. mexicana infection as a result of an impaired Th1 
response, therefore we could speculate that the infection of C3H or C57BL/6 
lines with the Δrdk1 would result in an appropriate Th1 response as a result of a 
subtle impaired differentiation phenotype in vivo. Such a scenario is unlikely 
however, as the attenuation of growth would be expected in all cells due to the 
complete loss of RDK1, and in addition the growth of CPB deficient parasites in 
Balb/c mice is attenuated (Denise et al. 2003), further evidence for RDK1 not 
being necessary for virulence. A potential issue is the low number of mice 
inoculated in this study, however this was a preliminary experiment to establish 
whether further investigation by generation of a diCre conditional expression 
line was necessary. The equal rate of lesion development compared with the 
wild-type infected line in both infected mice, in conjunction with the extraction 
of viable amastigotes from footpad lesions leads to the conclusion that RDK1 
does not function to block differentiation in vivo. These data lead to the 
conclusion that RDK1 does not regulate differentiation in L. mexicana in a 
similar manner to that of TbRDK1. The lack of a pronounced and discernible 
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differentiation phenotype following complete loss of RDK1, we did not generate 
an L. mexicana line where RDK1 expression could be conditionally regulated for 
further in vivo studies (see Research Aims 5.1.4). 
5.3.2 Considerations for data mining of T. brucei RNAi screens 
The use of genome-wide and more targeted RNAi approaches are generating a 
wealth of information about cell cycle control and differentiation in T. brucei 
(Subramaniam et al. 2006; Alsford et al. 2011; Jones et al. 2014; Mony et al. 
2014). Aspects of Leishmania biology are less well understood due to the 
absence of broadly applicable strategies for regulating the expression of 
transcripts, yet the relatedness of kinetoplastids is such that ‘hits’ derived from 
T. brucei screens can be used to form testable hypotheses in Leishmania. We 
utilised such an approach in this study to investigate RDK1 as virulence factor 
with a role in repressing differentiation, based on the amino acid conservation 
and structural homology in both transmembrane and kinase domains (Figure 
5:1). This study demonstrates that RDK1 does not function as a repressor of 
differentiation, yet there still holds promise for utilising such an approach for 
other kinases involved in differentiation such as the MAPKs.  
A potential factor in explaining an absence of differentiation to promastigotes in 
vivo following RDK1 deletion are potential differences in the regulation of 
growth between Leishmania and T. brucei. The induction of stumpy arrested 
cells to facilitate transmission is crucial for life cycle progression in T. brucei, 
with the effect of RDK1 knock and procyclic differentiation taking effect in 
monomorphic ‘stumpy-star’ 2T1 cells (Jones et al. 2014), which are present at a 
population of around 20% in culture. Such growth arrest prepares the cells for 
procyclic differentiation once taken up by the Tsetse fly, however less is known 
about the development of such a quiescent stage of Leishmania amastigotes. 
Recent work (Kloehn et al. 2015) has established that the doubling rate of 
L.mexicana amastigotes in Balb/c mouse lesions takes around 12 days, with 
metabolism and protein synthesis during infection being dramatically reduced 
compared with axenic amastigotes or amastigotes infecting macrophages in 
vitro. The authors describe these lesion amastigotes as ‘semi-quiescent’, a 
necessary mechanism to cope with intracellular immune stresses such as iNOS 
and residence in an acidic phagolysosome. Amastigotes in a lesion may not 
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compose an entirely homogenous semi-quiescent population, as a small 
proportion of hyper-infected macrophage are present, suggestive of a more 
rapid growth rate and reduced quiescence. In contrast, we may speculate that a 
population of transmissible, stumpy-like amastigotes which are fully quiescent in 
vivo could be present, but these would likely be represented in very low 
numbers and are entirely hypothetical. TbRDK1 actively represses differentiation 
in quiescent stumpy cells, therefore an absence of an identified, fully quiescent 
stage in L. mexicana suggests an alternative mechanism to regulate amastigote 
to procyclic promastigote differentiation. The finding that RDK1 is not repressing 
differentiation in L. mexicana compared with T. brucei is analogous to the 
finding that MAPK5 induces procyclic arrest in T. brucei (Müller et al. 2002) but 
not promastigote arrest in L. mexicana (Wiese 2007). The underlying biology 
controlling differentiation between these kinetoplastids may be sufficiently 
divergent that conservation of protein sequence is not conducive to a 
homologous function in life cycle regulation.  
5.3.3 RDK2 and the remaining limitations of Leishmania mexicana 
genetic manipulation 
RDK2 may represent a better target to evaluate in the control of Leishmania 
differentiation because RNAi of the transcript results in a more rapid and higher 
number of cells undergoing procyclic differentiation relative to RDK1 knock 
down (Jones et al. 2014). Contrary to RDK1 ablation, this implies that 
differentiation is not as dependent on a prior differentiation step to a quiescent, 
cell cycle arrested stage such as the ‘stumpy*’ and could instead regulate 
differentiation in the semi-quiescent lesion amastigotes. Leishmania and 
Trypanosoma RDK2 share 63% amino acid sequence identity and have almost 
exactly the same number of residues (442 to 441 respectively), which may be 
indicative of a shared function in the cells. RDK2 regulation therefore represents 
a potentially fruitful target in the context of studying the control of 
differentiation, however as addressed above the location of the encoded gene 
on a supernumary chromosome is a major hindrance in conducting gene deletion 
studies. A time consuming drug cassette replacement and selection approach 
would have to be utilised to ablate the predicted four copies of the gene by 
replacement with four separate resistance cassettes. Despite the potential of 
such an approach, this method is further complication by the observation that 
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RDK2 RNAi is toxic to procyclic T.brucei; if such a phenotype occurs following 
targeted gene replacement of RDK2 in Leishmania a null mutant is unobtainable 
by gene replacement. Chapters 3 and 4 deal with the development of a method 
to regulate expression of such essential genes in Leishmania which would permit 
conditional excision of RDK2, however the reliance on replacement of target 
genes through transfection and homologous recombination by this method 
remains a severe time limitation for targeting high copy number genes. Cas9-
CRISPR technologies has real potential for deletion of multiple copies of RDK2 by 
targeting all gene alleles simultaneously (Sternberg & Doudna 2015; Sollelis et 
al. 2015) and in combination with diCre methodology could allow replacement of 
endogenous RDK2 with floxed versions to enable inducible gene deletion of RDK2 
and previously unobtainable genes such as LmxMPK4, 5 and 10, thereby 
elucidating their role in differentiation. This study into the role of LmxRDK1 
serves as an example as to the complications in translating ‘hits’ obtained from 
the study of the more amenable T. brucei to Leishmania sp.  
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6 General Discussion 
The search for novel anti-leishmanial drugs is of crucial importance to address 
the currently sub-optimal repertoire of existing medicines. An elegant method to 
identify and assess the role of proteins that are not necessary for the survival of 
the parasite is by gene replacement and the generation of null mutant procyclic 
promastigotes. This approach has been used to a great extent since it was 
developed in 1990 (Cruz & Beverley) to generate null mutant clones to 
phenotypically assess parasite biology resulting from gene loss. As some 
phenotypes manifest once promastigotes differentiate to amastigotes, null 
mutants that remain viable as promastigotes enable further studies to be carried 
out in vitro or in vivo. Infection assays with such mutants can identify the gene 
as essential for survival in the mammalian host (Wiese 1998) or as virulence 
factors such as LPG and ISP where gene loss results in attenuation of infection 
(Späth et al. 2003; Eschenlauer et al. 2009). Gene replacement also enables the 
identification of genes that are essential to promastigote viability whereby 
replacement of the target alleles can only occur by expression of a transgene 
integrated elsewhere in the genome or present as an episome. Additionally, the 
retention of an episome during in vivo infection can be interpreted as selective 
pressure for gene expression and therefore an essential role during the 
amastigote life cycle stage (Wiese 1998). The loss of essential genes prevents 
growth during in vitro culture, therefore current techniques for genetic 
manipulation of Leishmania are limited to the confirmation of essentiality by the 
survival of clones which retain the gene. Recent expansions of this method by 
plasmid shuffle analysis is being utilized to explore the role of such essential 
genes through the generation of partial null mutants, and also by enabling a 
conditional complementation approach to identify active sites encoded within a 
gene sequence. Despite this improvement, reverse genetics of Leishmania and 
the assessment of essential genes encoding proteins which represent druggable 
targets remain limited. A conditional method of gene deletion is required to 
probe this, therefore this study sought to address this by applying the diCre 
system to conditionally delete cdc-related kinase CRK3 in Leishmania mexicana, 
which classic gene knockout approaches suggested is essential (Paul Hassan et 
al. 2001). By utilizing the existing approach of gene replacement by 
electroporation with transgenes flanked by gene homology, both copies of the 
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gene were replaced by the diCre sequence and a regulatable, loxP flanked CRK3 
open reading frame. Loss of the gene is rapid and stringently regulated, resulting 
in the cessation of procyclic promastigote growth due to a cell cycle arrest at 
the G2/M transition. The application of this method to the therapeutically 
significant amastigote stage was feasible by conditional deletion in infectious, 
stationary phase promastigotes and subsequent murine infection. The impaired 
growth of CRK3 deficient amastigotes establishes the essentiality of CRK3 in vivo 
and builds on previous research to confirm that the protein kinase is a validated 
drug target (Grant et al. 1998; Paul Hassan et al. 2001; Gomes et al. 2010; 
Walker et al. 2011). The application of this approach to other essential genes in 
Leishmania such as the MAP kinases (Wiese 1998; Wang et al. 2005; Dacher et al. 
2014) or NMT (Price et al. 2003) will yield important information about the 
function of the target gene, in addition to the assessment of its potential as a 
suitable drug target. There are considerations that must be addressed to 
maximize the utility of diCre mediated recombination in Leishmania. 
6.1 Considerations for in vivo application of the diCre 
system in Leishmania 
The approach utilized in this study was conditional loss of CRK3 in stationary 
phase promastigotes, however to better assess a gene as a drug target an 
approach to ablate the gene during murine or in vitro macrophage infection is 
desirable. A challenge in developing this system for in vivo use will be obtaining 
sufficient levels of diCre activity in intracellular amastigotes. An effective route 
of rapamycin administration is therefore a necessity. A chief consideration is 
that rapamycin is a potent immunosuppressant, and has been approved for oral 
use as Rapamune to prevent graft rejection in humans for over 15 years (Fogel et 
al. 2015). As such, the extensive and complex effect rapamycin exerts on the 
immune response through mTORC1 inhibition has been studied in particular 
depth; mTORC1 activity regulates immune cell proliferation, the generation of 
memory or effector cells and modulation can result in unexpected effects such 
as increasing longevity (reviewed by Araki et al. 2011). In this respect, in vivo 
administration of rapamycin to mice infected with diCre inducible deletion 
Leishmania would have to be stringently controlled to ensure rapamycin 
treatment alone is not influencing survival. There are a number of methods for 
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administration of rapamycin; orally, by intraperitoneal injection or topical 
application.  
Oral treatment is an undesirable method due to the systemic side-effects that 
can come as a result of dissemination of rapamycin (Wheless & Almoazen 2013). 
With regards to species of Leishmania where pathology results in cutaneous 
lesions, topical application of rapamycin would be a rational administration 
route to induce deletion (Garnier & Croft 2002). Clinical studies into the use of 
topical rapamycin treatment have been conducted to treat symptoms caused by 
the autosomal-dominant genetic disorder tuberous sclerosis (TS) in humans 
which results in the formation of benign tumours in multiple organs. TS patients 
frequently present with facial angiofibromas in the skin as a result of impaired 
regulation of mTOR activation in dermal fibroblasts, causing the release of an 
epidermal growth factor (epiregulin) which results in proliferation of epidermal 
cells and the formation of skin papules (Koenig et al. 2012). To down regulate 
epiregulin production by mTOR inhibition, rapamycin has been administered 
topically in formulation with a cosmetic barrier cream (Koenig et al. 2012), a 
hydrophilic ointment (Wheless & Almoazen 2013) and by direct application of 
oral rapamycin (Mutizwa et al. 2011). Such studies hold promise for the topical 
application of rapamycin to a cutaneous lesion to induce diCre activity in vivo, 
however optimisation of the extensive dosing regimen of once or twice daily 
over the course of months used in these studies would have to be evaluated in 
terms of deletion efficacy. A limitation of this procedure is the application of 
creams to mice; personal communication from colleagues applying drug 
compounds in ointment report that the mice often groom the areas applied with 
cream, and that application can lead to variability in dosage.  
An alternative to ointment could be the application to a lesion using rapamycin 
in formulation with a penetration enhancer such as DMSO or oleic acid (Garnier 
& Croft 2002), in a volatile carrier such as ethanol to facilitate rapid evaporation 
of the solution from the lesion and prevent loss through grooming. Again, the 
concentration of rapamycin used and the dosing regiment would need to be 
sufficiently optimised for in vivo deletion to be conducted. A pilot study using 
this method to dose the lesion of a mouse infected with the Δcrk3::DICRE/CRK3 
[SSU GFP Flox] line by direct application of 20µl 2µg/ml rapamycin in 10% DMSO, 
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90% ethanol over three days did not induce deletion, suggesting a higher dose 
and longer treatment is necessary. An issue with topical delivery is the multiple 
dermal layers which require penetration by the compound (Garnier & Croft 
2002), in conjunction with the necessity to enter the infected host phagocytes, 
cross the parasitophorous vacuole membrane and enter the amastigotes. In 
addition, transmigration of immune cells harbouring Leishmania to the draining 
lymph node results in the establishment of infection (Baldwin et al. 2004) away 
from the infection site, therefore rapamycin treatment of the lesion would not 
induce deletion of these parasites, acting as a reservoir for subsequent re-
infection.  
Intraperitoneal (IP) administration of rapamycin has been established in many 
mouse and rat models due to the variety of cellular functions regulated by 
mTORC1. More relevant to this study is the induction of diCre activity in mice 
(Jullien et al. 2007) and studies which utilise the FRB and FKBP12 domains to 
regulate gene expression by reconstituting an active transcription factor in the 
presence of the rapamycin ligand in vivo (Wang et al. 2004; Koh et al. 2006). For 
in vivo induction of diCre activity and deletion of species causing visceral 
leishmaniasis, IP administration would allow systemic dosage and induction of 
deletion in the cells harboured by phagocytes in the viscera. However, there are 
a number of pharmacokinetic properties which render rapamycin a poor 
compound to administer by this route; 95% of rapamycin is sequestered by 
erythrocytes thereby hindering bioavailability, and the poor solubility of the 
drug makes preparation of injectable formulations difficult (Rouf et al. 2009). A 
liposomal formulation of rapamycin has been developed which the authors 
present as a more amenable delivery system, and one which will not be 
sequestered so highly by erythrocytes (Rouf et al. 2009). This represents a 
potentially valuable method for diCre induction in vivo because in contrast to 
free rapamycin, uptake of liposomes occurs highly in mononuclear phagocytic 
system (MPS) cells (Kelly et al. 2011) which represent the main immune cell 
niche of Leishmania. This would facilitate enhanced uptake in the cells infected 
with Leishmania, and this natural process can be enhanced by the addition of 
targeting proteins to the surface of liposomes, such as mannosylation to enhance 
uptake by macrophage and DC. The lipid formulation medicine AmBisome is the 
most efficacious anti-leishmanial drug available for treatment of visceral 
178 
 
leishmaniasis, showing that the uptake of liposomal formulations into 
intracellular parasites is a feasible method of delivery. In addition to 
intraperitoneal administration, this method could be utilised to directly inject 
rapamycin liposomes into cutaneous lesions to induce diCre activity, ablating the 
need for topical application. This may represent and an advantageous method 
for delivery of rapamycin directly to macrophage and dendritic cells harbouring 
the parasites, thereby inducing gene deletion in intracellular amastigotes in 
vivo. 
The study of genes which encode virulence factors which influence the immune 
response requires strict control to dissect the effect of gene deletion from the 
influence of rapamycin treatment. Three treatment groups would be sufficient 
for in vivo analysis; the diCre conditional line with or without rapamycin 
administration, and a diCre or loxP heterozygote line with rapamycin 
administration. By this method, the background influence of rapamycin alone 
can be identified and the resulting effect on immune response and parasite 
burden compared between induced and uninduced infections. To further develop 
this methodology, the use of rapamycin analogues (rapalogs) represents an 
improved ligand for in vivo conditional deletion induction as these compounds 
have been developed by modification of the chemical structure to prevent 
inhibition of mTOR and differential binding to FRB binding domain mutants 
(Bayle et al. 2006). The rapalog C-16-(S)-7-methylindolerapamycin (AP21967) 
inhibits mTOR mediated phosphorylation of p70 S6K at an IC50 of 10nM 
compared to 0.1nM for rapamycin (Edwards & Wandless 2007) with no inhibitory 
effect on proliferation of rat fibroblasts in vitro, whilst still able to induce diCre 
activity with an FRB T2098L mutant (Jullien et al. 2007). The use of this raplog is 
also efficacious during in vitro studies requiring a rapamycin ligand (Wang et al. 
2004; Koh et al. 2006) and represents a preferable compound for inducing diCre 
in vivo with a reduced immunosuppressive activity. However, these studies 
switched to rapamycin for in vivo dosage due to the high cost and volume 
necessary for efficacious gene expression so no reference can be made to the 
efficacy of AP21967 in vivo. DiCre induction by this rapalog was not effective in 
vivo (Jullien et al. 2007), however the successful in vivo administering of 
AP21967 by IP to induce protein dimerization of proteins regulating endothelial 
junctions during leukocyte extravasations does not entirely rule out the use of 
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this compound for diCre induction in vivo (Broermann et al. 2011). In addition, 
the low dose of rapamycin necessary to induce deletion of GFP (Figure 3:5) 
suggests a diCre efficiency that will facilitate sufficient rates of rapalog 
mediated diCre induction in vivo. The use of this rapalog will need to be 
validated and optimised in the context of Leishmania infection, however it 
represents a preferable ligand to prevent experimental caveats as a result of 
immune modulation by rapamycin treatment. With these considerations, a 
desirable method for diCre induction and conditional deletion of Leishmania 
encoded essential or virulence factors in vivo would be IP administration of 
rapalog in liposomal formulations to target the compound to phagocytes, whilst 
reducing mTOR inhibition in those cells.  
6.2 Alternative inducible gene deletion: double floxing  
This study has demonstrated efficient floxed GFP and CRK3 excision in both 
promastigotes and amastigotes, whereby expression of each diCre subunit from 
the CRK3 locus is driven by the presence of actin and beta-tubulin regulatory 
elements. Integration at this locus enables the generation of a heterozygote cell 
line with further complementation with a loxP flanked CRK3 copy (Figure 6:1a), 
however the generation of a ‘parental’ diCre expression line has been applied in 
T. gondii (Andenmatten et al. 2012). The benefit of this strategy is consistent 
expression of diCre, as opposed to gene replacement and subsequent 
quantification of protein expression for each gene targeted (which is made 
problematic due to a limited repertoire of low affinity, anti-FRB and anti-FKBP12 
antibodies). The generation of such a parental line in Leishmania is desirable to 
establish a quantified level of diCre protein expression prior to gene targeting. 
Altered ploidy in response to replacement of a single gene copy has been 
evidenced when replacing essential genes (Ambit et al. 2008), therefore by the 
strategy used in this study conditional regulation would be impractical. Instead, 
transfection of the diCre parental line to replace both gene alleles by loxP 
flanked ‘add-back’ gene copies would prevent any altered gene ploidy in 
response to gene replacement by diCre (Figure 6:1b). The cell line would then be 
amenable to diCre mediated gene loss of both copies. An issue may arise by the 
recombination between loxP sites, however a number of heterozygote loxP 
mutants exist which can be used to preferentially mediate recombination 
between specific sites and therefore prevent cross-over from gene alleles. To 
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prevent this, the loxP sites could contain mutations within the 8bp central 
spacer region where active diCre generates a 6bp staggered cut, and sequence 
homology to the second loxP is essential to enable recombination and therefore 
gene excision (Langer et al. 2002). These mutations generate heterospecific loxP 
sites which confer specificity to the corresponding loxP site mutant integrated 
on the same allele, thereby preventing chromosomal cross-over. The 
heterospecific lox511 and lox2272 sites have been applied to recombinase-
mediated exchange (RMCE) of gene cassettes in mouse embryonic stem cells (ES) 
(Araki et al. 2002). Such mutant lox sites could be exploited to apply double 
allele deletion in L. mexicana as an alternative strategy to regulate essential 
gene expression.  
Some aspects of diCre mediated gene deletion may be problematic when applied 
to essential genes. Gene expression levels may be altered by replacement of 
endogenous genes with floxed gene copies flanked by exogenous splice and poly-
adenylation sites. This is an important consideration as inappropriate gene 
expression may result in a toxic phenotype, particularly if the gene is 
subsequently overexpressed or expressed at an insufficient level. A similar 
difficulty has been seen previously by the application of tet-operon based 
systems to regulate protein kinase expression in T. brucei. Insufficient T7 
promoter repression can result in gene silencing and a subsequent impaired 
growth and survival, whilst poor regulation of inducible expression can result in 
a toxic phenotype being manifest prior to induction. If the replacement of 
endogenous Leishmania genes with floxed copies leads to altered expression, 
deleterious effects on cellular proliferation may manifest and render further 
phenotypic analysis by conditional gene deletion impractical. In this respect, the 
desired strategy of gene replacement can be decided upon. 
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Figure 6:1- Strategies for diCre mediated gene regulation by mutant loxP orientation. A. The 
strategy used for inducible deletion requires replacement of a target gene by the diCre coding 
sequence (blue) and the target gene (blue) flanked by ‘wild-type’ loxP sequences (black arrows). 
Recombinase activity results in excision. B. Integration of the diCre coding sequence into an 
exogenous locus (grey) to confer expression and target gene replacement at each allele with 
distinct central spacer mutant lox sites (dashed or white arrows). Recombinase activity results in 
each gene being excised without cross over recombination. C. Inducible expression can be 
conferred by incorporating the diCre gene and an inverted target gene flanked by left and right 
element (LE/RE) mutated lox66 and 71 sequences (mixed black and red arrows). Recombinase 
activity results in the generation of a wild-type loxP site and a double mutant (*) with less affinity for 
Cre.  
6.3 Expanding loxP site recombination: flip-flox 
Inducible overexpression of a target gene would be a useful method to further 
explore the effects of the encoded protein on the physiology or virulence of 
Leishmania. The recent study by Kraeva et al. (2014) utilizes a T7-driven Tet-
inducible system to accomplish this, however the flexibility of loxP mediated 
recombination opens up the possibility of achieving inducible gene expression by 
diCre mediation. Inducible expression requires an inverted gene of interest to be 
flanked with cis rather than trans orientated loxP sites (Figure 6:1c). In this 
orientation, there should be no read-through transcription of the gene and 
therefore no protein expression until diCre recombinase activity is induced by 
rapamycin treatment, whereupon the gene will ‘flip’ into a transcriptional 5’-3’ 
orientation for expression. The application of method is complicated in 
Leishmania because of the evidence that transcription of both strands occurs 
(Belli et al. 2003). Therefore incorporation of this construct must be in a region 
where antisense transcription is silent to prevent protein expression in the 
absence of diCre activity. The identification of possible hairpin-loop forming 
transcription terminators around T1 and T2 sites in L. infantum (Abreu-Blanco et 
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al. 2010) suggests such sites could be utilized to prevent reverse read through 
transcription to silence the gene until ‘flipped’ at the ribosomal locus. In 
addition, integration of the gene into the ribosomal small subunit downstream of 
the PolI promoter would confer high levels of expression (Misslitz et al. 2000) to 
achieve inducible overexpression. Optimisation of a method to prevent reverse 
strand transcription by the addition of exogenous transcription terminators or by 
integration into a locus where the orientation of transcription is known would 
enable such gene invertion as a viable strategy in Leishmania.  
The use of wild-type loxP sites would result in the gene constantly ‘flipping’ as 
Cre activity would continually catalyse recombination, however the use of left 
and right element (LE/RE) mutated lox sites such as lox66 and lox71 would 
prevent continual recombination; these have mutations in the inverted repeat 
regions flanking the loxP spacer where the Cre mediates a break in the DNA 
sequence (Albert et al. 1995). Despite not affecting Cre activity at the spacer, 
recombination between LE and RE mutants results in both a loxP site and a 
double mutant which has a dramatically reduced affinity for Cre. As such, the 
reaction can be skewed to undergo a single recombination event to prevent 
repeated inversion. This methodology opens up the possibility of inducible 
expression by diCre mediated recombination, and given the stringent regulation 
of diCre activity we may hypothesise that this would be more advantageous due 
to the ‘leakiness’ associated with tetracycline inducible systems in T. brucei 
(Barrett et al. 2004). 
6.4 Applying diCre with existing molecular techinques 
The flexibility of Cre:lox recombination potentiates its application to existing 
methods of Leishmania manipulation. A chief problem of such approaches is an 
absence of conditional regulation of activity, therefore the inversion strategy 
may be particularly desirable. The recent publication of tet-inducible gene 
expression in L. mexicana may also be applied in some cases, however the 
stringent control of activity by diCre may make it more desirable.  
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6.4.1 Active site analysis by conditional mutant complementation 
The use of conditional complementation of floxed CRK3 in this study has enabled 
the confirmation of the essentiality of T-loop phosphorylation for activity. This 
strategy is a useful method for probing active sites, but to enable a more high-
throughput method to probe multiple coding sequence mutants by conditional 
complementation, a transposon based approach may be practical; this enables 
mutated coding sequences to be generated simultaneously by shuttle 
mutagenesis, enabling the cloning of multiple open reading frame (ORF) mutants 
for subsequent transfection into diCre:flox parental cells (Damasceno et al. 
2010). Treatment with rapamycin will induce diCre activity to excise the floxed 
gene copy, and enable survival of clones expressing differentially mutated 
complementary ORFs (Figure 6:2 i). Dependent on the desired application, 
multiple cell lines could be generated and pooled to enable a high-throughput 
approach. In a simplistic example, survival or death within the population is the 
criteria for active or inactive complementation and therefore loss of cells 
bearing their respective mutant expresser could be identified by an approach 
similar to RIT-Seq. Such a conditional complementation (CC)-seq approach may 
be useful in determining multiple sites for chemical inhibition within a potential 
drug target. A similar approach to study multiple mutations in a gene sequence 
has been conducted by plasmid shuffle mediated conditional complementation 
(Dacher et al. 2014), however an advantage to the diCre approach is the 
potential to invert the mutant coding sequences and flank them with inverted 
LE/RE lox mutants to conduct inducible overexpression. This would enable 
dominant negative phenotypes to be assessed by transfection of plasmids into a 
wild-type expressing diCre cell line, and may represent a useful strategy to 
further probe the function of active sites.  
6.4.2 RNAi 
The current method for RNA interference in Leishmania braziliensis relies on the 
transfection of dsRNA or a stem-loop construct to initiate gene silencing. 
However, both approaches lack temporal regulation of the generation of dsRNA 
and therefore the siRNA generated by the RNAi pathway. A stem-loop inducible 
system is feasible with diCre, whereby one of the repeat sequences expressed to 
produce a hair-pin loop is flanked by inverted loxP sites and orientated in such a 
184 
 
way that no loop is produced (Figure 6:2 ii). Upon diCre activity, the sequence 
will invert to produce transcript that subsequently generates the stem loop, 
dsRNA and subsequently activates RNAi mediated degradation of transcript. The 
process of cloning such constructs may be made amenable by a PCR cloning 
based method such as Gibson Assembly, or by Gateway mediated cloning as used 
for high-throughput cloning of RNAi libraries for application to T. brucei (Jones 
et al. 2014). This system could potentially be applied for conditional RNAi in L. 
braziliensis, but first diCre expression and loxP mediated recombination would 
have to be developed in this species first.  
 
Figure 6:2- Application of diCre mediated recombination to other molecular methods for 
Leishmania manipulation. i.  Multiple plasmids each containing an individual mutated gene of 
interest (GOI) cell lines can be generated to express mutant variants of the target. Rapamycin 
treatment to initiate diCre activity will result in floxed gene loss to induce a measurable phenotype 
resulting from expression of only the mutant sequence, and inactive or active mutants can be 
identified by sequencing.  ii. Inducible RNAi by inversion of an open reading frame fragment (ORF 
f) by inverted lox recombination. Prior to rapamycin treatment no stem loop is formed by ribosomal 
promoter (P rRNA) driven transcription (blue arrow). After rapamycin treatment the gene fragment 
(Gene f) becomes orientated to enable read-through of both fragments and spacer (grey) to 
produce a stem-loop. Generation of dsRNA results in downstream silencing. iii. Generation of a cell 
line expressing guide RNA (gRNA), diCre and an inverted Cas9 ORF enables inducible Cas9 
regulation. DiCre activity orientates the gene for expression, resulting in guide RNA binding and 
subsequent genome editing activity. An exogenous transcription termination site (*) at the 3’ end 
would prevent reverse transcription. 
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6.4.3 CRISPR/Cas9 
The use of CRISPR/Cas9 mediated genome tailoring has been applied in 
Leishmania to enhance homologous recombination for integration of exogenous 
genes (Sollelis et al. 2015) or to cause gene disruption and endogenous gene 
tagging (Zhang & Matlashewski 2015). However the application of such a method 
to target essential genes is still limited by a lack of conditional regulation of 
activity. There are regulated Cas9 enzymes available, such as destabilization 
domain (ddCas9) which may ameliorate this, however the use of diCre mediated 
Cas9 expression may also be a viable option. In this instance, the Cas9 coding 
sequence would be flanked with inverted loxP sites and integrated into the 
genome in the reverse orientation. Inducible diCre activity would therefore 
invert the gene and enable transcription and expression of the enzyme. A 
suitable method to retain the Cas9 guide DNA would have to be included in this 
plan, however expression downstream of the ribosomal promoter is a functional 
strategy. Incorporation of the diCre coding sequence elsewhere in the genome 
would confer the necessary expression, whilst the Cas9 coding sequence would 
be inserted in the reverse orientation and flanked by inverted LE/RE lox mutants 
(Figure 6:2 iii). In this reverse orientation there should be no transcription, 
however by diCre mediated recombination the Cas9 sequence will be flipped to 
enable read through transcription of the full sequence. Subsequent expression 
will drive the downstream CRISPR/Cas9 editing, depending on the guide 
sequence incorporated into the cell.  
 
6.5 Concluding remarks 
This study presents the efficacious utilisation of diCre inducible gene deletion in 
L. mexicana and its application to the cell cycle protein kinase CRK3. CRK3 has 
been shown to be essential for the progression of mitosis in promastigotes, 
whilst an active CRK3 is necessary to maintain murine infection. We can 
therefore conclude that CRK3 is a validated drug target, and that the application 
of this methodology to other essential genes will confirm further drug targets. 
Application of inducible deletion of essential genes, combined with the 
bioluminescent infection model will enable the development of amenable 
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murine assays of parasite burden and immune recruitment. Such studies will 
yield crucial information to accelerate drug development programs and help 
address the paucity of available drugs for leishmaniasis. Ideally, this work will 
form a basis for the establishment of a model of visceral infection to identify 
suitable targets in the disseminating Leishmania species which cause the deadly, 
visceral form of the disease.
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